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General introduction 
 
Oculopharyngeal muscular dystrophy  
 
Oculopharyngeal muscular dystrophy (OPMD) is a rare muscle disorder that is 
usually autosomal dominantly inherited. It has its onset in the adult age. The 
characteristic clinical pattern is the combination of bilateral ptosis, dysphagia 
and, later, limb girdle weakness.[1] Disease progression is usually slow. The 
disorder is histologically characterized by insoluble aggregates within the 
nucleus of the skeletal muscle fibres. [2] 
In 1998, Brais discovered the mutation causing OPMD.[3] It is an expanded 
trinucleotide (GCN) repeat in the gene encoding for Poly-Adenylate-Binding-
Protein-Nuclear 1 (PABPN1). At that time, OPMD had already been described 
to occur in various ethnic groups, such as in French-Canadian, Bukhara Jews, 
Hispanic New Mexicans, French, Uruguayans, Italians, Germans and in the UK 
population.[4-11]  
Oculopharyngeal muscular dystrophy in the Netherlands 
 
In the Netherlands, however, OPMD was not yet well recognized at the time of 
the discovery of its genetic cause. This was at least in part due to a patient 
delay: the first patients we encountered at our outpatient department interpreted 
the dropping of the upper eyelids and difficulties of swallowing and walking as 
normal features of ageing in their family. All adult family members knew how to 
perform a Heimlich maneuver1  on their affected relatives or spouses in case of 
choking. We hypothesized that there was also a doctor’s delay due to limited 
recognition of this rare disorder.  
 
 
  
                                                          
1 The Heimlich maneuver is a first aid procedure used to treat choking: a rescuer stands 
behind an upright patient using his hands to exert pressure on the bottom of the 
diaphragm. This compresses the lungs and exerts pressure on any object lodged in the 
trachea with the goal of expelling it. 
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Figure 1. An old family portrait of a Dutch OPMD family, the fourth and fifth 
woman from the right at the first row have severe ptosis. They tilt their heads 
backwards to be able to look underneath the hanging eyelids. 
 
 
 
 
 
 
 
 
 
 
 
Descriptive case 
A 78-year-old man was evaluated at our outpatient department for 
progressive walking difficulties. He had suffered from swallowing difficulties 
from the age of 52, which were slowly progressive over time. He needed to 
mash his food to prevent pharyngeal or esophageal stasis, and used food 
supplements to avoid weight loss. Choking occurred several times a week; 
once, a food particle had to be surgically removed from his trachea. At the 
age of 56, his upper eyelids began to drop, and he underwent a surgical 
ptosis correction at the age of 59. Afterwards, the ptosis reoccurred for 
which crutch glasses were prescribed. At the age of 61, cycling became 
difficult and he gradually developed difficulties walking. He could not rise 
from a chair without support of his arms and he had difficulties climbing 
stairs. He needed a walking frame to walk.  
His family history revealed similar complaints in his grandmother, father, two 
sisters and a brother of his father, and three of his sisters. His 48-year-old 
daughter was also affected; she had remarked swallowing difficulties since 5 
years, dropping of the upper eyelids since 3 years, and she had recently 
experienced fatigue of her legs. 
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We observed that pelvic girdle and proximal leg weakness was more 
pronounced in Dutch OPMD patients than in reported cohorts. This low 
prevalence or awareness of pelvic girdle and proximal leg weakness is reflected 
by the diagnostic criteria for OPMD,[4,12,13] which include limb girdle 
weakness only as a minor criterion. Whether pelvic girdle and proximal leg 
muscle weakness belongs to the pattern of OPMD is of clinical importance, 
because of  the differential diagnosis of the limb girdle phenotype, the most 
common presenting muscle phenotype (figure 2).  
  
Figure 2. Limb girdle phenotype 
The blue areas indicate the distribution of muscle weakness in patients with a 
limb girdle phenotype. 
 
To increase the knowledge of the clinical, histopathological and genetic features 
of Dutch OPMD patients, we decided to perform a cross-sectional observational 
study in the first families identified at our outpatient department. This was the 
start of the research reported in this thesis. Our first goal was to elucidate 
whether the Dutch OPMD cohort is similar to the other populations reported in 
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literature, both clinically and genetically. This would enhance counselling and 
symptomatic treatment.  
Secondly, most research on OPMD so far had focused on the genetic and 
pathophysiological aspects, while data on the patients’ perspective were limited. 
The disease usually manifests itself in late adulthood, and at diagnosis many 
carriers of the OPMD mutation participate normally in society. Disease 
progression is usually slow and physical and functional impairments develop 
gradually. Consequently, OPMD was often considered a “benign” muscle 
disease with a relatively mild initial disease course with no or only mild 
functional disabilities. However, the occurrence of fatigue, pain and functional 
impairments other than dysphagia had never been studied systematically.[6] 
Therefore, we added a questionnaire study focusing on limitations in daily life, 
fatigue and pain. 
Thirdly, the insoluble aggregates within the nucleus of the skeletal muscle fibres 
had been recognized as the histopathological hallmark of OPMD. However, the 
impact of these aggregates on cellular defects in OPMD was not yet fully 
understood.[14,15] Furthermore, it was unknown whether the aggregates occur 
before clinical onset or only during disease progression. Therefore, we 
investigated muscle specimens of presymptomatic PABPN1 carriers. 
Meanwhile, the results of our first observational study had increased the 
awareness and the recognition of OPMD. The Dutch cohort had gradually 
increased. This enabled us to perform a larger systematic study in 40 
symptomatic patients, including muscle biopsies in 24 patients and 18 not yet 
affected children. 
Other cohorts had shown a variable prevalence of pelvic girdle and proximal leg 
weakness over the years: weakness of limb muscles was reported in 52% of the 
patients in a French cohort, and weakness of proximal legs was reported in 
71% in the French-Canadian cohort.[7,4] In contrast, proximal weakness 
occurred only in 20% of an OPMD cohort in Israel.[16] As a result, no 
consensus on involvement of the pelvic girdle and proximal legs muscles was 
reached. Various reviewers suggested that the high prevalence in the Dutch 
cohort was secondary to the relatively old age of the patients and severe 
genetic defects (long repeats) in the participants. To investigate whether this 
could fully explain the weakness in the Dutch cohort, we recently performed a 
cross-sectional study, that included muscle imaging and functional outcome 
measures in a younger cohort of OPMD patients.  
A detailed outline of this thesis will be presented on page 24. Next we present a 
summary of the history of OPMD.  
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Figure 3. A time frame showing key publications about OPMD until the 
end of the 20th century. 
The first four publications mentioned in this time frame are clinical descriptions, 
followed by two publications on histopathological features. In the 90’s Brais 
published a number of reports on the clinical diagnostic criteria and the genetics 
of OPMD. In 1997 Neuromuscular Disorders published a supplementary journal 
(7(Suppl 1)) on the first international symposium on OPMD, which had taken 
place in 1995 in Quebec.[17-22,2,12,23,3]  
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History of OPMD  
 
In 1915, Taylor was the first to report four members of a French-Canadian 
family with a late-onset progressive ptosis and dysphagia leading to starvation 
and death. Taylor postulated that the clinical features were the result of 
selective neuron loss of the nuclei of the vagus, glossopharyngeal and 
oculomotor nerve. He named the disorder “progressive vagus-glossopharyngeal 
paralysis with ptosis”. [17] 
Thirty years later, Amyot reported ten French-Canadian families with late-onset 
progressive ptosis and dysphagia including a review of the literature in two 
journals simultaneously (in English in “The Canadian Medical Association 
Journal” and in French in “l’Union Medicale du Canada”).[18,19] He was the first 
to recognize the myopathic nature of the disorder based on the pattern of 
involved muscles, i.e. the levator palpebrae and the superior rectus and 
pharyngeal muscle. [24] In 1962, Victor et al. published an article including 10 
new cases: one of which was a sporadic case and nine who were relatives of a 
three-generation American-Jewish family originating from West-Europe. They 
all had late-onset progressive ptosis and dysphagia. Based on their own and 
previous observations, Victor et al. also classified this disorder as myopathic or 
dystrophic and named it “oculopharygeal muscular dystrophy” (OPMD).[20] 
Since 1962, OPMD has been described in patients of different ethnic descents. 
Most patients are Caucasian, but one African-American family (living in the USA 
and originating from Barbaros) and a few Asian families have also been 
reported. The majority of patients has been identified in Europe, North America, 
South America (Uruguay), The Middle East (Israel), and Asia. The prevalence 
of OPMD is very variable. In France the prevalence has been estimated to be 1 
per 200.000. (4-9,25,10,26,11] The largest OPMD cohort consisted of 249 
French-Canadian patients reported by Barbeau (1965/1966), and lead to a 
prevalence of 1 per 7.500 in the region Saguenay-Lac-St-Jean in Quebec. All 
patients appeared to be descendents of a French couple (Zacharie Cloutier and 
Xainte Dupont), who immigrated to Quebec in 1634 with their five children 
(figure 4). Their eldest son returned to France to marry Madeleine Aymard and 
they returned to Quebec. At a later stage Barbeau assumed that the founder 
effect  in the French-Canadian population originated from this second couple. 
All the OPMD patients in Quebec had familial bonds with the couple Cloutier 
and Aymard.[21] As a result of the work of Barbeau in the field of OPMD, 
OPMD is also known as “La maladie de Barbeau” in Canada.[21] 
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Figure 4. The French-Canadian OPMD cohort reported by Barbeau 
Left: The ancestor couple of the French-Canadian OPMD kindred, Zacharie 
Cloutier and Xainte Dupont. Remarkable is that both are depicted with severe 
ptosis, whereas Barbeau thought that the French-Canadian OPMD population 
were descendants of either Zacharie Cloutier or the sisters Aymard and not 
from Xainte Dupont.[21]   
Right: Genealogic tree of the large OPMD French Canadian kindred around 
1967. The central couple is Jean Aymard and Marie Bineau, the three Aymard 
sisters are depicted on the second row, with more than 200 cases in their 
descendants.[21] 
The second largest group of OPMD patients is a Jew population who lives in 
central Israel and originates from Bukhara in Uzbekistan, with an estimated 
prevalence of 1 in 600. The phenotype in this cohort is similar to that of the 
Quebec cohort.[5,16] 
Clinical diagnostic criteria 
 
As part of a large genetic linkage study in large French-Canadian families, Brais 
et al. drafted clinical diagnostic criteria for OPMD (see Table 1).[12] Ptosis was 
defined as at least one palpebral fissure measuring less than 8 mm at rest or 
previous corrective surgery for ptosis. Dysphagia was defined as a failure to 
drink 80 cc of cold water in less than 8 seconds.[4] The minor criteria were not 
quantified. Exclusion criteria were added to differentiate between OPMD and 
chronic progressive external ophthalmoplegia and myotonic dystrophy type 1, 
two myopathies that can also manifest as a ptosis, and of which myotonic 
dystrophy is especially common in the French Canadian population. These 
criteria have been broadly used even after genetic testing became widely 
available for diagnostics. 
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Major criteria Minor criteria Exclusion criteria 
x positive family 
history of OPMD  
x age at onset ≥ 40 
years 
x severe external 
ophthalmoplegia 
before the age of 60 
x symptomatic or 
corrected eyelid 
ptosis 
x limitations of eye 
movements 
x presence of myotonia 
x symptomatic 
dysphagia 
x facial weakness  
 x tongue weakness  
 x limb weakness  
Table 1. Clinical diagnostic criteria of OPMD 
OPMD is diagnosed in case of the combination of all three major criteria with 
two or more minor criteria and the absence of the two exclusion criteria.[12,4] 
Figure 5. Clinical features of OPMD 
Left: Weakness pattern of OPMD indicated by the blue areas: the major 
diagnostic criteria include ptosis and dysphagia.  
Right: Ptosis and facial weakness in a 78-year old patient; to correct his bilateral 
ptosis he raises his eyebrows by contracting the frontalis muscles, the thin 
muscle covering the skull above the eyes and serving for facial expression.  
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Genetic characterization 
 
The linkage study of Brais et al. resulted in the identification of the OPMD locus 
on chromosome 14q11.2-q13 in a large group of individuals of the French-
Canadian descendent.[23] Stajich et al. confirmed the locus on chromosome 
14q11.2-q13 in four French-Canadian and one English Scottish family.[27] Brais 
et al. isolated the poly-A-binding-protein 2 (PABP2) gene (later named poly(A)-
binding protein nuclear 1, PABPN1, gene) from the OPMD locus.[3] PABPN1 
protein is exclusively localized in the nucleus, where it acts as a factor in the 
mRNA polyadenylation. The PABPN1 mRNA is highly expressed in skeletal 
muscle, therefore the PABPN1 gene was considered to be a good candidate 
gene for OPMD. Sequencing the PABPN1 gene revealed that the gene 
comprises 7 exons. The first exon contains a (GCG)6-repeat, which codes for 
the first six alanine residues of a stretch of ten. The stretch of ten alanine 
residues is encoded by a (GCG) repeat followed by (GCA)3(GCG), together 
(GCN)10 (figure 6). 
The (GCN)10-allele was found in 98% of French-Canadian control 
chromosomes. The other 2% of control chromosomes carried a (GCN)11 
polymorphism, in which the (GCG)6 repeat was enlarged with one GCG-
trinucleotide. Further investigation in 144 OPMD families revealed expansion of 
the GCG-repeat to 8-13 ((GCN)12-17). The most frequent observed mutation in 
de French-Canadian population was the (GCN)13 expansion (figure 6). 
Therefore OPMD proved to be based on a trinucleotide repeat expansion 
causing alanine expansion mutations. OPMD is categorized together with 
neurodegenerative disorders that are caused by a single amino acid repeat.[3]     
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Figure 6. Genetic characteristics of OPMD  
OPMD is caused by a repeat expansion (GCN) in the PABPN1 gene on 
chromosome 14q11.2-q13. The first exon of a wild type PABPN1 gene contains 
a (GCG)6-repeat, which codes for the first six alanine residues of a stretch of 
ten. The stretch of ten alanine residues is encoded by a (GCG) repeat followed 
by (GCA)3(GCG), together (GCN)10. 
Phenotype-genotype coupling of French-Canadian (GCN)13 mutations carriers 
showed a good correlation between disease severity and the three different 
genotypes that occurred. A number of patients had a more severe phenotype 
than observed in the heterozygous carriers of the (GCN)13 mutation. First, 
homozygotes for the (GCN)13 mutation had an age at onset before the age of 
40 and more severe swallowing difficulties. The other genotype corresponding 
with a more severe phenotype is the compound heterozygosity for the (GCN)13 
mutation and the (GCN)11 polymorphism. In one family two brothers were 
affected; the oldest brother had genotype (GCN)13/(GCN)11 and had more 
symptoms than his younger brother who had the more common genotype 
(GCN)13/(GCN)10. Apparently, the (GCN)11 polymorphism is a severity 
modifier of the dominant OPMD phenotype. Furthermore, the (GCN)11 allele 
can act as a recessive mutation; homozygosity for the (GCN)11 polymorphism 
is associated with a less severe OPMD phenotype with later age at onset.[3]  
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Muscle histology 
 
The key histological feature of rimmed vacuoles was already recognized by 
Dubowitz and Brooke.[22] This finding is not specific, however. In 1980 Tomé 
and Fardeau discovered aggregates in the nuclei of muscle fibres of several 
OPMD patients. These aggregates are a pathognomic morphological feature of 
the OPMD (figure 7). The aggregates consist of tubular filaments with an outer 
diameter of 8.5 nm and an inner diameter of 3.0 nm and a length of 0,25 
micrometer and they are arranged in tangles and palisades. They are observed 
with electron microscopy in ultrathin coupes in 2-5 % of the nuclei of muscle 
fibres. The aggregates in the nuclei are recognizable because they are clearer 
than the normal nuclear content.[2] Calado et al. detected PAPBN1 in the 
OPMD-specific aggregates, using both immunoelectron microscopy and 
fluorescence confocal microscopy.[28] In addition, the aggregates were labelled 
with antibodies directed against ubiquitin and the subunits of the proteasome, 
and contained a less soluble form of PABPN1 as well as poly(A) RNA. The 
authors suggested that the polyalanine expansions in PABPN1 induce a 
misfolding and aggregation of the protein into insoluble inclusions, which is 
comparable to processes in neurodegenerative diseases that are caused by 
CAG/polyglutamine expansions. They also suggested that in OPMD, the 
polyalanine expansions in the PABPN1 protein may interfere with the cellular 
traffic of poly(A) RNA. 
  
514290-L-sub01-bw-vdSluijs
Processed on: 6-10-2017 PDF page: 22
General Introduction 
 
 
22 
 
Figure 7. Muscle histology and EM in OPMD 
Left: Vacuole in Hematoxylin-phloxine staining. Granules occur in small 
polygonal or angular muscle fibres, have an irregular shape and are centrally or 
subsarcolemmally located. 
Right: an electron microscopic image of part of a nucleus of a muscle fibre 
showing an aggregate; the aggregate is brighter than the surrounding normal 
nuclear content. An aggregate consists of tubular filaments, which are arranged 
in tangles and palisades. The aggregates contain PABPN1, poly(A) RNA, 
ubiquitin and subunits of the proteasome. 
This summary of the history of OPMD shows that it is a clinically and genetically 
well-defined entity: it is clinically characterized by eyelid ptosis and dysphagia, 
which is reflected in the name of the disorder and the diagnostic criteria. 
Although the disorder has been described in different ethnic groups, a 
description of the Dutch OPMD population was still lacking. Similarly, the 
burden of OPMD from a patient perspective had not yet been investigated at the 
onset of this thesis. Histopathologically, OPMD is characterized by a 
pathognomic morphological feature, i.e. the aggregates. However, it had 
remained unsolved so far whether the aggregates occur before or after the 
clinical onset. OPMD is caused by an expanded trinucleotide (GCN) repeat in 
the gene encoding for Poly-Adenylate-Binding-Protein-Nuclear 1 (PABPN1).  
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Aims of the study 
 
At the onset of the study presented in this thesis, there were several reasons to 
investigate the Dutch OPMD population. The discrepancy of the clinical 
observations of the first OPMD patients at our outpatient department and the 
reports of other OPMD populations called for a study on the clinical, 
histopathological and genetic features of Dutch OPMD patients. Another reason 
was to increase the knowledge on the clinical spectrum and natural course of 
OPMD. Furthermore, most of the OPMD studies at that time focused on 
histopathological and genetic aspects, while knowledge on the patients’ 
perspective was limited. 
Hence, the initial clinical encounter with the Dutch OPMD patients at the 
beginning of this century resulted in the design of this study with the following 
aims (the numbering corresponds with the parts of this thesis):  
 
 
 
 
 
 
 
 
This study was expected to improve the clinical recognition, to promote 
symptomatic treatment, to contribute to the knowledge on the pathophysiology 
of OPMD needed for targeted therapies, and to improve the outcome measures 
required for trial preparedness. In addition, this study enabled collaboration with 
Dr V. Raz (Department of Human Genetics, Leiden University Medical Centre) 
on the translational aspects of the disease by combining clinical data and 
histological materials with OPMD animal models and cellular studies. 
  
II-III: to investigate and report the clinical, genetic and histopathological 
features of Dutch OPMD patients, and to compare these features with those 
of OPMD patients in other cohorts 
IV: to explore the patients’ perspective of OPMD, and 
V: to confirm the results of our pilot study (part II) in a larger cohort and by 
obtaining more detailed information of the clinical spectrum of OPMD; to 
investigate the histopathological features in presymptomatic PABPN1 
carriers; and to examine the pelvic girdle and proximal leg muscles 
involvement with a multidimensional approach in early OPMD patients and 
presymptomatic PABPN1 carriers.  
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Outline of this thesis  
This first part (Part I) of this thesis presents an introduction with a description of 
OPMD and a summary of the history of OPMD, aims of the study, and outline 
(This chapter 1). 
In Part II, our initial clinical and genetic observations are presented. Chapter 2 
is an observational study on clinical, genetic and histopathological features of 
Dutch OPMD patients. Medical history with the aid of a standardized 
questionnaire, modified Rankin scale, structured clinical examination (including 
standardized measurement of muscle strength), muscle biopsies, and genetic 
analyses were performed in 16 Dutch OPMD patients from five families. 
Chapter 3 describes a mutation analyses study in four unrelated Dutch families.   
Part III of this thesis comprises “lessons” from specific clinical observations: 
Chapter 4 is a neurological picture about the astrologists’ posture as a useful 
clinical observation. Chapter 5 is a study which tested the hypothesis whether 
the severity of ptosis is related to the degree of retroflexion of the head and 
whether this is responsible for a deterioration of the dysphagia in OPMD 
patients. In addition, the effect of a slightly flexed head position on dysphagia 
was investigated. Chapter 6 is a description of two unrelated OPMD patients 
with severe genetic defects who developed frontotemporal dementia.  
Part IV continues with a description of the questionnaire study to assess the 
prevalence of fatigue and pain, the limitations in daily-life activities and social 
participation, and the psychological well-being of OPMD patients. We used an 
open questionnaire with spontaneously reported complaints and a 
multidimensional assessment method including Sickness Impact Profile (SIP-
136), Checklist Individual Strength (CIS), The McGill’s Pain Questionnaire 
(MPQ), Symptom Checklist 90 (SCL90) and Beck’s Depression Inventory of 
Primary Care (BDI-PC). Furthermore, we determined whether limitations in daily 
life activities and social participation were related to fatigue severity, pain and 
disease duration. 
The final part, Part V, presents the results of the two systematic studies of 
OPMD. To confirm the results of our pilot study in chapter 2, a detailed 
description of the clinical symptoms in a larger cohort was required. Therefore, 
we performed a prospective, observational study in 40 OPMD patients and 18 
adult children of genetically confirmed OPMD patients (chapter 8). This study 
included a structured history, a detailed neurological examination, muscle 
histology and biochemical analysis. One patient died during the study and had 
given permission to perform autopsy on his body. This study in presymptomatic 
expPABPN1 carriers and OPMD patients enabled us to investigate the 
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spectrum of OPMD from different perspectives: 1) by focusing on the clinical 
aspects of this Dutch OPMD spectrum; 2) by investigating subjects from 
presymptomatic to progressive disease stages; and 3) by studying variably 
affected muscles within the same patients. 
Although weakness of pelvic girdle and proximal leg muscles is not part of the 
major diagnostic criteria of OPMD, it was frequently observed in the studies in 
Dutch OPMD patients and other cohorts. It has been debated that this results 
from the relatively old age of our cohort or the severity of the genetic defect. 
Therefore, we conducted a study to investigate weakness of pelvic girdle and 
proximal leg muscles with a multidimensional approach in early OPMD (chapter 
9). We examined daily living activities and disease impact, physical activity, 
muscle strength, histopathology and fatty infiltration with use of questionnaires, 
actometer, functional tests, manual and quantitative muscle testing, muscle 
biopsy and muscle MRI respectively. 
Part VI contains a summary of all chapters and the general discussion with 
future perspectives. 
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Part II  
Dutch OPMD phenotype:  
Initial clinical and genetic 
observations 
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Chapter 2 
Oculopharyngeal muscular dystrophy with limb girdle weakness as major 
complaint. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from 
Barbara M. van der Sluijs, Lies H. Hoefsloot, George W. Padberg, Silvere M. 
van der Maarel, Baziel G.M. van Engelen 
Journal of Neurology 2003; 250(11):1307-12 
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Abstract   
This first description of the oculopharyngeal muscular dystrophy (OPMD) 
phenotype in Dutch patients shows that limb girdle weakness can occur early in 
the course of disease and can give the first and major complaint in OPMD 
patients. The aim of this study was to examine clinically, histologically and 
genetically all Dutch OPMD-patients known at the Neuromuscular Centre 
Nijmegen, to measure the limb girdle weakness (MRC scale) and to quantify the 
consequences of the limb girdle weakness on daily activities (Rankin scale). 
Remarkable in this population was the early onset and the severity of the limb 
girdle weakness. We found a higher percentage of patients with limb girdle 
weakness than  reported before in non-Dutch OPMD populations. This limb 
girdle weakness caused of limitations in daily activities more than the other 
symptoms of OPMD. It was difficult to compare the severity of the limb girdle 
weakness of Dutch patients with other patients because of the lack of data 
related to quantification of limb girdle weakness in non-Dutch OPMD-patients. 
Because of the influence of the limb girdle weakness on the daily activities of 
the patients, we recommend that more attention is paid to the proximal limb 
muscles in OPMD patients early in the course of the disease. 
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Introduction 
Oculopharyngeal muscular dystrophy (OPMD) is an established entity clinically, 
histologically as well as genetically. The disease was first described as an 
independent clinical entity in a kinship of French-Canadian lineage in 1915 [19]. 
Later this muscle disorder was described in various ethnic groups [1-3,8,14-16]. 
OPMD is a late-onset autosomal dominant dystrophy, and is clinically 
characterised by slowly progressive ptosis of the upper-eyelids, dysphagia, and 
dysphonia [23]. Symptoms such as external ophthalmoplegia, and facial and 
proximal limb weakness develop subsequently [7, 21]. Sporadically limb girdle 
weakness has been described as the initial symptom of OPMD [10, 12].  
OPMD is histologically characterised by unique nuclear filamentous inclusions 
within skeletal muscle fibres observed by electron microscopy [20]. A typical, 
but not specific, finding in muscle biopsy specimens of OPMD patients is the 
presence of basophilic-rimmed vacuoles of autophagic nature [24]. 
Genetical investigation in OPMD patients has revealed close linkage to 
chromosome 14q11.2-q13 [4,9]. A GCG repeat expansion has been found in 
exon 1 of the polyadenylate binding protein nuclear 1 (PABPN1) gene 
(previously called poly (A) binding-protein 2, PABP2, gene) at this locus. It has 
been suggested that the GCGn-repeat, encoding a polyalanine tract, could be 
responsible for the accumulation of undegradable polyalanine rich molecules 
forming the unique nuclear filaments [5]. In 2000 Uyama et al. did confirm that 
the intranuclear filamentous inclusions indeed contain mutated PABPN1 protein 
[22]. How the accumulation of mutated PABPN1 protein in the nucleus of the 
skeletal fibre leads to the symptoms of OPMD is still subject of research. 
Based on our observation of large variation of the OPMD phenotype in Dutch 
patients, with remarkable frequency of complaints of limb girdle weakness, we 
wondered if the limb girdle weakness is indeed an important complaint in Dutch 
OPMD-patients, and if this group differs from the previously reported OPMD-
patients. The aim of this study was to examine clinically, histologically as well as 
genetically all Dutch OPMD-patients known at the Neuromuscular Centre 
Nijmegen, to measure the limb girdle weakness and to quantify the 
consequences of the limb girdle weakness on daily activities.  
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Methods 
Patients 
A review of the patient database of the Neuromuscular Centre Nijmegen yielded 
eight patients from six families recorded having OPMD. All these patients were 
visited and a family tree of all six families has drawn up. The relatives of the 
patients, who had the same symptoms as the patients already known to us, 
were also contacted and asked to participate in this study. All participating 
persons gave their informed consent before they were included in this study.  
To verify the diagnosis of OPMD we have used the diagnostic criteria described 
by Brais [6]: the three major criteria being 1) positive family history, 2) ptosis or 
previous surgical correction, and 3) dysphagia. Other minor criteria were 
analysed, such as age at onset (after 40 years), limitation of eye movements, 
and facial, tongue and limb weakness. Exclusion criteria were also checked: 
severe external ophthalmoplegia before the age of 60 and the presence of 
myotonia. 
Using these clinical diagnostic criteria of Brais one family with 2 affected 
siblings of non-consanguineous healthy parents, was excluded from this study 
owing to the early appearance of symptoms (at 20 and 25 years), severe 
external ophthalmoplegia before the age of 60, limb weakness which was more 
distal than proximal and presumably autosomal recessive inheritance. PABPN1 
mutation screening in both patients showed a normal GCN repeat of 10. These 
two siblings suffered from oculopharyngodistal myopathy, and have previously 
been described in a case report [11]. 
The five remaining families with 6 patients from our centre fulfilled the Brais 
criteria. These families included 50 members known to be affected clinically, 22 
of whom were still alive. Sixteen (10 men and 6 women) of the 22 OPMD 
patients agreed to participate in this study (table 1). 
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Table 1. Clinical features of the presented 16 patients from 5 OPMD 
families.                      
Family 
number 
Patient Sex Age at 
onset 
(years) 
First 
complaint 
First 
symptom 
GCG 
repeat  
in 
proband 
Histology of 
muscle 
Rankin 
score 
EM LM 
1 III 7 M 49 limb girdle 
weakness 
ptosis 10   2 
1 III 4 M 53 Ptosis ptosis 10 + (a) + 3 
2 III 1 M 58 limb girdle 
weakness 
ptosis 10   4 
2 III 8 M 50 limb girdle 
weakness 
ptosis 10   1 
2 III 10 M 52 limb girdle 
weakness 
ptosis 10 +  2 
2 III 4 M 49 Ptosis ptosis 10 + + 4 
2 III 28 M 45 limb girdle 
weakness 
limb girdle 
weakness 
10 +  2 
2 III 16 F 43 Ptosis ptosis 10   1 
2 III 18 F 50 limb girdle 
weakness 
ptosis 10   3 
2 III 13 F 48 limb girdle 
weakness 
ptosis 10   4 
3 III 19 M 52 dysphagia dysphagia 10 +  3 
3 IV 3 M 52 dysphagia dysphagia 10   2 
3 IV 11 M 45 ptosis ptosis 10   2 
3 IV 31 F 41 dysphagia dysphagia 10   1 
4 III 11 F 58 ptosis ptosis 10 + + 3 
5 II 1 F 44 ptosis and 
dysphagia 
ptosis and 
dysphagia 
NA + + 2 
NA = not available; + = has been perform; LM = Light microscopy; EM = Electron 
microscopy;  
(a) = m. constrictor pharyngis 
 
Medical history 
A standardised questionnaire was developed for this study in which special 
attention was paid to the age at onset, the initial symptom, the progression of 
clinical symptoms, dropping of the upper eyelid, swallowing difficulties, location 
of weakness, difficulty climbing stairs, rising from a low seat, difficulty combing 
hair and lifting something above the head. The questionnaire has been 
completed by all patients.  
Because of the results of the questionnaire we were wondered if patients who 
said to have weakness of the proximal muscles of their legs before the ptosis 
appeared, really did not have a ptosis when the complaints of their legs started. 
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To investigate this photographs of the face of these patients were studied at the 
age of onset of complaints of limb girdle weakness. 
To quantify the consequences of OPMD on daily activities of the patients we 
used the Modified Rankin scale (0 to 5) [18]. 
Clinical evaluation 
Each patient underwent a structured clinical neurological examination 
performed by one of us (B vd S), including a standardised measurement of 
muscle strength of the arms and legs, proximal and distal, using the Medical 
Research Council (MRC) grading scale (0 to 5). The following muscles were 
measured: m.deltoideus, m.triceps brachii, m. biceps brachii, extensors and 
flexors of the hand, m. gluteus maximus, m. iliopsoas, m. quadriceps femoris, 
m. tibialis anterior, m. soleus. 
Muscle Biopsies 
Quadriceps muscle biopsy specimens in each of these families’ proband were 
studied with histochemical reactions routinely performed at our laboratory. 
Specimens were also prepared for electron microscopy according to standard 
procedures [13]. 
Genetic investigations 
To screen and sequence the PABPN1 gene genomic DNA was extracted from 
the blood lymphocytes according to standard protocols, and amplified by 
polymerase chain reactions essentially as described [5] using forward primer 5’-
TGGCGCAGTGCCCGCCTTAGA-3’ and reverse primer 5’-
ACAAGATGGCGCCGCCGCCCCGGC-3’. After purification the same primers 
were used for sequence analysis of the amplified fragment on an ABI 3700 
sequence analyser with the BigDye terminator kit (version 2, Applied 
Biosystems, Nieuwerkerk a/d Yssel, The Netherlands). 
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Results   
Medical history 
The data obtained from the questionnaire showed that the presenting symptom 
had been limb girdle weakness in 7 (44%) patients, bilateral ptosis in 5 (30%) 
and dysphagia in 3 (19%) patients. In one patient bilateral ptosis and dysphagia 
appeared at the same time. The mean age at symptom appearance was 49 
years (range, 41-58 years). Assessing the exact age at onset was difficult 
because of the very slow progression of the symptoms. The time lag between 
the first symptom of OPMD and the second varied considerably (mean 3 years, 
range 1-11). Different patterns of progression of the clinical features (revealed 
by completing the questionnaire) were observed (table 2).  
Table 2. Patterns of progression of muscle weakness in 10 to 20 years.   
n = number of patients 
Because of the relatively large percentage of patients who reported limb girdle 
weakness as first symptom we have studied photographs of their faces made at 
the time of onset of the complaints of limb girdle weakness and found that 6 of 
the 7 patients already had ptosis when they start complaining of weakness of 
the limb girdle muscles (table 2). Thus, although ptosis appeared earlier than 
weakness of the limb girdle, the first complaint made by the patients was the 
loss of strength of the proximal leg muscles.  
At the time of this study all patients suffered from ptosis. Seven patients had 
undergone surgery for bilateral ptosis and in three cases surgical correction was 
planned. All patients complained of dysphagia. They ate very slowly compared 
to others, and needed more time to chew and swallow to avoid choking. Four 
patients lost weight as a result of severe dysphagia, 2 patients were on a high-
caloric diet, and 2 others had undergone a cricopharyngeal myotomy.  
The Rankin scale quantifies the independence of patients. Even though ptosis 
and dysphagia give limitations both do not influence the independence of the 
Patterns of progression of the clinical 
symptoms 
Result of 
questionnaire 
Results of studying 
photographs of the  
face 
Ptosis and dysphagia o Limb girdle weakness  6 %   (n = 1) 6 %   (n = 1)    
Ptosis o Limb girdle weakness o Dysphagia   30 % (n = 5) 69 % (n = 11)  
Dysphagia o Ptosis o Limb girdle weakness   19 % (n = 3) 19 % (n = 3)    
Limb girdle weakness o Ptosis and dysphagia  25 % (n = 4) 0 %        
Limb girdle weakness o Ptosis o Dysphagia    19 % (n =3) 6 %   (n = 1)    
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patient, but limb girdle weakness does. In our population 4 of 16 patients had 
Rankin score 3, i.e. these patients had moderate disability, required some help, 
but were able to walk without assistance (table1). Three other patients scored 4, 
they had moderately severe disability, were unable to walk without assistance, 
and unable to attend to their own bodily needs without assistance. Thus the 
limb girdle weakness is really an important complaint, which influences the daily 
activities and independence of the OPMD patients.  
Clinical evaluation 
At neurological examination all 16 patients (mean age 60 years, range 46-79) 
showed ptosis, which was often accompanied by compensatory contractions of 
the frontalis muscles. Four patients had a bilateral symmetrical ptosis. Three 
patients over the age of 60 years had minor limitations of eye movements and 
13 patients also showed weakness of other facial muscles than external ocular 
musculature.  
Most remarkable in our patients was the limb girdle weakness of the hip and 
thigh muscles (figure 1) found by measurement of the muscle strength using the 
MRC scale. The mean strength of hip and thigh muscles was MRC 3 (range 1-
5). Thirteen patients had difficulty climbing stairs and nine of them also had 
problems getting up out of a chair. Seven patients also showed weakness 
(MRC 3-4) of the shoulder musculature. 
Figure 1. The mean (with one SD) muscular strength (MRC scale) of 16 
Dutch OPMD patients, showing that OPMD is a limb girdle syndrome more 
pronounced in lower than upper limbs. 
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Muscle Biopsies 
Histological data were available of all five families (table 1): six patients from 
four families underwent a biopsy of the quadriceps muscle. In the other family, 
we examined a biopsy of the m. constrictor pharyngis, which was obtained 
during a cricopharyngeal myotomy. All muscle biopsies showed non-specific 
myopathic findings, including abnormal variation in fibre size, increased 
endomysial connective tissue, increased percentage of type 1 fibres, and a 
larger number of internal nuclei. The typical, but not specific, basophilic-rimmed 
vacuoles were observed in all specimens. Electron microscopy of the 
specimens revealed intranuclear inclusions typical for OPMD in 4 of the 5 
families investigated. 
Genetic investigation 
Sequence analysis was performed in patients of families 1,2,3 and 4, and 
showed a GCG repeat expansion (from 6 to 10 GCG repeats for all patients) in 
exon 1 of the PABPN1 gene on chromosome 14q11.2-q13. All patients were 
heterozygous for the GCG-repeat mutation. Two families [2,3] showed a perfect 
repeat, which contained (GCG)10. The patients of the other two families [1,4] 
did not show a perfect one, their repeat contained (GCG)6(GCA)2(GCG)2 [17]. 
  
Discussion 
This first description of Dutch OPMD patients shows that limb girdle weakness 
can occur early in the course of the disease and can give the first and major 
complaint in OPMD patients. The diagnosis OPMD was made clinically 
according to the diagnostic criteria of Brais [6] and confirmed histologically and 
genetically by respectively the finding of characteristic intranuclear tubular 
filaments and a GCG repeat expansion in the PABPN1 gene. The clinical 
examination of the Dutch patients was comparable to those of non-Dutch 
OPMD families described in the literature [1-3, 8, 14-16], but remarkable was 
the early onset and severity of the limb girdle weakness. A relatively large 
percentage of patients had complaints of limb girdle weakness before they had 
noticed ptosis themselves. It is important to notice the weakness of the limb 
girdle muscles, because it is the symptom that causes evident limitations in 
daily activities and influences the independence of OPMD patients.  
Information on the course of the disease until this investigation was obtained 
from the patients themselves by completing the questionnaire; therefore 
conclusions have to be drawn with care. To confirm the data about the initial 
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symptom given by the patients, especially if patients whose first complaint was 
limb girdle weakness really did not have ptosis when started the complaints of 
proximal leg weakness started, we studied photographs of the face of our 
patients. We found that even though the patients said to have weakness of the 
limb girdle muscles before having a ptosis, 6 of the 7 patients already had a 
ptosis when they started complaining of limb girdle weakness. The reason that 
ptosis is noticed relatively late by the patient might be multifaceted. First 
complaints of ptosis begin just when the upper eyelid has dropped so far that it 
gives limitations of the fields of vision. Second when the upper eyelid drops 
patients unconsciously raise the eyebrows. Third when compensation by 
contraction of the muscle frontalis fails patients automatically hold their head 
backwards (astrologist’s posture). 
Although the disease is named oculopharyngeal muscular dystrophy, it is 
generally stated that the muscular weakness is not restricted to the ocular and 
pharyngeal muscles. Symptoms such as facial and proximal limb weakness are 
reported in different OPMD populations. In the presented Dutch population a 
relatively high percentage of OPMD patients had proximal weakness compared 
with non-Dutch populations (table 3), whereas the histological and genetical 
characteristics were comparable. From the literature we deduced that in non-
Dutch populations OPMD patients complain of dropping of upper eyelids 
several years before they notice weakness of the limb girdle muscles, this in 
contrast to our observations in Dutch patients. We appear to be the first to 
systematically quantify the muscle force of muscles of the extremities of OPMD-
patients. It is difficult to compare the severity of the limb girdle weakness of our 
patients with others because of the lack of data related to quantification of this 
weakness in non-Dutch OPMD-patients.  
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Table 3. Clinical features of the 16 patients presented compared to 7 other 
groups of OPMD patients, published in the literature [1-3, 8, 14-16].        
 Number of patients (%) 
Clinical 
features 
The 
presented 
Dutch 
patients 
Italy     
[15]  
Uruguay 
[14] 
France   
[8] 
Quebec   
[3] 
Israel    
[2] 
Germany 
[16] 
New 
Mexico  
[1] 
Ptosis 
 
 
16 (100) 5 (100) 65 (100) 28 (97) 72 (100) 115 
(98) 
16 (100) 45 (92) 
Dysphagia 
 
 
16 (100) 4 (80) 65 (100) 20 (69) 72 (100) 87 (73) 10 (62) 37 (76) 
Dysfonia 
 
12 (75) ND ND 10 (34) 48 (67) 82 (70) 4 (25) ND 
Eye 
movement  
 limitations  
  
 
3 (19) 
 
ND 
 
43 (66) 
 
16 (55) 
 
35 (49) 
 
24 (21) 
 
5 (31) 
 
ND 
Proximal  
 Weakness 
 
 
13 (81) 
 
3 (60) 
 
22 (34) 
 
15 (52) 
 
51 (71) 
 
23 (20) 
 
9 (56) 
 
32 (65) 
Facial  
 weakness 
 
13 (81) 
 
3 (60) 
 
44 (68) 
 
ND 
 
31 (43) 
 
20 (17) 
 
2 (13) 
 
ND 
         
ND = Not Described 
Sporadically limb girdle weakness has been described as initial symptom of 
OPMD [10, 12]. Hill described the phenotypical and genetical features of OPMD 
in a UK population, 3 patients had limb girdle weakness as initial symptom. 
Lampe et al. described one patient with genetically proven OPMD, who 
presented with exercise-induced proximal muscle pain and weakness of the 
lower limbs. One year later she noticed dropping of her upper eyelids bilaterally 
and dysphagia. In both papers it is not obvious if the order of presentation of 
symptoms is confirmed by the investigator or if the information is obtained by 
history taking only, an investigation of photographs of the face of the patients to 
confirm if they really did not have a ptosis when they start complaining of 
weakness of the limb girdle muscles is not mentioned. It might be that all the 
patients of Hill and Lampe also had ptosis before they complained of weakness 
of the proximal leg muscles, as we found in our own patients.  
To investigate prospectively the age at onset and the development of muscle 
weakness of the extremities in Dutch OPMD patients we have to follow up 
(pre)symptomatic patients. During this study we have become acquainted with 
five large OPMD families with many family-members under the age of 40 years, 
some of whom will certainly be presymptomatic carriers of the PABPN1 
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mutation. Future investigations will be directed towards prospectively studying 
the limb girdle weakness in Dutch OPMD patients.  
On the basis of our findings we conclude that limb girdle weakness can give the 
first complaint and the major complaint in OPMD patients, even before the 
patients mention ptosis and that limb girdle weakness give evident limitations in 
daily activities of these patients. Therefore we recommend that more attention is 
paid to the proximal musculature in OPMD patients early in the course of the 
disease. 
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Abstract 
Oculopharyngeal muscular dystrophy (OPMD) is a late onset autosomal 
dominant muscle disorder. The OPMD-locus has been mapped to chromosome 
14q11.2-q13. The polyadenylate binding protein nuclear 1 (PABPN1; PABP2) 
gene has been identified as the mutated gene. The mutation consists of a short 
meiotically stable trinucleotide repeat in the first exon of PABPN1 gene. We 
have investigated Dutch OPMD patients from four unrelated families and 
identified a new mutation in two of the four families. Instead of a repeat 
expansion we found a duplication in the first exon of the PABPN1 gene (27-
28ins12, AAAA11-12 ins). The identification of this new mutation supports the 
theory of unequal crossing-over as molecular mechanism causing the mutation 
in the PABPN1 gene responsible for OPMD, and not the slippage model.  
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Introduction 
Oculopharyngeal Muscular Dystrophy (OPMD, OMIM 164300) is a muscle 
disorder with autosomal dominant inheritance, which becomes symptomatic 
after the age of 40. OPMD has been described in different ethnic groups around 
the world.  
OPMD is clinically characterised by slowly progressive bilateral dropping of the 
upper eyelids (ptosis), swallowing difficulties (dysphagia) and proximal limb 
weakness.  The histological hallmark of OPMD is the accumulation of unique 
intranuclear filaments in skeletal muscle fibers (Tome et al. 1995).  
The largest OPMD population has been found in Quebec, most patients are 
offspring of a French couple, who emigrated to Canada in 1634. In 1995 Brais 
et al. showed linkage to chromosome 14q11.2-q13 in this French-Canadian 
OPMD population (Brais et al. 1995). Three years later they identified the gene 
responsible for OPMD (Brais et al. 1998). They demonstrated short meiotically 
stable trinucleotide (GCG) expansions (between 8 and 13) in the first exon of 
the polyadenylate binding protein nuclear 1 (PABPN1) gene (previously called 
polyadenylation binding protein 2, PABP2, gene). A normal PABPN1 gene 
contains a (GCG)6 repeat followed by (GCA)3(GCG). This stretch is translated 
into 10 alanine residues in the protein, because GCG as well as GCA is 
translated into an alanine residue. The most frequently occurring mutation in the 
French-Canadian population is the expansion from (GCG)6 to (GCG)9 repeats, 
adding three extra alanine residues to the protein. Studies confirmed that the 
intranuclear filamentous inclusions indeed contained mutated PABPN1 protein 
(Uyama et al. 2000.; Calado et al. 2000), suggesting that the expansion of the 
polyalanine tract of the protein causes aggregation of the mutated protein. 
Dorsman et al. suggest on the basis of their data that it is likely that expanded 
polyglutamine repeats are relatively well tolerated in nature compared with other 
homopolymeric amino acid repeats sequences such as hydrophobic polyleucine 
and polyalanine, owing to their strong propensity for aggregation. They show 
that polyleucine stretches are more toxic to mammalian cells than polyglutamine 
stretches and suggest that polyalanine stretches may also be toxic via similar 
mechanisms (Dorsman et al. 2002).  
After the identification of the mutation in the French-Canadian OPMD population 
genetic analysis has been performed in other OPMD patients from different 
ethnic origin. In patients from Germany, USA, Israel, UK, Italy and Japan the 
same mutation has been observed (Muller et al. 2001; Grewal et al. 1999; 
Blumen et al. 2000; Hill et al. 2001; Mirabella et al. 2000; Nagashima et al. 
2000). 
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Because of our interest in the Dutch OPMD population, we contacted all OPMD 
patients known at the Neuromuscular Centre Nijmegen, The Netherlands. We 
prospectively examined 16 OPMD patients (from 4 families) clinically, 
histologically as well as genetically. The clinical and histological characteristics 
of these patients, which were typical for OPMD are summarised in the results 
section. Here we present the results of the genetic analysis.  
  
Subjects and methods 
Subjects 
Sixteen Dutch patients from 4 different families with OPMD have participated in 
this study (see Table 1). The diagnosis OPMD has been made according to the 
clinical criteria of Brais et al. (Brais et al. 1995): three major criteria 1) positive 
family history, 2) ptosis or previous surgical correction, and 3) dysphagia. 
Exclusion criteria were severe external ophthalmoplegia before the age of 60 
and the presence of myotonia.  
Methods 
We have prospectively examined the 16 OPMD patients. A standardised 
questionnaire was developed for this study in which special attention was paid 
to the clinical characteristics of OPMD. After completion of this questionnaire by 
the patients, a structured clinical neurological examination was performed by 
one of us (B. M. van der Sluijs). Finally blood was obtained for DNA analysis. 
Genomic DNA was extracted from blood lymphocytes according to standard 
protocols, and amplified by polymerase chain reactions essentially as described 
(Brais et al. 1998) using forward primer 5’-TGGCGCAGTGCCCGCCTTAGA-3’ 
and reverse primer 5’-ACAAGATGGCGCCGCCGCCCCGGC-3’. After 
purification the same primers were used for sequence analysis of the amplified 
fragment on an ABI 3700 sequence analyser with the BigDye terminator kit 
(version 2, Applied Biosystems, Nieuwerkerk a/d IJssel, The Netherlands). 
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Table 1. 16 Dutch OPMD patients 
Sex / 
Age 
(yrs)    
Family 
number 
Age  
at onset 
(yrs) 
First 
symptom 
(paresis) 
Bilateral 
ptosis, 
dysphagia 
Arm prox. 
Muscle 
Strength 
(MRCb) 
Leg prox. 
Muscle 
Strength 
(MRCb) 
GCG 
Expansion or 
Duplication 
M/59 1 49 Ptosis + 4 3 Expansion 
M/63 1 53 Ptosis + 3 2 Expansion 
F/48 2 43 Ptosis + 5 4 Duplication 
F/53 2 48 Limb girdlec + 5 4 Duplication 
M/53 2 45 Limb girdle + 4 3 Duplication 
M/58 2 52 Ptosis + 5 4 Duplication 
M/61 2 50 Ptosis + 5 4 Duplication 
F/64 2 50 Ptosis + 4 4 Duplication 
M/66 2 58 Ptosis + 4 2 Duplication 
M/66 2 49 Ptosis + 4 2 Duplication 
F/46 3 41 Dysphagia + 5 5 Duplication 
M/53 3 50 Ptosis + 5 5 Duplication 
M/55 3 45 Ptosis + 5 4 Duplication 
M/64 3 52 Dysphagia + 5 4 Duplication 
M/79 3 52 Dysphagia + 3 2 Duplication 
F/71 4 58 Ptosis + 5 3 Expansion 
M/F 
11/5 
 50(41-58)  + 4 3  
a: M = male; F = female 
b: MRC = Medical Research Council scale (a practical clinical classification to quantify 
muscle strength of individual muscle groups: zero movement in the muscle is MRC 0, full 
strength is MRC 5 and antigravity power  MRC 3) 
c: Limb girdle weakness of proximal limb muscles                                                                                
 
Results 
The phenotype of the 16 patients (see Table 1) was comparable to those of 
non-Dutch OPMD patients described in the literature. At the time of this study all 
the patients suffered from ptosis and dysphagia. Thirteen patients had difficulty 
climbing stairs and nine of them also had problems getting up out of a chair as 
result of limb girdle weakness. We noticed that although it is generally stated 
that the initial symptoms of OPMD are ptosis and dysphagia, limb girdle 
weakness can be the major complaint, and not only an important symptom later 
on in the course of the disease. Quadriceps muscle biopsies showed aspecific 
dystrophic alterations, rimmed vacuoles and on electron microscopy the 
intranuclear filamentous inclusion bodies that are typical for OPMD.  
DNA analysis revealed two different mutations. First we found an expansion of 
the GCG repeat in the first exon of the PABPN1 gene as described by Brais et 
al. (Brais et al 1998) in two of the four families. One family showed an 
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expansion to 10 (GCG) trinucleotides and the second family to 12. The patients 
of the two other families did not show expansion of the GCG repeat, but a 
duplication of (GCA)2(GCG)2 (27-28ins12, AAAA11-12ins). They showed 
(GCG)6(GCA)2(GCG)2(GCA)3GCG instead of normal (GCG)6(GCA)3GCG in 
the first exon of the PABPN1 gene. 
  
Discussion 
The main finding of the genetic analysis of the Dutch OPMD patients from four 
different families was a new mutation in the first exon of the polyadenylate 
binding-protein nuclear 1 (PABPN1; PABP2) gene. Patients from two families 
showed besides a normal allele (GCG)6(GCA)3(GCG), a mutated allele 
(GCG)6(GCA)2(GCG)2(GCA)3(GCG). Instead of expansion of the GCG repeat 
from 6 to 8 – 13, they had a duplication of (GCA)2(GCG)2. The patients of the 
other two families showed GCG repeat expansion as described by Brais et al. 
(Brais et al. 1998). Because GCG and GCA are both translated into an alanine 
residue the duplication like the trinucleotide repeat expansion causes an 
enlargement of the alanine stretch on the level of the protein (the total number 
of alanine residues resulting from the duplication is 14, instead of 10 in a normal 
PABPN1 protein). Thus both mutations cause the same alteration in the protein. 
Accordingly we found a comparable phenotype in the four families and this 
phenotype is similar to that described in literature. 
The identification of an identical new mutation in two different families suggests 
that a founder effect exists. Although we traced one family back to 1640 and the 
other to 1860 a relationship between the two families could not be established. 
Therefore the relationship between both families and the mutation 
((GCG)6(GCA)2(GCG)2(GCA)3(GCG)) have to be older than 150 years. This 
suggests that this mutation is meiotically very stable. 
This new mutation can be helpful in the understanding of the molecular 
mechanism causing the mutation in the PABPN1 gene responsible for OPMD. 
The slippage model has been put forward as the molecular mechanism 
responsible for the GCG repeat expansion. The slippage model can be used to 
explain the pathologic repeat expansions, which are responsible for some 
hereditary neurodegenerative disorders, such as Huntington disease, and 
neuromuscular disorders, such as Myotonic Dystrophy (Wells R.B, 1996). 
Myotonic Dystrophy type 1 (DM1) is caused by a CTG repeat expansion in the 
Myotonic Dystrophy Protein Kinase (DMPK) gene on chromosome 19q13.3. 
The differences between the trinucleotide repeat expansions of OPMD and the 
expansions in trinucleotide repeat diseases as for example DM1 are several. 
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First, the OPMD mutation shows meiotic stability. The length of the GCG repeat 
is the same in subsequent generations, whereas the repeat length of DM1 can 
vary considerably in consecutive generations. Second, the OPMD mutation 
shows mitotic stability. That means that all cells of an OPMD patient have the 
same repeat length, while the CTG repeat in patients with DM1 can differ from 
cell to cell. Third, the nature of the repeat differs. In DM1 the CTG repeat is a 
perfect one. In OPMD the GCG repeat is not perfect, the GCG trinucleotides are 
interspersed with GCA trinucleotides. Fourth, the length of the repeats is 
different. The GCG repeat is normally (GCG)6 followed by (GCA)3GCG, and in 
OPMD expanded to GCG8-13. The normal CTG repeat is 5 to 37, and patients 
with Myotonic Dystrophy have increased repeats between 50 and several 
thousands. It is proposed that a perfect trinucleotide repeat has to consist of at 
least 25 to 35 trinucleotides to become unstable and sensible to expand via 
slippage (Kunst et al. 1994). All in all, the GCG repeat in OPMD seems not 
sensitive to expansion via slippage. 
Our finding of a (GCA)2(GCG)2 duplication resembles the results of two 
previously published reports. First Scacheri et al. (Scacheri et al. 1999) have 
performed DNA analysis in three Cajun families and found unexpectedly a 
different haplotype as identified in the French-Canadian families. Sequencing of 
the expanded allele of the Cajun families revealed an insertion of 3 
trinucleotides consisting of a GCA codon in combination with two GCG codons 
instead of three GCG codons. The mutated allele found in the Cajun families 
showed (GCG)6(GCA)(GCG)2(GCA)3(GCG), whereas a normal PABPN1 allele 
shows (GCG)6(GCA)3(GCG).  
In another publication Nakamato et al (Nakamato et al. 2002) showed the 
results of the PABPN1 gene analysis in patients from two unrelated Japanese 
families with pathologically confirmed OPMD. They found two different mutated 
alleles: (GCG)6GCA(GCG)3(GCA)3GCG and 
(GCG)6(GCA)3(GCG)2(GCA)3GCG instead of the normal (GCG)6(GCA)3GCG 
allele. Nakamato (Nakamato et al. 2002) postulated that the slippage model 
could not be the molecular mechanism responsible for the OPMD mutation, but 
that the mutation is the result of unequal crossing-over.  
Our conclusion is that all these mutations in the two Dutch, three Cajun and two 
Japanese families result from unequal crossing-over. Our data support the 
theory that unequal crossing-over, and not slippage, is the molecular 
mechanism causing mutations in the PABPN1 gene responsible for OPMD. 
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The astrologist’s posture: a useful clinical observation
The astrologist’s posture is characterised by retroflexion of the neck combined 
with downward gaze and is a common compensation for severe bilateral ptosis. 
The term was probable first described by Sir Jonathan Hutchinson although 
references to his original publication are lacking.[1] Although the term 
astrologist’s posture is widely used, we propose that it can be very helpful in 
differentiating between two of the commonest types of adult onset ocular 
myopathies: oculopharyngeal muscular dystrophy (OPMD) and chronic 
progressive external ophthalmoplegia (CPEO).
Although genetically very distinct, the phenotypes can be very alike: both 
disorders commonly present with a grossly symmetrical ptosis which is 
progressive over years, often combined with dysphagia and mild proximal 
myopathy.[1,2] Apart from this overlap in phenotype, there are also differences: 
for example, weakness of muscles involved in ocular motility (ie, external 
ophthalmoplegia) often becomes a prominent feature in CPEO while it is mild or 
absent in OPMD.
As ocular motility is largely unaffected in OPMD, patients commonly use the 
astrologist’s posture to compensate for their ptosis (figure1A). In contrast, 
because of restricted downward gaze, CPEO patients are unable to use the 
astrologist’s posture (figure 1B). A retrospective review of all genetically 
confirmed OPMD and CPEO patients in our centre revealed that 35 of the 39 
(89.7%) OPMD patients use (or, because of surgical eyelid correction, used) the 
astrologist’s posture. In contrast, we observed the astrologist’s posture in only 
two of 28 (7.1%) CPEO patients, both with only mild downward gaze paralysis
(Pearson chi-squared test, p<0.001).
We therefore suggest that the astrologist’s posture can be helpful to make a 
“diagnosis from the door” in patients with slowly progressive bilateral ptosis: the 
absence of the astrologist’s posture suggests downward gaze paralysis which is 
compatible with a diagnosis of CPEO.
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Figure 1. Patient with oculopharyngeal muscular dystrophy
(A) compensates for his bilateral ptosis with the astrologist’s posture. Because 
of restricted downward gaze, the patient with chronic progressive external 
ophthalmoplegia (B) is unable to use this compensation.
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Abstract 
Background: Ptosis and dysphagia are two important features in 
oculopharyngeal muscular dystrophy (OPMD). 
Objective: Retroflexion of the head is a well-known compensatory mechanism 
for ptosis, but generally retroflexion has a negative effect on swallowing. We 
hypothesised that the severity of ptosis is related to the degree retroflexion and 
that this compensation is responsible for deteriorating dysphagia. 
Methods: Nine OPMD-patients were examined in the conditions ‘head position 
adapted to ptosis’ and ‘head position slightly flexed’. Ptosis was quantified by 
photogrammetry and retroflexion of the head by digital photographs. The 
severity of dysphagia was measured using visual analogue scales (VAS) and by 
calculating the swallowing volumes and the oropharyngeal swallow efficiency 
(OPSE) based on videofluoroscopy. 
Results: Statistical analyses show a significant relationship between ptosis and 
degrees of retroflexion. The degrees retroflexion of the head correlated 
significantly with the VAS scores and with the maximum swallowing volume. 
The slightly flexed head position significantly improved VAS scores as well as 
the swallowing volumes and OPSE.  
Conclusion: In OPMD-patients, ptosis significantly correlates with retroflexion of 
the head, which has a negative effect on swallowing. A subjective and objective 
reduction of swallowing problems was found when patients were instructed to 
eat and drink with a slightly flexed head position. 
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Introduction 
Oculopharyngeal muscular dystrophy (OPMD) is an adult onset, usually 
autosomal dominant, slowly progressive muscle disorder.[1] The most striking 
feature is bilateral ptosis, which ultimately limits the vision. To compensate for 
ptosis, patients contract their frontal muscles and hold their head in retroflexion 
(astrologist’s posture).[1] Another important feature is dysphagia, which can 
cause life threatening complications, for instance aspiration pneumonia.  
We hypothesised that in OPMD-patients, the combination of astrologist’s 
posture and pre-existing dysphagia can aggravate dysphagia. In healthy 
people, retroflexion of the head has a negative effect on swallowing, by 
widening of the laryngeal entrance, narrowing the valleculae and decreasing the 
upper oesophageal sphincter relaxation, causing less adequate bolus 
passage.[2-3] 
In this study, we tested the hypothesis that the severity of ptosis is related to the 
degree of retroflexion of the head and that this is responsible for a deterioration 
of the dysphagia in OPMD-patients. In addition, we investigated the effect of a 
slightly flexed head position on dysphagia. 
  
Methods 
Subjects 
Nine consecutive, genetically proven OPMD-patients (five women and four 
men) were included in the study. The mean age was 57 years (range 43 - 69 
years). Patients who had undergone a cricopharyngomyotomy or were going to 
undergo operation were excluded, as were those who had had ptosis corrected 
surgically. Informed consent was obtained from each patient and the local 
ethical committee approved the study. 
Procedure 
The ophthalmologist quantified the ptosis by photogrammetry. Frontal digital 
photographs of each patient’s face were taken while the patient was positioned 
in a standard ophthalmic headrest. The patients were instructed to relax their 
face and to look at a fixed distant point straight ahead. A 245 mm lens was used 
and the camera to subject distance was 3 m. A metal ruler was fitted on the 
headrest in the plane of the patient’s eyes to serve as a scale. Ptosis was 
defined as the distance between the edge of the upper eyelid and the midpoint 
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of the pupil in millimetres.[4] Ptosis of both eyes was measured and the average 
ptosis was calculated. 
During the study, each patient was examined in two different conditions: first in 
the condition “head position adapted to ptosis”, that is patients were asked to 
eat and drink without any instructions, and second “head position slightly 
flexed”, that is after instructions. In the condition “head position adapted to 
ptosis” retroflexion was measured using digital photography. 
Functional swallowing measurements were performed by a speech therapist. 
Patients were asked to quantify their disabilities as regards eating and drinking 
for the conditions described above on a visual analogue scale (VAS). To 
objectively investigate the dysphagia, the maximum swallowing volume (the 
amount of water the patient is able to take with only one swallow) was 
measured in both conditions. The oropharyngeal swallow efficiency (OPSE) 
was also calculated in both conditions using videofluoroscopy with 20 ml of thin 
liquid barium and 20 ml of thick liquid barium. OPSE is a measure to quantify 
patient’s ability to transport a food bolus efficiently and safely from the oral 
cavity to the oesophagus.[5] It is the ratio between the amount of the bolus that 
is swallowed during the first swallow and the oropharyngeal transit time. OPSE 
increases when a larger amount of material is swallowed during the first 
swallow and when the oropharyngeal transit time decreases.  
Statistical analyses 
Statistical analyses were conducted with SPSS 11.0 (SPSS, Chicago, IL, USA). 
The Spearman correlation coefficient was used for calculating the correlation 
between the degree of retroflexion of the head and the severity of the ptosis, 
between the degree of retroflexion and the VAS-scores in the condition “head 
position adapted to ptosis”, and between the degree of retroflexion and the 
maximum swallowing volume. With the Wilcoxon non-parametric test, the effect 
of changing head position from retroflexion to slight flexion on the VAS-scores, 
the maximum swallowing volume, and the OPSE were tested. The level of 
significance was set at 0.05. 
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Results 
In the condition “head position adapted to ptosis”, the degree of retroflexion of 
the head (table 1) correlated significantly with the average ptosis (r=-0.824; 
p=0.006) as well as with the VAS-scores in the same condition (eating: r=0.701; 
p=0.035 / drinking: r=0.767; p=0.016), and also with the maximum swallowing 
volumes (r=-0.831; p=0.011). 
In the condition “head position slightly flexed”, the VAS scores improved 
significantly compared to “head position adapted to ptosis” (eating: z=-2.533, 
p=0.011; drinking: z=-2.375, p=0.018). The swallowing volumes were 
significantly larger in the “head position slightly flexed” than in the condition 
“head position adapted to ptosis” (z=-2.527; p=0.012) (figure 1). This 
corresponds with the significant increase of the OPSE in the condition “head 
position slightly flexed” (thin liquid: z=-2.240; p=0.025 and thick liquid: z=-2.201; 
p=0.028). 
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Table 1. Characteristics of and results in OPMD patients.  
9 8 7 6 5 4 3 2 1 
N
o 
Patient 
characteristics 
69 
52 
57 
60 
43 
63 
62 
56 
55 
A
ge 
F F F 
M
 
F 
M
 
F 
M
 
M
 
S
ex 
2.45 
1.76 
2.66 
0.53 
2.84 
0.61 
2.54 
3.46 
1.18 
A
verage 
Ptosis 
(m
m
) 
19 
24 
4 
26 
1 7 
16 
1 
24 
H
ead 
retro- 
flexion 
(degrees) 
84 
83 
85 
72 
96 
83 
100 
96 
78 
retr 
VA
S-scores, 
fluid 92 
87 
91 
76 
96 
90 
100 
97 
84 
flex 
82 
53 
56 
47 
77 
56 
71 
86 
56 
retr 
VA
S-scores, 
solid 90 
81 
66 
70 
87 
73 
71 
96 
65 
flex 
15 
5 
30 
10 
45 
12 
# 
35 
25 
retr 
Sw
allow
 
volum
es     
(m
l) 30 
8 
38 
17 
55 
20 
# 
40 
30 
flex 
### 
60.3 
# 
43.6 
64.4 
90 
57.6 
64 
41.9 
retr 
O
PSE 20 m
l 
thin liquid 
### 
89.29 
# 
75.89 
79.17 
132.4 
60.63 
81.07 
60.8 
flex 
### 
## 
# 
70.8 
40.8 
54.1 
41 
47.3 
50.5 
retr 
O
PSE 20 m
l 
thick liquid 
### 
## 
# 
73.3 
69 
75.9 
43.5 
64 
52.4 
flex 
 
# Patient 3 and 7 were excluded since they became emotional and anxious because of the risk of 
aspiration; 
## in patient 8, residue after swallowing in extended position could not be rinsed away which made 
interpretation of the videofluoroscopy unreliable;  
### patient 9 aspirated during the first examination with thin liquid barium and had to be excluded 
from further radiological examination.  
Retr, retroflexion: “head position adapted to ptosis”; flex, flexion: “head position slightly flexed”. 
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Figure 1. Maximum swallowing volumes per patient under the conditions 
retroflexion (“head position adapted to ptosis”) and flexion (“head 
position slightly flexed”). 
 
 
Discussion and conclusion 
This study shows that retroflexion of the head because of ptosis results in 
deterioration of pre-existing dysphagia in OPMD-patients. In addition, we 
showed that a slightly flexed head position improves swallowing. Changing 
head position also improves the subjective VAS scores as well as the objective 
swallowing volumes and radiological results. The slightly flexed position 
reduces the time needed for eating and drinking, reduces the amount of 
residue, and thus reduces the lifethreatening risk of aspiration in OPMD. 
It is remarkable that patients are unaware of the negative effect of the 
retroflexion of the head on dysphagia. They accept swallowing problems as part 
of the pharyngeal muscle weakness in OPMD. Furthermore, even instructed 
patients report that they often forget to change head position during eating 
because eating is a social activity during which looking around and facing 
others sitting at the table is normal behavior; while looking continuously 
downwards, to improve swallowing, is not common. Additional support for the 
correlation between ptosis and dysphagia is a patient’s experience of 
improvement of swallowing after surgical ptosis correction; this patient was 
unaware of the effect of head position on swallowing. 
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Based on our data, speech therapists, neurologists and ophthalmologists can 
alleviate the swallowing problems by teaching patients to eliminate the 
compensatory retroflexion of the head during eating and drinking. 
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Abstract 
Oculopharyngeal muscular dystrophy (OPMD) is an adult-onset inherited 
myopathy characterized by progressive eyelid drooping (ptosis), swallowing 
difficulties and proximal limb weakness. Cognitive impairment has long not been 
recognized as a feature of OPMD.  
We report two unrelated OPMD patients with severe genetic defects who 
developed frontotemporal dementia (FTD). These cases support the earlier 
reports of the occurrence of cognitive impairment in OPMD and its possible 
relation to expanded PABPN1 load and add that the cognitive decline may even 
precede limb or girdle muscle weakness.  
Severe PABPN1 mutations should be considered in FTD patients with muscle 
weakness (including dysphagia and ptosis), or those with a positive family 
history of either FTD or muscular dystrophy. Future studies on cognition in 
OPMD patients and on brain tissue from autopsy of OPMD patients are needed 
to better understand the cognitive symptoms in OPMD. This could start with 
cognitive screening of a larger number of patients with different GCN repeat 
length and functional MR studies. 
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Introduction 
Oculopharyngeal muscular dystrophy (OPMD) is an adult-onset inherited 
myopathy, caused by an expanded GCN repeat (12-18; normal repeat length is 
10) in the gene encoding for Poly-Adenylate-Binding-Protein-Nuclear 1 
(PABPN1). The expanded PABPN1 is prone to aggregation forming insoluble 
nuclear aggregates. Nuclear aggregates were found in affected muscles, but 
also in muscle from expPABPN1 carriers at pre-symptomatic stage.  Whether 
PABPN1 aggregates are toxic in OPMD is still unsolved. 
In spite of the ubiquitous expression of PABPN1 protein, symptoms have long 
been considered to be restricted to muscle (ptosis, dysphagia and limb girdle 
weakness).[1] Recently, a number of reports have pointed to brain involvement 
in OPMD patients with long repeat length and those with homozygous 
mutations. Mizoi et al. reported two sibs with genetically confirmed OPMD with 
a (GCN)17 repeat who both presented with dementia at age 63 and 45 years, 
approximately 10 years after the onset of the myopathy.[2] Jouan et al. 
presented four family members (three sibs and a father) with a (GCN)18 repeat 
who all presented with psychiatric and cognitive impairments in middle 
adulthood.[3] Furthermore, a neuropsychological evaluation in 11 heterozygous 
OPMD patients (age range range 35–83 years; repeat lengths (CGN13) to 
(CGN16)) showed executive dysfunctions. There was a negative correlation 
between GCN expansion size and some neuropsychological scores.[4] Brain 
involvement was also described in a case series of 10 homozygous (GCN)13 
OPMD patients. Most patients were followed by psychiatrists due to cognitive 
decline, recurrent depression, or psychotic episodes, starting in early or middle 
adulthood.[5] These observations suggest that brain involvement is linked to the 
severity of the genetic defect and consequently observed in homozygous 
patients and possibly also in heterozygous patients with larger expansion.[4] 
Here we report two unrelated OPMD patients with severe genetic defects who 
developed frontotemporal dementia (FTD). These cases confirm the occurrence 
of cognitive impairment in OPMD and its relation to expanded PABPN1 load. 
Case 1 
A 51-year-old man was referred because of slowly progressive ptosis, memory 
disturbances, and loss of personal and social awareness for 5 years (Fig. 1). 
The patient was unaware of his cognitive limitations. He was fired from his job 
as a prison guard because of malfunctioning at the age of 39, most likely due to 
cognitive decline which had already started earlier. At the age of 51, he lived 
independently and was active in sports, but needed help in his personal and 
financial administration.  He was the only child of non-consanguineous parents. 
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His father had genetically confirmed OPMD. His mother suffered from ptosis, 
dysphagia, and walking difficulties, but had never been tested for OPMD. The 
family history was negative for dementia. PABPN1 genetic analysis revealed a 
compound heterozygous (GCN)12/(GCN)16 mutation. 
Neurological examination revealed mild ptosis and facial weakness. Muscle 
strength was otherwise normal. The Mini Mental State Examination (MMSE; 
table 1) revealed impairments in episodical and semantic memory and writing. 
The Frontal Assessment Battery (FAB, table 1) showed limitations in 
conceptualization, lexical fluency, programming, and inhibitory control. Further 
neuropsychological examination showed a declined intelligence level, disturbed 
attention, inertia, short term memory loss, behavioral problems (mostly of 
disinhibition) and decreased insight. Based on these observations, FTD was 
diagnosed.[6] Further clinical characteristics and results of ancillary 
investigations are presented in table 1.  Follow-up over three and a half years 
showed a mild increase of the ptosis for which he was operated and difficulties 
walking the stairs. An administrator was appointed since he could not manage 
his financial and legal affairs independently. 
Figure 1. Pedigrees of the two cases of oculopharyngeal muscular 
dystrophy (OPMD) with frontotemporal dementia (FTD) 
  
 
GCN16 
? ? 
GCN17 GCN12 GCN16 
Case 1 Case 2 
= No expanded PABPN1 
= One allele with expanded PABPN1 
= Two alleles with expanded PABPN1, index  
   case in family 1 (GCN 16/GCN 12) 
† died of cancer 
GCN12 
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Table 1. Clinical characteristics and results of ancillary investigations. 
 
 
 
 
 
 
 
 
 
 
 
 
M: male; F: female; FAB: Frontal Assessment Battery; PABPN1: Poly-Adenylate-
Binding-Protein-Nuclear 1 
*mild: MRC ≥ 4 
 
Case 2  
A 64-year-old woman was referred with proximal muscle weakness, ptosis and 
difficulty speaking (reduction of speech, volume and stereotypy) since 10 years. 
Her husband noticed loss of initiative, neglect of personal hygiene, diminished 
coherent behavior, and stereotyped behavior. She used a bronchodilator for 
asthma. Her parents were not consanguineous and the family history revealed 
no neuromuscular disorders. Her father had suffered from dementia starting 
around the age of 75, after the loss of his wife. He was admitted at a nursing 
home and died at the age of 80. Her two sons are asymptomatic. 
Neurological examination showed ptosis, dysphagia, dysarthria, and mild 
symmetric muscle weakness of biceps, hamstrings and tibialis anterior (all 
Medical Research Counsil grade 4 over 5). The MMSE (table 1) showed 
impairments in episodical and semantic memory, attention, language 
 Case 1 Case 2 
Age  51 64 
Sex m f 
Medical history none asthma  
Age at onset symptoms 40 50  
Highest level of education Secondary school  
Muscular symptoms  
Ptosis 
 
yes 
 
yes 
Dysphagia 
Muscle weakness: 
Proximal 
no 
 
no 
yes 
 
yes (mild)* 
Distal no yes (mild)* 
MMSE score 20/33 18/33 
FAB score 15/18 7/18 
PABPN1 repeat 
expansion 
(GCN)12/(GCN)16  (GCN)10/(GCN)17 
Brain MRI  Generalized cortical 
atrophy, most 
prominent 
frontotemporal areas 
Aspecific white 
matter lesions, 
frontotemporal 
cortical atrophy 
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understanding, writing and constructive skills. The FAB (Table 1) showed 
impairments in conceptualization, lexical fluency, programming, sensitivity to 
interference and inhibition control. Neuropsychological examination confirmed 
the diagnosis FTD.[6] OPMD was confirmed by PABPN1 genetic analysis, 
revealing a heterozygous (GCN)17 repeat expansion. Further clinical 
characteristics and results of ancillary investigations are presented in table 1. 
Six-year follow-up revealed that the cognitive problems had gradually 
increased. Walking had become more difficult with frequent falls when walking 
unassisted. The ptosis was surgically corrected at the age of 67 years, with a 
good effect. Swallowing was difficult but she was still able to eat. She had a 
developed apathy and was  admitted in a nursing home at the age of 70. She 
died a few months later due to choking after aspiration during a meal. 
  
Discussion 
We report here two unrelated OPMD patients diagnosed with FTD and OPMD 
simultaneously. Both patients had have severe genetic defects: the first patient 
had a compound heterozygous (GCN)12/(GCN)16 mutation, and the other 
patient a heterozygous mutation with long repeat length (GCN)17. These 
findings support the earlier reports of brain involvement in a subset of OPMD 
cases and add that the cognitive decline may even precede limb or girdle 
muscle weakness.[2-5] 
Cognitive impairment has long not been recognized as a feature of OPMD. In 
OPMD patients with a less severe genetic defect, brain involvement does 
probably not occur or might not be severe enough to become manifest during 
the normal life span. Neuropsychological evaluation in 11 heterozygous OPMD 
patients without cognitive complaints showed that patients were less efficient 
than a matched control sample on several tests, particularly those testing 
executive functions.[4]  
Occurrence of cognitive decline in the most severe genotypes (homozygous or 
compound heterozygous mutations, and possibly also long repeat lengths) is 
most likely related to the longer repeat or higher expanded PABPN1 load in 
these cases.[2,3,5] Expanded PABPN1 forms insoluble intranuclear aggregates 
which also contain ubiquitin, proteasome and poly(A) RNA.[7] An age-
associated decrease in proteasome activity causes an increase in protein 
accumulation, which could contribute to disease acceleration during ageing.[8] 
In transgenic mice expressing the expanded form of human PABPN1, 
ubiquitinated PABPN1-positive intranuclear aggregates (the pathological 
hallmark for OPMD) were found in neuronal cells.[9] Fluorescent 
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immunohistochemistry using the same antibodies against PABPN1 on 
postmortem brain tissue of a OPMD patient showed INI’s containing PABPN1 in 
cerebellar neurons.[9] 
The sequence in which the neuromuscular symptoms and cognitive impairment 
occurs differs among the patients reported so far.[2,3] The patient reported by 
Mizoi et al. had limb girdle weakness without ptosis or ophthalmoplegia at onset 
of dementia,[2] whereas the patient described by Jouan et al. presented with 
mental illness in her early 30s and manifested muscle weakness only ten years 
later. This suggests a large phenotypical variability that might be caused by 
additional genetic and environmental factors. 
Notably, in both of our patients the cognitive symptoms were more pronounced 
than the muscle weakness at the time of referral. PABPN1 mutations should 
therefore also be considered in FTD patients with mild muscle weakness 
(including dysphagia and ptosis), or those with a positive family history of either 
FTD or muscular dystrophy. As such, OPMD is an important differential 
diagnosis of the spectrum of motor neuron disease and FTD. Future studies on 
cognition in OPMD patients and on brain tissue from autopsy of OPMD patients 
are needed to better understand the cognitive symptoms in OPMD. This could 
start with cognitive screening of a larger number of patients with different GCN 
repeat length and or functional MR studies. 
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Abstract 
Research on oculopharyngeal muscular dystrophy focuses mainly on genetic 
and pathophysiological aspects. Clinically, oculopharyngeal muscular dystrophy 
is often considered as a disease with a relatively mild initial disease course with 
no or only mild functional disabilities. However the occurrence of fatigue, pain 
and functional impairments other than dysphagia has never been studied 
systematically. The aim of this study is therefore to assess the prevalence of 
fatigue, pain, and functional limitations, and the social participation and 
psychological well-being of oculopharyngeal muscular dystrophy patients. 
We performed a questionnaire study on fatigue, pain, functional impairments, 
social participation and psychological distress in 35 genetically confirmed 
oculopharyngeal muscular dystrophy patients with an average disease duration 
of 11.6 years.  
We showed that 19 (54%) of the patients experienced severe fatigue and also 
19 (54%) experienced pain. Limitations in daily life activities and social 
participation were detected in 33 (94%) of the patients. Many patients reported 
pelvic girdle weakness and limitations in ambulation. Fatigue severity was 
related to functional impairments, while pain and disease duration were not. 
Psychological distress was not different from healthy adults. 
In conclusion, fatigue and pain are present among approximately half of the 
patients, and almost all patients are impaired in daily life activities, social 
participation and ambulation. These data should be taken into account in 
symptomatic management of oculopharyngeal muscular dystrophy. 
  
  
514290-L-sub01-bw-vdSluijs
Processed on: 6-10-2017 PDF page: 89
Chapter 7  The Dutch patients’ perspective on oculopharyngeal muscular 
dystrophy: a questionnaire study on fatigue, pain and impairments 
 
 
 
89 
Introduction 
Oculopharyngeal muscular dystrophy (OPMD) is a rare late-onset, usually 
autosomal dominantly inherited, muscle disorder. Most research on this 
myopathy focuses on genetic and pathophysiological aspects, while data on the 
patients’ perspective are limited [1]. 
OPMD usually manifests in late adulthood, and many carriers of the OPMD 
mutation participate normally in society at the moment of diagnosis. The 
characteristic clinical pattern is the combination of bilateral ptosis, dysphagia 
and, later, limb girdle weakness [2]. Disease progression is usually slow and 
physical and functional impairments develop gradually. Consequently OPMD is 
considered to have a relatively mild course in the first years [3,4]. However, in 
2001, Becher et al. described a Hispanic New Mexicans OPMD cohort and 
found that the phenotype was highly variable, ranging from physically active 
individuals with mild ptosis to patients of similar age with substantial dietary 
restrictions due to dysphagia and debilitating muscle weakness [5]. Also in our 
experience many OPMD patients become severely limited in daily-life activities 
and social participation in the course of their disease. Furthermore, OPMD 
patients in our cohort tend to underreport their limitations and some patients do 
not even visit a doctor. This is likely due to the slow progression, the fact that 
symptoms are considered part of normal ageing in their families, and the 
absence of a cure. This probably contributes to underestimation of the impact of 
the disease by physicians and researchers. 
Over the recent years, a growing number of studies has investigated quality-of-
life (QOL) aspects of various neuromuscular disorders (NMD). This shows that 
in facioscapulohumeral muscular dystrophy (FSHD), fatigue and pain occur 
frequently and impair daily life activities [6,7]. Furthermore, psychological 
distress is reported to impair daily life activities and social participation and to 
increase fatigue of patients suffering from various NMDs [6-9]. These studies 
did not include OPMD patients. Krause-Bachand reported the results of a 
qualitative pilot study (an unstructured interview format) of ten OPMD patients 
about their perspectives of living with ptosis, dysphagia, and a genetic disorder. 
All participants suffered both from physiological and psychosocial burdens 
related to living with OPMD. They formulated five comprehensive themes that 
described the essence of the experience: adjusting to change, managing 
misconception, seeking normality, facing the future, and informing children. 
They suggested that exploring QOL issues with larger groups of various 
ethnicity would provide additional data related to the experience of living with 
OPMD [10]. Further research on fatigue and pain in OPMD and on the 
psychological well-being of patients is limited to some anecdotal clinical 
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observations. One case-report described an OPMD patient with proximal 
weakness and exercise-induced pain [11]. Another report described 22 Mexican 
OPMD patients, four of which had non-specific fatigue [12]. 
The principal aim of this study is therefore to assess the prevalence of fatigue 
and pain, the limitations in daily-life activities and social participation, and the 
psychological well-being of OPMD patients using an open questionnaire with 
spontaneously reported complaints and a multidimensional assessment method 
[7,13]. Secondly, we determined whether limitations in daily life activities and 
social participation were related to fatigue severity, pain and disease duration. 
This study is performed in a Dutch cohort of OPMD patients, with relatively 
large mutation sizes. The average disease duration was 11.6 years. 
 
Methods  
The study was approved by the local ethical committee (CMO Regio Arnhem-
Nijmegen) and written informed consent was obtained from all participating 
patients. 
Participants 
We used a cross sectional design. All genetically confirmed OPMD patients, 
known at the Dutch OPMD referral centre (Neuromuscular Centre Nijmegen), 
were invited to participate in this study. This is estimated to be approximately 
half of the Dutch OPMD population. Exclusion criteria were the presence of 
disabling systemic or psychiatric disease. 
Assessment 
The subjects received questions on general and specific OPMD symptoms and 
five validated questionnaires: Sickness Impact Profile (SIP-136), Checklist 
Individual Strength (CIS), The McGill’s Pain Questionnaire (MPQ), Symptom 
Checklist 90 (SCL90) and Beck’s Depression Inventory of Primary Care (BDI-
PC). 
The following demographical characteristics were collected: current age, age at 
onset of the symptoms, disease duration (from the onset of the symptoms), 
marital status and educational level. Furthermore, patients were asked to report 
all the complaints they attributed to OPMD (“spontaneously reported 
complaints”). 
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Fatigue 
To investigate the presence and severity of experienced fatigue, which is 
defined as an overwhelming sense of tiredness, lack of energy and feeling of 
exhaustion, we used the subscale fatigue severity of the CIS [14,15]. The 
subscale fatigue severity consists of 8 items (score range 8-56). A CIS-fatigue 
severity score equal to or higher than 35, being two standard deviations above 
the mean of healthy controls, indicates severe fatigue [16]. 
Pain 
MPQ was used for the assessment of pain intensity, distribution of pain and use 
of analgesic drugs [17]. Patients indicate pain intensity on a visual analogue 
scale (VAS) for current pain, a minimal pain score and a maximal pain score; a 
VAS score of 0 mm indicates no pain, and 100 mm worst possible pain. The 
MPQ includes a whole body outline to indicate the distribution of the pain, and 
an inventory of the use of analgesic drugs. 
Functional impairments in daily life 
To evaluate the functional impairments we used the Dutch version of the SIP-
136 [18]. This questionnaire consists of 136 items measuring functional 
impairments in 12 different domains of functioning: sleep and rest, emotional 
behaviour, body care and movement, household management, mobility, social 
interaction, ambulation, alertness and intellectual functioning, communication, 
work limitations, recreation and pastimes, and eating. A total weighted SIP 
score is calculated and higher scores indicate more impairment. 
Psychological well-being 
To evaluate the psychological well-being of the patients we used the SCL-90 
and BDI-PC [19,20]. The SCL-90 consists of 90-items. The total score ranges 
from 90 to 450. Low total scores reflect good psychological well-being, and high 
scores indicate more distress. The BDI-PC is a 7-item questionnaire assessing 
cognitive and affective symptoms of depression. Each item is scored on a 4-
point scale (0-3). A total score equal to or higher than four indicate the presence 
of clinically relevant depressive symptoms. We used the BDI-PC, instead of the 
full BDI, to prevent an overlap in disease related somatic symptoms and the 
somatic symptoms of depression [20]. 
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Statistical analysis 
Data analysis was carried out using SPSS (version 16) for Windows. 
Descriptive statistics were used to describe the cohort and the scores on the 
different measures. Correlation between disease duration and age and fatigue 
severity (CIS-fatigue) and pain severity (VAS of current pain, maximal pain and 
minimal pain) was calculated by Pearson correlation coefficient. Multiple 
regression analysis was performed, method enter, with SIP total score as 
dependent variable and CIS-fatigue severity, VAS pain score and disease-
duration as possible predictors. Statistical significance in all analyses was 
assumed at p<0.05. Difference in prevalence and severity of fatigue and pain 
between the age groups (< or ≥ 60 years of age) and disease duration groups 
(< or ≥ 10 years disease duration) were tested with the independent t-test for 
continuous variables and with Chi-Square test for dichotomous variables. 
 
Results 
Of 45 Dutch genetically confirmed OPMD patients three were excluded because 
of disabling co-morbidity: one had cancer, one had a unilateral paresis due to 
stroke, and one had a depression. Seven patients (all relatives of responders) 
did not return the questionnaires: five women and two men, with a mean age of 
64.9 years (age range 48–77 years; SD 10,5 years). The repeat lengths were 
GCN 14 in two patients and GCN 16 in five patients. Hence, 35 patients 
(response rate 83%) were included in this study. The patients were members of 
16 different Dutch families. The GCN expansion size was 13 in two patients, 14 
in 21 patients, 15 in one patient and 16 in 11 patients. 
Demographics 
The cohort consists of 18 men and 17 women, the average age of the 
participants was 57.7 years (SD = 9.7; range: 41-79 years) and the average 
duration of disease was 11.6 years (SD = 8.1; range 1-41 years). Thirty-four 
patients (97%) were married or living together. Thirty-two patients (91%) had 
children (range 1-4). Thirty-two patients (91%) had more than 12 years of 
education starting at the age of six years. Seven patients (20%) were retired, 11 
patients (31%) were receiving disability pension and 12 patients (34%) had a 
paid job. 
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Spontaneously reported complaints 
The spontaneously reported complaints revealed a large number of different 
complaints, which are grouped in seven categories (Table 1), of which “muscle 
weakness of the pelvic girdle” was the most frequent. The average number of 
complaints per patient was four (range 0-10), some patients have reported more 
than one complaint per category. Eleven patients (31%) mentioned one or more 
complaints categorized as “pain”. Complaints categorized as “fatigue” were 
mentioned by seven patients (20%). None of the patients reported “mood 
disturbances”.  
 
Table 1. Spontaneously reported complaints attributed to OPMD grouped 
in seven categories.  
Categories of symptoms 
 
Number of patients reporting 
complaints (%) 
Difficulties in swallowing 28 (80) 
Weakness of pelvic girdle muscles 21 (60) 
Dropping of upper eyelids 17 (49) 
Difficulties in speaking 12 (34) 
Pain 11 (31) 
Weakness of shoulder girdle muscles 9 (26) 
Fatigue 7 (20) 
Some patients reported more than one complaint per category. 
 
 
Fatigue 
Nineteen patients (54%) had a score of 35 or more on the CIS fatigue subscale 
indicating severe fatigue (table 2). Patients of 60 year or older were more 
frequently severely fatigued than patients younger than 60 year. There was no 
difference in the prevalence of severe fatigue between patients with a short and 
long disease duration (table 3). 
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Table 2. Results of the SIP 12, CIS, MPQ, SCL-90 total, and BDI-PC.  
Functional impairments in daily life 
(SIP) 
Mean and SD of test scores in 
total OPMD cohort (n=35)(%) 
 Sleep and rest 34.4 ± 38.9 
 Emotional behavior 18.3 ± 66.9 
 Body care 179.4 ± 278.1 
 Household 100.9 ± 110.2 
 Mobility 64.7 ± 103.7 
 Social interaction 70.4 ± 107.7 
 Ambulation 150.1 ± 136.4 
 Alertness 21.3 ± 47.2 
 Communication 68.1 ± 113.6 
 Work limitations 11.9 ± 38.5 
 Recreation 53.3 ± 60.4 
 Eating 28.0 ± 50.0 
 Total 800.8 ± 805.8 
  
Fatigue (CIS)  
 Fatigue 32.0 ± 13.9 
 Number of patients with severe fatigue 
(CIS fatigue ≥ 35)(%) 
19 (54) 
 
  
Pain (MPQ)  
 Current VAS pain (mm) 28.1 ± 21.4 
 Minimal VAS pain (mm) 12.9 ± 16.1 
 Maximal VAS pain (mm) 54.9 ± 22.1 
 Number of patients with pain (%) 19 (54) 
  
Psychopathology  
BDI-PC 1.0 ± 1.3 
Number of patients with  
BDI-PC score ≥ 4 (%) 
 
3 (9) 
SCL Total 119.2 ± 18.4 
In all these questionnaires higher scores indicate more disability, more symptoms or 
more psychological distress. (values are mean ± SD unless otherwise indicated). 
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Table 3. The prevalence and severity of fatigue and pain in different age  
 < 60 years 
(n=19) 
≥ 60 years 
(n=16) 
Statistical 
significance 
/ p-value 
Disease 
duration  
< 10 years  
(n=16) 
Disease 
duration  
≥ 10 years 
(n= 19) 
Statistical 
significan
ce 
/ p-value 
CIS fatigue 
score 
26.5 ± 13.2 38.4 ± 12.2 0.009 2 29.7 ± 13.6 33.9 ± 14.2 n.s. 2 
CIS fatigue 
≥ 35 
37%  
(n=7) 
75%  
(n=12) 
0.024 3 43% 
(n=7) 
63% 
(n=12) 
n.s. 3 
Current VAS 27.4 ± 23.9 28.9 ± 20.1 n.s. 2 29.4 ± 23.1 26.8 ± 20.8 n.s. 2 
Occurrence 
of pain 
50%  
(n=9)1 
62%  
(n=10) 
n.s. 3 56 % 
(n=9) 
56 % 
(n=10) 
n.s. 3 
1 One patient < 60 years of age did not fill out the MPQ questionnaire. 
2 Independent t-test. 
3 Chi-square test. 
n.s.: not significant 
 
Pain 
Nineteen patients (54%) reported having pain on the first question the MPQ 
pain questionnaire. There was no difference in the prevalence and in severity of 
pain between patients in the two age groups or disease duration groups (table 
3). The severity of the current pain varied from VAS score of 2 mm to 78 mm 
and the mean VAS score was 28.1 mm (SD=21.4). Four patients scored a VAS 
score of 50-70 mm for current pain, indicating moderate pain, ten patients 
scored a maximal VAS score of 70 mm or more, indicating severe pain [21]. 
The localization of the pain also was variable: 13 patients (68%) had pain in the 
upper legs, 12 (63%) had pain in the neck and/or shoulder, nine (47%) at the 
upper arms, six (32%) at the low back, five (26%) at the lower legs, three 
patients (16%) had headache, two (11%) had pain at the stomach or chest, one 
(5%) at the forearms, (figure 1). Analgesic drugs were used by 10 patients. 
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Correlation with disease duration and age 
Furthermore, disease duration (years) did not correlate statistically significant to 
fatigue severity (CIS fatigue: 0.28, n.s.) or pain severity (VAS of current pain, 
maximal pain and minimal pain: r = -0.43, 0.07 and 0.11 (n.s.) respectively). 
Age did neither correlate statistically significant to fatigue severity (CIS fatigue: 
0.33, n.s.) or pain severity (VAS of current pain, maximal pain and minimal pain: 
r = 0.41, 0.05 and 0.14 (n.s.) respectively).  
Functional impairments in daily life 
Functional impairments in at least one of the categories of the SIP were present 
in all but two OPMD patients. Most common were limitations in body care 
(n=20; 57%), household (n=22; 63%), social interaction (n=17; 49%) and 
ambulation (n=24; 69%). Limitations in the categories emotional behavior (n=4; 
11%), alertness (n=7; 20%), work (n=5; 14%) and eating (n=13; 37%) were far 
less common. The mean scores of the different categories are summarized in 
Table 2. 
Psychological well-being 
The mean total score of the SCL-90 was 119.2 ± 18.4, which is comparable with 
the mean score of the general Dutch population [22]. Only three patients (9%) 
had a score of four or more on the BDI PC indicating the presence of clinically 
relevant depressive symptoms.  
Relations of fatigue severity, pain and disease-duration to functional 
impairments 
Multiple regression analysis showed that fatigue severity was a significant 
predictor of functional impairments in daily life, whereas pain and disease-
duration were not (Table 4). 
Table 4. Multiple regression analysis to predict functional impairments 
showed that only fatigue and not pain or disease duration severity 
predicts functional impairments in daily life. 
 
 
Dependent variable SIP-total 
Beta p-value 
Independent variables   
Fatigue severity 0.392 0.023 
Pain 0.055 0.729 
Disease-duration 0.305 0.066 
Total R2 (adjusted) 0.249  
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Discussion 
This study in genetically confirmed Dutch OPMD patients shows that fatigue 
and pain occur in more than half of the OPMD patients (54%) and that OPMD 
causes marked functional impairments in daily life in nearly all patients (94%). 
Additionally, fatigue severity was related to impairment in daily life activities, 
whereas pain and disease-duration were not. Finally, psychological distress 
was not increased compared to healthy adults.  
Remarkably, more than half of the OPMD patients experienced severe fatigue 
(on the CIS-fatigue), which is higher than in the general population (11% in a 
female healthy control group [23]). Furthermore, only one-fifth reported fatigue 
spontaneously. Underreporting of fatigue is common in various chronic 
diseases [24]. Also in other neuromuscular disorders, fatigue severity correlates 
with severity of impairment of daily life activities. Kalkman et al. showed that the 
majority of patients with FSHD (61%), myotonic dystrophy type 1 (MD; 74%) or 
hereditary motor and sensory neuropathy type I (64%) experienced severe 
fatigue, which was associated with severe impairment in daily life activities [7]. 
Hence, experienced fatigue in OPMD is a relevant problem that needs attention 
during clinical follow-up and as a potential patient-related outcome measure in 
clinical trials. Furthermore, symptomatic treatment trials of fatigue should be 
started, in line with findings in other neuromuscular disorders. For example, 
Voet et al investigated the effect of aerobic exercise training (AET) and 
cognitive-behavioral therapy (CBT) on chronic fatigue in patients with FSHD 
[25]. Their randomized clinical trial showed that AET and CBT reduce chronic 
fatigue and increases social participation in FSHD. Based on these results, AET 
and CBT could be offered to OPMD patients. Preferably the effect of AET and 
CBT on chronic fatigue in OPMD should be studied in a future trial. 
More than half of the patients reported having pain on the first question of the 
MPQ pain questionnaire. There was a difference between the spontaneously 
reported complaints attributed to OPMD (n=11 (31%) in table 1) and the 
prevalence of pain measured with the MPQ (n=19 (54%)) in table 2). 
Apparently, part of the OPMD patients does not spontaneously contribute their 
pain to OPMD whereas pain is reported if asked directly. The distribution 
pattern of the pain - mostly located in the muscles of the neck, upper arms and 
upper legs - suggested that it might be related to the muscle weakness pattern 
in OPMD. It may also be caused by the continuous retroflexion of the neck to 
compensate the ptosis [26]. However, a detailed clinical study in OPMD patients 
reporting pain is needed to better understand the origin and the course of the 
pain. Pain is common in many neuromuscular disorders. Abresch et al. 
described that in a sample of 811 patients, suffering from different forms of 
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slowly progressive NMD (not including OPMD), 83% reported having pain, 
which significantly interrupts daily life activities [8]. More recently Jensen et al. 
showed that 82% and 64% of patients with FSHD and MD, respectively, 
reported pain [6]. They also showed that pain interferes with daily life activities. 
In our OPMD cohort pain was not related to the level of disabilities. This is 
probably due to the higher prevalence and severity of pain in FSHD than in 
OPMD, which could be the result of the different patterns of muscle weakness, 
different pathophysiological mechanisms, or diverse modes of adaptation to the 
limitations and subsequent different degrees of overuse. In FSHD the trunk 
flexors are among the weakest muscle groups and the imbalance between the 
extensors and flexors of the trunk leads to low back pain [6]. Furthermore, the 
severity of pain in our sample was comparable to patients referred to physical 
therapy for pain symptoms [27]. 
The high prevalence of fatigue, pain, and disabilities might be partly related to 
the large average mutation size of the patients in this study, leading to a more 
severe disease course. Worldwide, most OPMD patients have the (GCN)13 
expansion; here only two out of 35 patients have this mutation and more than a 
third (16 out of 35) had the (GCN)16 expansion. Since the average disease 
duration was 11.6 years, reflecting moderately progression, pain and fatigue do 
not seem to be problems of end-stage OPMD only. A phenomenological study 
with unstructured interviews in ten patients with OPMD defined five themes that 
emerged describing the experience of living with OPMD: "Adjusting to Change", 
"Managing Misconceptions", "Seeking Normality", "Facing the Future", and 
"Informing Children" [10]. The patients reported negative aspects of their lives 
related to OPMD, including both psychological and physiological stressors. Pain 
and fatigue were not separately addressed. The authors conclude that it is 
important for health care workers to understand what it means to live with 
OPMD and how it affects the person’s life. 
All participants, except two, reported limitations in daily life activities and social 
participation. One third of the patients was no longer able to work and received 
disability pension. Only 37% of the patients experienced eating impairment 
according to the SIP, although 80% of patient spontaneously reported various 
difficulties swallowing. These included dysphagia, prolonged eating time, 
problems with swallowing saliva, near-choking experiences, and 
embarrassment when eating in social situations. This discrepancy might results 
from the very slow progression of the dysphagia, which enables patients and 
their surroundings to adapt, thus limiting the experienced limitations. Another 
factor might be that the items of the SIP subscore eating do only partly 
represent the swallowing disability.  
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Although pelvic girdle weakness is not part of the major diagnostic criteria [4,28] 
it was the most frequent spontaneously reported complaints in our cohort. The 
high prevalence of this weakness and the reported limitations in ambulation are 
in accordance with our previous observation of severe involvement of limb 
girdle muscles in the Dutch OPMD cohort [29]. The recent study of Youssof et 
al. also demonstrated that hip flexion weakness is statistically associated with 
impaired ambulation [30]. Therefore physicians and researchers should pay 
attention to the occurrence and consequences of limb girdle weakness in the 
diagnostic process, treatment and research projects. 
Despite the fatigue, pain and functional limitations, psychological distress was 
not more prevalent than in the healthy population. The insidious manifestation, 
slow progression and the familiar occurrence of the disease may allow the 
patients to gradually accept the impairments. The frequency of depression in 
our cohort was comparable with patients with other chronic diseases, and with 
other NMD [9,31]. 
In short, this study shows that fatigue and pain occur in more than half of the 
OPMD patients and that severe fatigue is associated with a higher level of 
disabilities. Furthermore, we confirmed that OPMD leads to limitations in daily 
life activities and social participation in almost all patients, even in patients 
younger than 60 years. Therefore, symptomatic management should include 
therapies aimed at the reduction of severe fatigue, pain and functional 
impairments, similarly as in other myopathies [24]. This should preferably be 
tested prospectively. In addition fatigue, pain and functional impairments could 
be included as patient-related outcome measures in future clinical trials. 
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Abstract 
Background: Oculopharyngeal muscular dystrophy (OPMD) has long been 
characterized by a combination of bilateral ptosis and dysphagia and 
subsequent limb girdle weakness. The role of the typical intranuclear inclusion 
in the pathophysiology is unresolved. 
Objective: The aim of this study was to describe the clinical and 
histopathological features of oculopharyngeal muscular dystrophy (OPMD). We 
examined this in a Dutch cohort including presymptomatic Ala-expanded-
PABPN1 carriers and late symptomatic patients. 
Methods: We performed a prospective, observational study in OPMD patients 
and adult children of genetically confirmed OPMD patients. The study includes 
a structured history, a detailed neurological examination, muscle histology and 
biochemical analysis. Forty patients and 18 adult children participated in this 
study, among whom were six presymptomatic mutation carriers. One patient 
died during the study and had given permission to autopsy.  
Results: In addition to the characteristic OPMD symptoms including ptosis and 
dysphagia, other symptoms such as limb girdle and axial weakness, and 
external ophthalmoplegia were frequently observed. Intranuclear aggregates 
were observed in the biopsies of presymptomatic carriers. Biochemical analysis 
of the biopsies of the presymptomatic carriers showed no mitochondrial 
dysfunction. The autopsy showed that muscle weakness correlated with 
histopathological findings in five different muscles in an individual patient. 
Conclusions: The main findings of this nationwide study are the presence of 
intranuclear aggregates before clinical onset and the absence of mitochondrial 
changes in Ala-expanded-PABPN1 carriers. This indicates that the expression 
of Ala-expanded-PABPN1 causes the formation of nuclear aggregates before 
the onset of muscle weakness. Normal results of biochemical analysis in 
presymptomatic carriers suggest that possible mitochondrial dysfunction occurs 
later. Furthermore we confirmed that limb girdle weakness occurs frequently in 
Dutch OPMD patients. This study thus expands the OPMD research towards 
characterization of presymptomatic carriers. 
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Introduction 
Oculopharyngeal muscular dystrophy (OPMD) has long been characterized by 
a combination of bilateral ptosis, dysphagia and subsequent limb girdle 
weakness [1,2]. Accumulation of expanded (exp)PABPN1 into insoluble 
intranuclear inclusions in skeletal muscles is the pathological hallmark of OPMD 
[1]. Our Dutch pilot study and a recent Danish report showed that limb girdle 
weakness is the first and prominent symptom in a minority of patients [3,4].  A 
more detailed description of the clinical symptoms in a larger cohort is required 
to confirm this.  
Next, it is largely unknown whether the intranuclear inclusions occur before 
clinical onset or only during disease progression [1]. Furthermore, the impact of 
aggregated PABPN1 on cellular defects in OPMD is not fully understood [5,6]. 
We therefore performed a clinical and histopathological study of a cohort of 40 
OPMD patients (of whom 36 genetically confirmed) and 18 adult children, 
comprising an unique wide spectrum starting with mutation carriers at a 
presympomatic stage to late symptomatic patients. In addition to nuclear 
aggregates, biopsy specimens from OPMD patients show dystrophic changes 
and mitochondrial abnormalities, the latter of which are generally considered a 
secondary phenomenon [6]. The availability of presymptomatic muscle tissue of 
Ala-expanded-PABPN1 carriers in this study offered an unique opportunity to 
study the histopathological and biochemical changes before clinical onset. We 
included an autopsy in an OPMD patient, enabling a qualitative correlation of 
the severity of histopathological changes to the degree of muscle weakness in 
five different muscles. 
This study in presymptomatic expPABPN1 carriers and OPMD patients enabled 
us to investigate the spectrum of OPMD from different perspectives: by 1) 
focusing on the clinical aspects of this Dutch OPMD spectrum; 2) investigating 
subjects from presymptomatic to progressive disease stages; and 3) by 
studying variably affected muscles within the same patients. 
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Methods 
Participants 
All Dutch OPMD patients known at our national OPMD referral centre were 
invited to participate in this study. Adult children of genetically confirmed OPMD 
patients were also invited without disclosure of their individual histological and 
genetic results as required by the local ethical committee. The histological and 
genetic investigation of the children was performed for scientific purposes only. 
If patients desired genetic counseling this was performed separately in a clinical 
setting. 
Genetic investigations 
Genetic testing for PABPN1 expansion mutation was performed on all patients 
and children as previously described [3]. 
Medical history and clinical evaluation 
A structured medical history and a neurological examination including manual 
muscle strength testing were performed in all participants [7]. This included 
assessment of facial muscle force, including forced eye closure, raising the 
eyebrows, blowing the cheeks, showing the teeth, pursing the lips and smiling. 
Facial weakness was defined as weakness of any of these tests. Dysphagia, 
ptosis and dysphonia were assessed qualitatively. Both the initial 
symptoms/signs (retrospective evaluation of the start of the disease according 
to the patient) and the current symptoms/signs (at the time of the study) were 
assessed. 
Muscle biopsies and autopsy 
Patients and children underwent a needle biopsy of the right vastus lateralis 
muscle. One autopsy was performed which included specimens of the vastus 
lateralis, biceps brachii, diaphragm, pharyngeal and tibialis anterior muscles.  
Histological analysis. The muscle samples were examined as reported 
previously, including COX staining [8]. The intranuclear aggregates were 
counted using Electron Microscopy (EM) in 150 to 200 nuclei of each muscle 
sample. The samples obtained during autopsy were additionally evaluated on 
semi-thin sections. The extent of the histopathological changes in the autopsy 
muscles samples was assessed qualitatively (absence; limited presence; 
moderate presence; extensive presence) and related to the clinical assessment 
of muscle strength (MRC scores) and the occurrence of dysphagia. 
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Biochemical analysis Measurement of total energy-generating capacity of 
mitochondria and oxidative enzyme activities was performed in children of 
OPMD patients (asymptomatic carriers and non-carriers) as previously reported 
[9]. Any disturbance of the mitochondrial energy generating system, apart from 
complex II deficiency, results in a lower pyruvate oxidation rate and ATP 
production, and will be detected in this way.  We thus aimed to find out whether 
any mitochondrial changes arose before or after the typical histopathological 
changes of OPMD and whether they preceded or followed clinical onset. 
 
Results 
Study population 
Fifty-eight persons, including 40 patients and 18 asymptomatic adult children of 
genetically-confirmed OPMD patients participated in this study. In 36 patients 
OPMD was genetically confirmed by detection of the PABPN1 repeat 
expansion. In three patients, genetic testing had been performed in a first 
degree relative. In one patient, OPMD was diagnosed based on the phenotype 
and the presence of intranuclear aggregates in the biopsy. Six of the 18 
asymptomatic children were PABPN1 mutation carriers; the others did not have 
the mutation (Table 1). The Alanine expansion mutation ranges from GCN13 to 
GCN16, with most of the patients (63%) had a GCN14 repeat and 31% had 
GCN16. The small number of patients with GCN13 or GCN15 repeat does not 
allow to draw conclusions on the correlation between repeat expansion size and 
phenotype. The patient who died during the study had a GCN 14 repeat. 
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Table 1. Characteristics of all participants (patients and adult children 
including six presymptomatic mutation carriers and 12 noncarriers), 
PABPN1 mutations and clinical symptoms. 
 
* In 36 patients OPMD was genetically confirmed by detection of the PABPN1 repeat expansion. In 
three patients, genetic testing had been performed in a first degree relative. In one patient, OPMD 
was diagnosed based on the phenotype and the presence of intranuclear aggregates in the biopsy. 
 
  
 Patients  
(n=40) 
Adult children  
(n=18) 
Men (number of persons (%)) 20  (50) 9  (50) 
Age at onset (years):  
mean (SD; range) 
45.2 (5.1; 33-57) not applicable 
Age at examination (years):  
mean (SD; range) 
60 (10.3; 41-81) 33 (9.8;19-47) 
Age cohorts (years of age: number of patients in that 
age cohort) 
41-49: n = 6 
50-59:  n = 14 
60-69: n = 12 
≥ 70: n = 8 
19-26: n = 6 
31-35: n = 2 
36-40: n = 6 
41- 47: n = 4 
(Suspected*) carrier of mutation (number of patients (%)) 40 (100) 6 (33) 
PABPN1 mutation (number of patients  (% of carriers))  
(GCG)10(GCA)3GCG (GCN14) 
(GCG)6(GCA)2(GCG)2(GCA)3GCG (GCN14) 
(GCG)12(GCA)3GCG (GCN16) 
(GCG)9(GCA)3GCG (GCN13) 
(GCG)6(GCA)1(GCG)3(GCA)3GCG (GCN14) 
(GCG)6(GCA)3(GCG)2(GCA)3GCG (GCN15) 
 
11  (31) 
10  (29) 
11  (31) 
2   (6) 
1   (3) 
1   (3) 
 
3 (50) 
1 (17) 
1 (17) 
1 (17) 
Symptoms (number of patients (%)) 
Dysphagia 
Ptosis 
Proximal leg weakness 
Dysphonia 
Facial weakness 
Proximal arm weakness 
External ophthalmoplegia 
Distal leg weakness 
Distal arm weakness  
Diplopia 
 
39  (98) 
35  (88) 
34  (85) 
28  (70) 
24  (60) 
22  (55) 
17  (43) 
13  (33) 
10  (25) 
7 (18) 
not applicable 
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Medical history and clinical evaluation 
The initial symptom/sign was ptosis in 17 patients (43%), dysphagia in 12 
(30%), limb girdle weakness in 10 (25%), and ptosis plus dysphagia in only one 
patient (3%). The age at onset and the age of examination was variable in this 
cohort (table 1), and was not significantly different for any of the initial 
symptoms. Dysphagia was the most frequent current symptom (98% of 
patients). Ptosis and proximal leg weakness also occurred frequently at the time 
of the study (88% and 85% respectively). Other common current 
symptoms/signs were: dysphonia and facial weakness/limited facial expression 
(70 % and 60% respectively). Two patients had isolated dysphagia; all other 
patients had more than one symptom/sign. The weakness of the pelvic muscles 
varied from mild (MRC 4) to severe (MRC 2). In addition, axial muscles were 
also affected: neck flexor weakness and neck extensor weakness occurred in 
respectively 19 (48%) and in 11 (28%) patients. None of the patients initially 
presented with external ophthalmoplegia and diplopia, but during progression it 
developed in 17 (43%) and 7 (18%) patients respectively (mean age 60 and 63 
years). All 18 children had a normal neurological examination. 
During the study, one patient died due to pneumonia at the age of 69 years. He 
did not have any pulmonary complaints before, neither dyspnoea nor 
orthopnoea or signs of nocturnal hypoventilation. Neurological examination 
performed at a check-up shortly before falling ill had shown bilateral ptosis and 
atrophy of proximal muscles, mostly pronounced in the legs. Muscle weakness 
was symmetrical: elbow flexors (MRC 3), wrist flexors (MRC 4), wrist extensors 
(MRC 4), hip flexors (MRC 2), knee extensors (MRC 2), and foot extensors and 
flexors (MRC 4). 
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Muscle biopsies  
Twenty-four patients and 18 children underwent a needle biopsy. The biopsy of 
one patient only contained fatty tissue and was excluded in this study. 
Histological analysis. The biopsies in children without the PABPN1 mutation 
(n=12) were normal as expected. Histopathological investigation of the six 
biopsies from presymptomatic carriers revealed nuclear aggregates in four, and 
additionally rimmed vacuoles in one. Three biopsies with aggregates showed an 
increased variation of fiber size (figure 1), one did not show any dystrophic but 
few atrophic fibres. The biopsies of 23 symptomatic patients showed non-
specific alterations including increase in fibre size variation in all biopsies, mild 
changes in the checkerboard pattern without fiber type grouping (22%), and 
rimmed vacuoles (74%). Only two biopsies showed each one COX negative 
fiber. Electron microscopic examination showed subsarcolemmal aggregates of 
mitochondria in four biopsies, and mitochondria with crystalline inclusions in two 
biopsies. In 83% of the biopsies intranuclear aggregates were observed in 1.8% 
of the nuclei (range 0.4-4.9) (Table 2a).  
The histopathological investigations of the muscle samples obtained by the 
autopsy showed that the severity of the dystrophic alterations varied between 
different muscles. The severity of muscle weakness corresponded with the 
severity of the dystrophic alterations of the muscles: the muscles that were most 
severely affected clinically in this patient - proximal limb muscles - showed the 
most extensive pathological alterations (Table 2b; Figure 2). In all examined 
muscles nuclear aggregates were observed and their presence did not correlate 
to muscle weakness  (Table 2b). 
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Figure 1. Transverse sections of vastus lateralis muscle obtained by 
needle biopsy of a presymtomatic PABPN1 mutation carriers showing 
variation of fibre diameter (H&E; scale bar = 500 μm). 
a: overview revealing important variation of fibre diameter, fibrosis and fatty 
degeneration  (H&E; scale bar = 500 μm) 
b: detail revealing muscle fibres with central nuclei, and vacuole with basophilic 
rim (arrow)  (H&E; scale bar = 100 μm) 
 
b 
a 
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Figure 2. Transverse sections of quadriceps muscle obtained by autopsy 
showing the dystrophic abnormalities. 
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Table 2a. Histopathological findings of needle biopsies from Vastus 
lateralis of 23 OPMD patients (showing  dystrophic alterations in all 
biopsies with increase in fibre size variation and mild changes in the 
checkerboard pattern) and six presymptomatic mutation carriers. 
Results of one biopsy containing only fibrous tissue were excluded. 
*% of nuclei of the 83% of biopsies with aggregates; **% nuclei of the 4 biopsies with aggregates 
 
  
 Patient 
(n=23) 
Presymptomatic mutation  
carriers (n=6) 
Normal 
 Mean Range Mean Range  
Type I fibres  
(% of myofibers) 
 
53.1 
 
16-92 
 
47.8 
 
36-75 
 
35-50 
Type IIA and IIB fibres  
(% of myofibers) 
 
45.6 
 
4-84 
 
51.8 
 
24-63 
 
50-65 
Type IIC fibres  
(% of myofibers) 
 
1.3 
 
0-11 
 
0.3 
 
0-1 
 
< 5 
Diameter type I fibres (μm) 29-131 (10-79)-(83-208) 52-99 (17-79)-(83-129) 40-80 
Diameter type II fibres (μm) 19-123 (10-67)-(67-225) 50-94 (17-79)-(75-125) 40-80 
Internal nuclei  
% of myofibers) 
 
13 
 
0-70 
 
1.5 
 
0-3 
 
≤ 3 
Fatty infiltration (%)  
Rimmed vacuoles 
 (% of biopsies) 
Intranuclear aggregates  
 
11 
 
74 
1.8* 
0-40 
 
not applicable 
0.4-4.9 
1.7 
 
17 
2.2** 
0-4 
 
not applicable 
0.67-3.5 
0 
 
0 
0 
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Table 2b. Histopathological findings in five muscles from autopsy of a 
symptomatic OPMD patient shows a correlation between MRC scores and 
the histopathological changes in five different muscles. 
 
The histopathological findings of the muscle samples obtained by autopsy and weakness of various 
muscles in a geneticallyconfirmed OPMD patient. 
NA: not available; no clinical signs of weakness: the patient experienced no dyspnoea and had no 
signs of nocturnal hypoventilation. 
 
Biochemical analysis  
Measurement of the mitochondrial substrate oxidation and the ATP production 
rates in muscle biopsies of five children without mutations and three 
presymptomatic PABPN1 mutation carriers was normal (Table 3a and 3b). 
  
Muscles Quadriceps Biceps Diaphragm Pharynx 
musculature 
Tibialis 
anterior 
Autopsy findings:      
Type I fibres (% (normal))  59 (35-50) 77 (42) 36 (42) 15 (26 ) 86 (73 ) 
Type II fibres (% (normal)) 41 (50-65) 23 (58) 64 (58) 85 (74) 14 (27) 
Abnormal variation in fiber size extensive moderate moderate moderate limited 
Rimmed vacuoles moderate limited limited limited limited 
Ragged red fibres limited limited limited limited none 
Interstitial fat (%) 50 20 15 10 5 
Interstitial fibrosis extensive moderate moderate limited limited 
Internal nuclei (%; N = 0-3%) r 100 95 10 14 18 
Checkerboard pattern normal Fibre type 
grouping 
normal Type II fibre 
overload 
Type I 
fibre 
overload 
Intranuclear aggregates (semi-
thin sections) (%) 
3 <3 3 1 NA 
Intranuclear aggregates on EM 
(%)(aggregates/number of 
myonuclei) 
2 
2/100 
4 
4/100 
4 
3/72 
4 
4/100 
NA 
Clinical data: 
Muscle strength (MRC score) 
 
2 
 
3 
 
no clinical 
signs of 
weakness 
 
dysphagia 
 
4 
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Table 3. Mitochondrial investigations in muscle biopsies of eight adult 
children of genetically confirmed OPMD patients. Measurement of the 
mitochondrial substrate oxidation, ATP production rates and enzyme activities 
in muscle biopsies of five children without mutations (white rows) and three 
presymptomatic PABPN1 mutation carriers (grey rows) was normal. 
Table 3a. Substrate oxidation rates and ATP metabolism  
carrier 
carrier 
carrier 
non-carrier 
non-carrier 
non-carrier 
non-carrier 
non-carrier 
N
orm
al 
values  
S
ubject 
  
5.41 
 
4.27 
5.05 
3.49 
3.11 
4 
4.48  
3.61-7.48 
(nm
olC
O
2
/ h.m
U
C
S
) 
[1-14C
] 
pyruvate 
+m
alate 
5.73 
 
4.08 
5.34 
3.15 
4.64 
4.1 
4.85 
2.84-8.24 
(nm
olC
O
2
/ h.m
U
C
S
) 
[1-14c] 
pyruvate 
+carnitine 
   
6.76 
4.91 
3.06 
3.16 
4.06 
5.27 
4.68-9.62 
(nm
olC
O
2
/ h.m
U
C
S
) 
[U
-14C
] 
m
alate+ 
pyruvate+ 
m
alonate 
6.49 
 
6.72 
6.02 
3.1 
2.41 
4.47 
6.42 
3.43-7.3 
(nm
olC
O
2
/ h.m
U
C
S
) 
[U
-14C
] 
m
alate+ 
acetylcarn
itine 
+m
alonate 
   
2.89 
3.93 
5.13 
4.04 
3.15 
4.87 
2.05-3.85 
(nm
olC
O
2
/ h.m
U
C
S
) 
[U
-14C
] 
m
alate+ 
acetylcarn
itine 
+arsenite 
   
3.81 
   
2.83 
3.94 
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Table 3b. Enzyme activity 
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non-carrier:   child without Ala-expanded-PABPN1 mutation 
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Three of the eight children were asymptomatic Ala-expanded-PABPN1 carriers, 
the five non-carriers are used as controls. Measurement of the mitochondrial 
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substrate oxidation and the ATP production rates in muscle biopsies of the 
three presymptomatic PABPN1 mutation carriers did not show mitochondrial 
dysfunction. * and #: normal values of tests performed according to slightly 
different protocols with their own normal values; the * and  # correspond to the 
results of these tests of the patients. 
  
Discussion 
The main finding of this prospective cohort study in OPMD families is the 
presence of intranuclear aggregates before clinical onset: aggregates were 
detected in biopsies of four of the six Ala-expanded-PABPN1 carriers. The 
youngest expanded-PABPN1 carrier showing aggregates was 35 years old, 
whereas clinical onset is on average at 45 years of age. Autopsy in one patient 
showed aggregates in most muscles, also in the clinically non-affected 
diaphragm. Overall this study calls for a more detailed study of the role of 
PABPN1 aggregates in OPMD pathology. This is of high relevance since clinical 
trials are now ongoing, e.g. for trehalose (http://bioblast-pharma.com/) [10]. 
Trehalose is a natural alpha-linked disaccharide with high water retention 
capabilities and an anti-oxidant that inhibits protein aggregation, that has proven 
to be effective in the OPMD mouse model [11]. 
Next, the mitochondrial energy generating capacity in fresh muscle tissue 
originating from presymptomatic carriers was comparable to controls. The 
observation that nuclear aggregates were observed in the muscle tissue from 
these carriers indicates that formation of expPABPN1 aggregates precedes 
possible mitochondrial dysfunction [12, 13].  This observation is compatible with 
the hypotheses that mitochondria are only secondarily involved in the 
pathogenesis of OPMD [6]. Alternatively,  the mitochondrial alterations might 
occur independently later in the course of the disease. A recent study in 
Drosophila flies overexpressing PABPN1-17ala showed that mitochondrial 
function was reduced in symptomatic flies (flightless with abnormal wings) 
[12,13]. Additional findings in this study shed light on the possible mechanism in 
which mitochondrial function becomes disturbed: alternative polyadenylation of 
mitochondrial genes causes reduced expression of these genes and impairs 
mitochondrial function. Because the authors also found accumulation of 
mitochondrial proteins in sternocleidomastoid muscle biopsies of OPMD 
patients, which is presumably less affected, they suggested that mitochondrial  
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activity is affected by expPABPN1 expression already early in the disease 
course [12,13]. A future study with mitochondrial evaluation of OPMD patients in 
different stages of the disease will be helpful to clarify if and when mitochondrial 
dysfunction plays a role in the pathogenesis of OPMD. 
The third important finding was the high variation in the clinical manifestation of 
OPMD in this Dutch cohort. Limb girdle weakness occurred more frequently 
than initially reported and even as initial symptom in some patients (25%) 
[14,15]. This is higher than the prevalence of 10% reported in an OPMD cohort 
in the United Kingdom  [16]. This might be partly related to the large average 
mutation size of the patients in this study, leading to a more severe disease 
course. Worldwide, most OPMD patients have the (GCN)13 expansion; here 
only two out of 40 patients (5%) have this mutation and 31% had the (GCN)16 
expansion.  However the two patients with the (GCN)13 expansion had limb 
girdle weakness as first symptom. Our findings confirm the recent observations 
in the Danish OPMD cohort (n=13): limb weakness can be common in OPMD 
and can be even the presenting symptom in five patients [4]. All our patients 
except one suffered from dysphagia, sometimes even as initial symptom. Ptosis 
occurred less frequently than dysphagia. The presence of diplopia did not 
exclude the diagnosis of OPMD. We did not find a relation between the severity 
of symptoms of OPMD and patients age, probably due to the large variation of 
age at onset and the relatively small size of the cohort. Progression over time 
was slow (data not shown).  
Finally, we showed a remarkable correlation between MRC scores and the 
histopathological changes in five different muscles of an individual patient. To 
our knowledge this is the first report presenting results of an autopsy of a 
genetically-confirmed and clinically characterized OPMD patient [17,18]. Dion et 
al. showed the presence of intranuclear aggregates in cerebellar neurons of 
brain sections of an OPMD patient [19]. Little et al. reported an autopsy of a 
French-Canadian not genetically-confirmed patient and found that limb muscles 
were less affected histopathologically than diaphragm and pharyngeal muscles 
[18]. We found that the quadriceps muscle was more severely affected than the 
diaphragm and pharyngeal muscles. This strengthens the suggestion of high 
variability in patterns of muscle weakness in OPMD patients. 
In conclusion, our study showed the presence of intranuclear aggregates 
without mitochondrial changes before clinical onset in Ala-expanded-
PABPN1carriers. This observation can direct future studies on the 
pathophysiology of this disease and the role of the intranuclear aggregates in 
OPMD pathology in particular. Furthermore this study confirmed our previous 
pilot study suggesting that limb girdle weakness occurs frequently and 
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prominently in this Dutch OPMD cohort with relatively long repeat lengths. As 
such, our observations will contribute to a better recognition of the OPMD 
phenotype. Importantly, our study demonstrated the broad spectrum of affected 
muscles, and the high variation in loss of strength of affected muscles during 
the progression of the disease. Since OPMD is likely to be underdiagnosed, 
these findings will have a direct clinical impact on disease recognition [20,21]. 
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Abstract
Although limb girdle weakness is not part of the major diagnostic criteria of 
oculopharyngeal muscular dystrophy (OPMD), it has frequently been observed 
in the Dutch and other OPMD cohorts. In the Dutch cohort, this might be related 
to the relatively old age or the severity of the genetic defect. This patient-control 
study (14 OPMD patients and 12 controls) investigated the involvement of limb 
girdle muscles with a multidimensional approach in early OPMD. We assessed 
functional abilities, disease impact, physical activity, muscle strength, 
histopathology and fatty infiltration using questionnaires, actometer, functional 
tests, manual and quantitative muscle testing, muscle biopsy and muscle MRI.
The study showed that involvement of pelvic girdle and proximal leg muscles 
can be a relatively early feature of OPMD,  resulting in impaired daily life 
activities. The fat fraction of the hip adductors and hamstrings was significantly 
higher in OPMD patients in controls.
Future studies should include assessment of hip flexors, hip adductors and 
hamstrings (muscle strength measurements and  MRI), functional tests and 
questionnaires. These findings are important in future diagnostics, management 
and for the design of outcome measures in trials. 
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Introduction
Pelvic girdle and proximal leg weakness is not part of the major diagnostic 
criteria of OPMD. However, it has repeatedly been observed in studies in Dutch 
OPMD patients and other cohorts.[1-6] Weakness of pelvic girdle and proximal 
leg muscles was one of the most frequent spontaneously reported symptoms in 
our questionnaire study (60%).[2] In a cross-sectional clinical study of Dutch 
OPMD patients weakness of the proximal arm muscles was observed in 55% of 
the patients and weakness of the proximal leg muscles in 85%.[3] The 
prevalence of pelvic girdle and proximal leg weakness in other cohorts is 
variable: weakness of limb muscles was reported in 50% of the patients in a 
French cohort, and weakness of proximal legs was reported in 71% in the 
French-Canadian cohort.[4,5] In contrast, proximal weakness occurred only in 
20% of an OPMD cohort in Israel.[6] 
The high prevalence of pelvic girdle and proximal leg weakness in the Dutch 
cohort might be related to a larger mean mutation size of the patients, leading to 
a more severe disease course. Worldwide, most OPMD patients have the 
(GCN)13 expansion.[7-10] However, in the Dutch cohort this mutation occurred 
in two out of 40 patients (5%), whereas 31% had a (GCN)16 expansion.[3] 
Another possible explanation was the relatively old age at the time of this study 
(mean age 60 years (range 41–81)).[3] 
A recent French study (n=354) indeed showed that limb-girdle weakness is 
more prevalent in late-stage OPMD and in patients with severe genetic defects: 
GCN repeat length was inversely correlated with age of diagnosis, and pelvic 
girdle weakness at the time of diagnosis was frequently observed in patients 
with the longer repeat lengths (> (GCN)14) or with homozygous mutations 
((GCN)12 or 13).[10]
To assess the involvement of pelvic girdle and proximal leg muscles in early-
stage OPMD we have investigated function and structure of these muscles with 
a multidimensional approach in early OPMD. This is important for diagnostics, 
counselling and rehabilitation of OPMD patients, and future research on OPMD.
Methods
Participants
A group of genetically confirmed patients was recruited from the Radboudumc 
OPMD cohort. Individuals without a history of neuromuscular disease were 
514290-L-sub01-bw-vdSluijs
Processed on: 6-10-2017 PDF page: 130
Chapter 9  Function of pelvic girdle and proximal leg muscles in early 
oculopharyngeal muscular dystrophy 
130
included as healthy controls. The distribution of age and sex was similar in both 
groups. These OPMD patients and the healthy controls participated in a larger 
study on disease specific features of various muscular dystrophies.[12] 
Exclusion criteria were: age <18 or >65 years, co-morbidity or therapy that 
could influence muscle strength (diabetes mellitus, chronic obstructive 
pulmonary disease, chronic heart failure, current malignancy or previous 
treatment with chemotherapy and/or radiation therapy, use of corticosteroids 
during more than two weeks in the past five years, use of statins in the past 
year, wheelchair bound), contra-indications for MRI or muscle biopsy, and 
pregnancy.[12]
The following demographical characteristics were collected: sex, age, age at 
onset. The disease duration was calculated. The medical history (including 
previous ptosis surgery in the OPMD patients) was assessed. Information about 
the repeat lengths of the PABPN1 mutation were collected.
Symptoms of OPMD
The OPMD patients were interviewed about current symptoms which they 
attributed to OPMD.
Daily life activities and disease impact
Validated questionnaires were used to assess participants' daily living activities 
and disease impact: Health Assessment Questionnaire (HAQ) and Sickness 
Impact Profile (SIP 68).[13,14] 
Physical activity
A Motor Function Measure (MFM) was obtained by a trained examiner.[15] In 
addition, a six-minute walk test (6MWT) and timed up and go test (TUGT) were 
performed.[16,17] Physical activity during 12 days was constantly assessed 
with use of an actometer, a device that is attached to the ankle (activity levels
expressed in mean number of accelerations per 5-min period over 24-
hours).[18,22]
Muscle strength
Manual muscle testing: Muscle strength was graded with the Medical Research 
Council (MRC) scale in the neck flexion, neck extension, trapezius, deltoideus, 
serratus anterior, biceps brachii, triceps, wrist extension, wrist flexion, finger 
extension, finger flexion, psoas, gluteus medius, quadriceps, hamstrings, tibialis 
anterior, gastrocnemius.
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Quantitative muscle studies: Isometric force recordings of voluntary maximum 
force generation of the quadriceps femoris were performed as described 
previously.[19] Participants were seated in a custom-built chair with the knee 
angle set at 120°. To prevent compensatory movements, participants were 
strapped at the hips and upper body to maintain their position. All 
measurements were performed in the right leg, unless in the presence of 
asymmetrical weakness in which case the weakest leg was measured. 
Participants were asked to perform a maximum voluntary isometric contraction 
(MVC) during three seconds. All participants were encouraged similarly to really 
perform a maximum contraction. The highest force from three contractions is 
used to represent the MVC. 
MRI
Imaging of the upper leg(s) was performed on a 3 Tesla MR system (Tim TRIO, 
Siemens, Erlangen, Germany) with a spine array coil and two phased-array 
coils placed around the legs. Patients were placed in the scanner feet first 
supine. Scout images were acquired in three orthogonal directions for accurate 
positioning of the MRI slices. Thereafter eight transversal slices (FOV 175×175 
mm2, thickness 4 mm, gap 6 mm, base resolution 256) were acquired with a T2 
multi spin echo sequence (TR: 3000 ms, 16 equally spaced echo times 7.7 –
123.2 ms). Subsequently 23 transversal slices (thickness 4 mm, gap 0.4 mm) 
were obtained with a T1 turbo spin echo sequence (FOV 250×244.5 mm2, 
TR/TE 600 ms/13 ms, base resolution 448). 
Fat fraction of the quadriceps (vastus lateralis, vastus medialis, vastus 
intermedius and rectus femoris), hamstrings (semitendinosus, 
semimembranosus, biceps femoris caput brevis and longum) and hip adductors 
(adductor longus and magnus) at the slice corresponding with 1/3 of the 
distance between the patella and spina iliaca anterior superior was quantified 
on T2 images using the methods described by Kan.[20,12] 
Muscle biopsies
A needle biopsy of the right quadriceps (vastus lateralis) was obtained from all 
but one participants, and one biopsy could not be evaluated. Biopsies were 
frozen in isopentane and stored at -80°C. 10 um thick frozen sections were 
stained for haematoxylin- phloxine and  studied with light-microscopy. The 
severity of the pathological changes was scored according to the FSHD 
pathology grade of quadriceps muscle, which is considered an useful marker of 
disease activity in FSHD.[21] It consists of an ordinal scale of 0 to 3  (0 = 
normal; 1 = mild; 2 = moderate; and 3 = severe) to rank four morphological 
features (I.Variability in fibre size; II.Extent of central nucleation; 
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III.Necrosis/regeneration; IV.Interstitial fibrosis). The pathological grade is the 
sum of the scores on the four features, which yields a score between 0 and 12 
(0 = normal to 12 = severe dystrophic changes).[21] Furthermore, the presence 
of rimmed vacuoles (RV) was scored in all assessable fibres (364-2361 per 
biopsy).
Statistics SPSS (version 22, IBM, Armonk, New York) was used to conduct the 
statistical analyses. Continuous data are described as mean with range, 
descriptive data as number (n). Statistical analyses to compare results of 
OPMD patients with controls were performed by t test or Mann-Whitney U test, 
where appropriate. To analyze if the presence of muscle weakness differed 
between groups, the Fischer exact test was used.  p < 0.05 was considered 
statistically significant.
Results
Participants
14 OPMD patients and 12 controls (six males in both groups) participated in this 
study. The mean age of the OPMD patients was 51.8 years (range 39-63 years) 
and of the controls 53.8 years (range 44-65 years) (p=0.437). The age at onset 
of self-reported symptoms in OPMD participants was 44.7 years (range 39-54 
years). Four patients reported no complaints and had no symptoms at 
investigation; they were classified as presymptomatic carriers. The disease 
duration ranged from 0 (presymptomatic carriers; n=4) to 20 years, with a mean 
of 10.2 years. Repeat length varied from 13 to 16. Most patients (57%) had 
(GCN)13 or (GCN)14 repeat expansions.
Symptoms of OPMD
Six of the OPMD patients (43%)  reported walking difficulties or other pelvic 
girdle or proximal leg motor symptoms. This subgroup of patients had a mean 
age of 56.5 years (range 47-63 years); the subgroup without these symptoms 
were younger (mean age of 48.5 years (range 39-56 years), p=0.027). Two of 
them had had a ptosis correction before without current symptoms of ptosis or 
dysphagia; two others reported dysphagia, and one both dysphagia and ptosis. 
Only one of these six patients had neither dysphagia nor ptosis (currently or 
before surgery).
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Daily life activities and disease impact 
The SIP total score was higher in the patients group than in the controls, with a 
mean score of 3.6 (± 4.8) and 0.1 (±0.3), respectively (p=0.007) (table 1). The 
scores of the SIP subcategories “physical mobility control” and “social 
behaviour” were higher in patients than in controls (p=0.006; p=0.012). HAQ 
scores did not differ between OPMD patients and controls (p=0.109).
Table 1  Demographic and genetic characteristics of the OPMD patients 
and controls, current symptoms attributed to OPMD, daily life activities 
and disease impact, physical activity, muscle strength, MRI and biopsies.
This table shows more limitations of physical mobility and social behaviour in 
relative young OPMD patients compared to healthy controls; and an increased 
fat fraction of the hip adductors in OPMD patients compared with controls, in 
combination with a decrease of cross sectional area of the hip adductors 
without a difference in physical activity in both groups.
Demographics Control 
subjects
OPMD 
patients
p
n 12 14
Sex ƃ ƃ
Age: mean (range)(years) 53.8 (44-65) 51.8 (39-63)
Age at onset: mean
(range)(years)
Not applicable 44.7 (39-54) 
*
Disease duration:
mean (range)(years)
10.2 (0-20)
Repeat length (n) 1 (GCN)13
7 (GCN)14
1 (GCN)15
5 (GCN)16
Current symptoms attributed to OPMD (number of patients)
Experienced limb girdle 
weakness
0 6 0.0171 **
Ptosis (complaint or previous 
operation)
0 7 0.0064 **
Dysphagia 0 7 0.0064 **
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Demographics Control 
subjects
OPMD 
patients
p
Daily life activities and disease impact
SIP Total: mean (SD) 0.1 (0.3) 3.6 (4.8) 0.007 ***
SIP physical somatic 
autonomy
0.0 (0.0) 0.7 (0.3) 0.355 ***
SIP physical mobility control 0.0 (0.0) 1.6 (2.0) 0.006 ***
SIP psychological autonomy 
communication
0.1 (0.3) 0.2 (0.6) 0.610 ***
SIP psychological emotional 
stability
0.0 (0.0) 0.3 (0.5) 0.048 ***
SIP social social behaviour 0.0 (0.0) 1.3 (2.0) 0.012 ***
SIP social mobility range 0.0 (0.0) 0.1 (0.5) 0.355 ***
HAQ scores mean (range) 0.04 (0.000-
0.375)
0.30 (0.000-
1.875)
0.109 ***
Physical activity
Actometer activity (mean 
number of accelerations per 
5-min period over 24-hours)
52 53 0.836 ****
MFM total: mean 0.99 0.95 0.060 ***
6MWT: mean (range)(meters) 513.22 (461-
600)
492.54 (356-
571)
0.395 ****
TUGT: mean 
(range)(seconds)
5.2045 (3.93-
6.28)
7.0179 (4.82-
10.26)
0.002 ****
Muscle strength
MRC Quadriceps 5 5
MRC hip flexors 5 4.5 0.042 **
MRC hamstrings 5 5
MVC Quadriceps (N) 572 490 0.263****
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Demographics Control 
subjects
OPMD 
patients
p
MRI
MRI Quadriceps fat fraction 
(%)
7.56 16.37 0.108****
MRI Hip Adductors fat fraction 
(%)
11.35 28.30 0.001**** 
MRI Hamstrings fat fraction 
(%)
9.04 21.81 0.040****
MRI Quadriceps cross 
sectional area (mm2)
2809 2400 0.120****
MRI Hip Adductors cross 
sectional area (mm2)
1069 671 0.000****
MRI Hamstrings cross 
sectional area (mm2)
1335 1071 0.058****
Biopsies
Muscle pathology grade (I –
IV)
1.25 2.75 0.077***
Number of biopsies with RV 0 7
* number of patients = 10; four did not yet have complaints of OPMD
**Fischer’s exact test 
*** Mann Whitney U test
**** T-test 
Statistically significant differences are printed in bold.
Physical activity
The results of the MFM total score (and subscales, not reported), 6MWT and 
actometer showed no difference between OPMD patients and controls. The 
TUGT was slower in patients than in controls (p=0.002), however the mean 
score of the patients was still within the normal range (table 1). 
Muscle strength
Manual muscle testing: The muscle strength measurements showed MRC 5 of 
all tested muscles in the controls. The muscle strength of the quadriceps 
muscles was preserved in 13/14 patients. Hip flexor weakness was present in 
5/14 (36%) OPMD patients, compared to 0/12 (0%) controls  (p=0.042). OPMD 
patients with weakness of the hip flexors were older than those without, 
respectively 58.8 years (range 55-63 years) and 47.9 years (range 39-57 
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years), p=0.002.  Furthermore, muscle strength of the neck flexors was reduced 
in six OPMD patients; of the neck extensors in only one patient; of the serratus 
anterior muscles in one patient; of the deltoideus muscles in one; of the medial 
gluteus in three patients; of the anterior tibialis in one; finger extensors in four 
patients; and wrist flexors, wrist extensors and triceps muscles in one patient.
Quantitative muscle function: The MVC of the quadriceps did not differ between 
OPMD patients and controls (table 1).
MRI
The MRI fat fraction and cross sectional area of the quadriceps did not differ 
between OPMD patients and controls. The fat fraction of the hip adductors and 
the hamstrings were higher in OPMD patients than in controls (p=0.001 and 
p=0.040). The cross sectional area of the hip adductors was smaller in OPMD 
patients, nearly 40% smaller than in controls. The cross sectional area of the 
hamstrings was also decreased, however this decrease failed to reach 
significant (figure 1 and 2).
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Figure 1 MRI slices of the thighs of the OPMD patients.
Transversal slices, corresponding with 1/3 of the distance between the patella 
and spina iliaca anterior superior (indicated with a fish-oil marker) , acquired 
with T2 multi spin echo sequence. The patients are ordered form youngest to 
oldest from top left to bottom right, showing more fatty infiltration of hip 
adductor and hamstring muscles in older patients.  
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Figure 2 The distribution of fat fraction and muscle fraction of the 
quadriceps, hamstrings and adductors muscles in healthy controls and 
OPMD patients. This diagram shows that the adductor muscles have most 
severe fatty infiltration.
Muscle biopsies
OPMD biopsies showed more dystrophic changes than the muscle biopsies of 
the healthy controls (p=0.009) whereas the four presymptomatic carriers did not 
show more dystrophic changes compared to healthy controls (p=0.089). Seven 
(58%) biopsies showed the presence of RV, and one of these biopsies was of a 
presymptomatic carrier. The  mean percentage of fibres containing RV was 
0.58% (range 0.04-1.92).
Discussion
The main finding of this study is that relatively young OPMD patients (mean age 
52 years; range 39-63 years) more frequently report pelvic girdle and proximal 
leg weakness and experience limitations of physical mobility and social 
behaviour compared to healthy controls. Weakness of the hip flexors was 
observed in 36% of the patients. These clinical findings were supported by 
imaging and biopsy results. MR imaging showed an increased fat fraction of the 
hip adductors and hamstrings in OPMD patients compared with controls, and a 
decrease of cross sectional area of the adductors. Quadriceps biopsies of the 
OPMD patients (with exclusion of presymptomatic mutations carriers) showed 
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more dystrophic changes than the muscle biopsies of the healthy controls. 
Seven (58%) biopsies showed the presence of RV, among them even one 
presymptomatic carrier. The physical activity measured by the actometer did not 
differ between OPMD patients and controls. It is therefore unlikely that the 
reported and observed weakness is related to disuse. Finally, the patients who 
reported symptoms and had hip flexor weakness were older than the patients 
without.
Together, these findings in a relatively young OPMD cohort confirm our 
previous observations of pelvic girdle and proximal leg muscles weakness, and 
specifically point to the involvement of the hip flexor, hip adductor and 
hamstring muscles. This is important for rehabilitation and future trial design. 
Limitations of daily life activities and increased disease impact were also 
reported in a questionnaire study on the health related quality of life (HRQoL) in 
OPMD (n= 89, mean age 66.2 years (range 37-84 years)).[22] This study 
showed that functional impairment of the lower extremities had more impact on 
the HRQoL than dysphagia. A retrospective chart review showed a high 
prevalence of hip flexion weakness (78%) and predominantly preserved knee 
extensors strength (weakness only in 14%). Moreover, hip flexion weakness 
was associated with use of assistive devices.[23]
The manual and quantitative muscle testing showed weakness of the hip flexors 
but not of the knee extensors. The observed functional limitations correspond to 
this pattern of weakness, since hip flexors, hip adductors and hamstrings are 
important muscles required for walking. The adductor magnus contracts and 
pulls the hip towards the body’s midline, which is a fundamental part of walking, 
sprinting and a variety of other bipedal motions. This is an important 
observation, both for rehabilitation and for future clinical trials. It might also 
partly explain the discrepancy in prevalence of proximal weakness in OPMD 
patients, since many study protocols focus on knee extensor strength. 
The MRI results of the thigh correspond with the findings of the MRI study of 
Fischmann et al. They also showed prominent involvement of the adductors.[24] 
Unfortunately, they did not include the pelvic muscles either. An earlier study on 
clinical and CT findings in OPMD showed diffuse atrophy and fatty degeneration 
of the psoas muscles in a 74-years-old male OPMD patient.[25] In our study the 
quadriceps did not show fatty infiltration, and the muscle strength of this 
muscles was preserved. 
Even though we did not observe quadriceps weakness, muscle biopsies did 
show histopathological alterations, including rimmed vacuoles in the biopsy of 
one of the presymptomatic carriers. We have previously reported the presence 
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of intranuclear aggregates in quadriceps muscle of Ala-expanded-PABPN1 
carriers before clinical onset.[3] Apparently, the quadriceps muscle is clinically 
and radiologically later affected than the hip adductors and hip flexors, and 
hamstrings. Hence, although frequently used as a functional outcome measure 
in neuromuscular disorders, the quadriceps muscle seems not to be the 
appropriate muscle to assess clinically as a measure of limb girdle function in 
OPMD. This study suggests that the hip flexors, hip adductors and hamstrings 
might be more appropriate muscles to test, both clinically and by imaging. 
This study has a number of limitations. First, the group size is relatively small 
due to our exclusion of older patients. Second, the patients had, as expected in 
the Dutch cohort, a relatively long repeat expansion ((GCN)13: n=1;  (GCN)14: 
n=7;  (GCN)15: n=1; (GCN)16: n=5) Our protocol did not include assessment of 
hip adductor strength, although this is an important muscle group for walking 
and keeping balance. Vice versa, the iliopsoas was not included in the MR 
protocol.
In short, this study demonstrates that involvement of pelvic girdle and proximal 
leg muscles can be a relatively early feature of OPMD, occurring long before 
the age of 60, resulting in impaired ability to perform activities of daily living, 
which may be related to early fatty infiltration and atrophy of hip adductor 
muscles. This occurs not only in patients with more severe genetic defects. This 
study suggests that the hip flexors, hip adductors and hamstrings are the most 
appropriate muscles to assess in addition to the quadriceps muscle, with 
functional tests as TUGT or climbing stairs and questionnaires focusing on 
these functions, and by (quantitative) muscle strength measurements combined 
with MRI fat fraction assessment. The quadriceps muscle can be the target 
muscle for biopsies. These findings are important in clinical setting, 
management, natural history studies and for the design of outcome measures in 
trials.
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Summary 
The introduction (Part I) presents an overview of the history of Oculopharyngeal 
muscular dystrophy (OPMD) from its first description by Taylor in 1915 to the 
discovery of the gene mutation in PABPN1 by Brais in 1998.[1,2] At the time of 
the discovery of its genetic cause, OPMD was clinically not well recognized in 
the Netherlands yet. This was caused by a patient delay in some of the cases. 
We assume that there was also a doctor’s delay due to limited recognition of 
this rare disorder at the time. Furthermore, we observed that pelvic girdle and 
proximal leg weakness was more pronounced in the Dutch OPMD patients who 
were the first to be diagnosed in the Netherlands than it was in the cohorts 
reported from other countries.  
We initiated an observational study to improve clinical recognition of OPMD and 
to investigate the prevalence of pelvic girdle and proximal leg muscle weakness 
in the Dutch OPMD population. Furthermore, since most of the OPMD studies 
at that time focused on histopathological and genetic aspects, we included a 
questionnaire study on the patients’ perspective of OPMD.  
 
This study was expected to improve the clinical recognition of the disorder, to 
promote symptomatic treatment, to contribute to the knowledge on the 
pathophysiology needed for targeted therapies, and to improve the outcome 
measures required for trial preparedness. In addition, through this study we 
initiated collaboration with Dr. V. Raz of the Department of Human Genetics at 
Leiden University Medical Centre on translational aspects of the disease by 
Aims (numbering corresponds with the parts of this thesis):   
 
II-III: to investigate and report the clinical, genetic and histopathological 
features of Dutch OPMD patients; and to compare these features with those 
of OPMD patients in other cohorts  
IV: to explore the patients’ perspective of OPMD, and; 
V: to confirm the results of our pilot study (part II) in a larger cohort and by 
obtaining more detailed information of the clinical spectrum of OPMD; to 
investigate the histopathological features in presymptomatic PABPN1 carriers; 
and to examine the pelvic girdle and proximal leg muscles involvement with a 
multidimensional approach in early OPMD patients and presymptomatic 
PABPN1 carriers. 
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combining our clinical data and histological materials with OPMD animal models 
and their cellular studies. 
Part II of this thesis presents our initial clinical and genetic observations. 
Chapter 2 is a clinical report of the five first identified OPMD families in the 
Netherlands (16 patients). OPMD was confirmed genetically in four families and 
histologically in one family. The clinical phenotype of these Dutch patients was 
mostly similar to that of previously reported non-Dutch OPMD families. All 
patients suffered from ptosis. Seven patients (44%) had undergone surgery for 
bilateral ptosis and in three cases surgical correction was planned. All patients 
complained of dysphagia. They needed more time to chew and swallow to avoid 
choking, which resulted in a longer eating time. Four patients lost weight as a 
result of severe dysphagia, two patients were on a high-calorie diet to prevent 
weight loss, and two others had undergone a cricopharyngeal myotomy. 
Remarkably, this study showed that weakness of the pelvic girdle and proximal 
leg muscles can occur early in the course of the disease and can remain the 
most  important symptom of OPMD.  
Chapter 3 describes the results of the genetic analysis of four unrelated Dutch 
OPMD families. We identified a new mutation in the PABPN1 gene in two of the 
four families. A normal PABPN1 gene contains a (GCG)6 repeat followed by 
(GCA)3GCG, together (GCN)10. This stretch is translated into ten alanine 
residues in the protein, because both codons (GCG and GCA) are translated 
into an alanine residue. Worldwide, the most prevalent mutation is the 
expansion of (GCG)6 to (GCG)9 repeats, adding three extra alanine residues to 
the protein. We found a duplication of (GCA)2(GCG)2  (27-28ins12, AAAA11-12 
ins) instead of a (GCG) repeat expansion in two families. These patients had a 
(GCG)6(GCA)2(GCG)2(GCA)3GCG repeat instead of the normal 
(GCG)6(GCA)3GCG allele in the first exon of the PABPN1 gene (figure 1B).  
In two unrelated Japanese families, Nakamato et al. had found two other 
mutations: (GCG)6GCA(GCG)3(GCA)3GCG and 
(GCG)6(GCA)3(GCG)2(GCA)3GCG instead of the normal (GCG)6(GCA)3GCG 
allele.[3] They had postulated that these mutations could not be caused by the 
molecular mechanism of the slippage model (figure 1A), but that they were in 
fact the result of unequal crossing-over (figure 1B). This theory of unequal 
crossing-over is supported by the identification of the new mutation in the two 
Dutch families.   
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Figure 1A: slippage model 
Slippage is thought to occur in sections of DNA with repeated patterns of bases 
(repeated single nucleotides, doublets or triplets such as GCG or CAG). During 
DNA replication polymerase slippage and subsequent re-attachment can cause 
a loop in the new strand, resulting in the insertion of one or more repeats on the 
newly-synthesized strand. 
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Figure 1B: The newly-identified PABPN1 mutation in two Dutch OPMD 
families. This mutation supported the theory of unequal crossing-over as a 
molecular mechanism causing OPMD. In equal crossing-over, the entire 
segment of allele A is exchanged with the entire segment of allele B; in unequal 
crossing-over, only part of the segment of allele B is exchanged with the entire 
segment of allele A. This results in a contracted segment B on chromosome A 
and an expanded segment on chromosome B (comprised of the entire segment 
of allele A and part of the segment of allele B). 
  
Part III comprises three specific clinical observations. First (Chapter 4), we 
observed that the posture of the head can be very helpful in differentiating 
between the two most common types of adult onset ocular myopathies: OPMD 
and chronic progressive external ophthalmoplegia (CPEO). As ocular motility is 
largely unaffected in OPMD, patients often compensate for their ptosis by 
retroflecting their neck. This phenomenon has previous been named by others 
the ‘astrologist’s posture’ (retroflexion of the neck combined with a downward 
gaze to compensate for severe bilateral ptosis). In contrast, CPEO patients are 
unable to use the astrologist’s posture due to a restricted downward gaze. If 
they retroflect their neck their visual field is reduced by the ptosis. A 
retrospective review of all patients in our centre with genetically confirmed 
OPMD and CPEO revealed that 90% of the OPMD patients use (or, because of 
surgical eyelid correction, used) the astrologist’s posture. In contrast, only 7% of 
the CPEO patients used this posture (only those with a mild downward gaze 
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paralysis could establish this posture). We therefore propose that the 
astrologist’s posture is a useful discriminative diagnostic tool in patients with a 
slowly progressive bilateral ptosis. 
In Chapter 5 we report that this astrologist’s posture has a negative effect on 
swallowing, although it is beneficial for patients to preserve their visual field,. 
This study showed that the degree of retroflexion of the head was related to the 
severity of dysphagia. Furthermore, instructions to eat and drink with a slightly 
flexed head position resulted in a subjective and objective reduction of 
swallowing problems. Based on these data, we concluded that speech 
therapists, neurologists and ophthalmologists can alleviate the swallowing 
problems by teaching patients to interrupt their compensatory retroflexion of the 
head while eating and drinking. 
In Chapter 6, we describe two unrelated patients with OPMD who developed 
frontotemporal dementia (FTD). Both patients had severe genetic defects: the 
first patient had a compound heterozygous (GCN)12/(GCN)16 mutation, and 
the second had a heterozygous mutation with long repeat length (GCN)17. 
These cases support the earlier reports of cognitive impairment in OPMD and 
its possible relation to expanded PABPN1 load. They also show that the 
cognitive decline may even precede limb or girdle muscle weakness. Severe 
PABPN1 mutations should be considered in FTD patients with muscle 
weakness (including dysphagia and ptosis), or those with a positive family 
history of either FTD or muscular dystrophy. 
In summary, the preceding three chapters offer clues for clinical recognition of 
OPMD and we provide an important symptomatic treatment advice for 
professionals who treat OPMD patients with dysphagia. 
Part IV (Chapter 7) describes a questionnaire study of the patients’ perspective 
on OPMD. So far, OPMD was generally considered as a “benign” muscle 
disease with a relatively mild initial disease course with no or only mild 
functional disabilities for patients. The aim of this study was to assess the 
prevalence and severity of fatigue, pain, and functional limitations, and the 
social participation and psychological well-being of OPMD patients.  
We included 35 genetically confirmed Dutch OPMD patients and we showed 
that fatigue and pain occurred in more than half of them (54%). Also, the 
disorder caused remarkable impairments in daily life activities in nearly all 
patients (94%), even in those younger than 60 years of age. An additional 
finding was that fatigue severity was related to these impairments, whereas pain 
and disease-duration were not. Finally, we saw that the prevalence of 
psychological distress was similar to that observed in healthy adults.  
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We discussed that the high prevalence of fatigue, pain, and functional 
disabilities could be partly related to the large average mutation size of the 
participating patients, leading to a more severe disease course. Worldwide, 
most OPMD patients have the (GCN)13 expansion; in our sample only two out 
of 35 patients had this mutation and more than a third (16 out of 35) had the 
(GCN)16 expansion. Since the average disease duration was 11.6 years, which 
reflects a moderate disease progression, pain and fatigue do not seem to be 
problems of end-stage OPMD only. Hence, the results of this study suggest that 
symptomatic management in OPMD patients should include therapies aimed at 
the reduction of fatigue, pain and functional impairments, similarly as in other 
myopathies. 
Part V involves the results of two systematic studies of OPMD. Chapter 8 is a 
prospective, observational study in 40 OPMD patients and 18 adult children of 
genetically confirmed OPMD patients among whom six were carriers of a 
mutation but were presymptomatic. The study included a structured history, a 
detailed neurological examination, muscle histology and biochemical analysis. 
By inclusion of muscle biopsies of presymptomatic carriers, we had the unique 
opportunity to study the histopathological and biochemical changes before the 
clinical onset of the disease and to shed light on the role of the typical 
aggregates in the pathophysiology of OPMD. One patient died during the study 
and had given permission to perform an autopsy, which allowed us to study the 
histopathology of multiple muscles in this patient.  
The main findings were the presence of intranuclear aggregates and the 
absence of mitochondrial changes in presymptomatic Ala-expanded-PABPN1 
carriers. This indicates that the expression of Ala-expanded-PABPN1 causes 
the formation of nuclear aggregates before the onset of muscle weakness, and 
that potential mitochondrial dysfunction occurs later in the disease course. The 
autopsy showed that muscle weakness was related to histopathological findings 
in five different muscles in this individual patient. 
Another important finding was the high variation in the clinical manifestation of 
OPMD in this Dutch cohort. In addition to the characteristic symptoms, ptosis 
and dysphagia, other symptoms such as proximal leg weakness (85%) and 
external ophthalmoplegia (43%) were frequently observed. This study confirms 
the findings of our previous pilot study, which is described in part II/chapter 2, 
and in which we observed that limb girdle weakness frequently and prominently 
occurs in the Dutch OPMD cohort. As such, our observations contribute to an 
improved recognition of the OPMD phenotype. Importantly, our study 
demonstrates the broad spectrum of affected muscles, and the high variation in 
loss of strength of affected muscles during the progression of the disease. 
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Since OPMD is likely to be underdiagnosed, these findings will have a direct 
clinical impact on disease recognition. 
Finally, in Chapter 9, we studied weakness of pelvic girdle and proximal leg 
muscles in early OPMD with a multidimensional approach. This study showed 
that involvement of pelvic girdle and proximal leg muscles can be a relatively 
early feature of OPMD, occurring before the age of 60, and resulting in impaired 
ability to perform activities of daily living. Furthermore, this study reveals that 
the hip flexors, hip adductors and hamstrings are most frequently affected and 
they are the appropriate muscles to test clinically and radiologically to monitor 
the clinical course of the disease. In addition, these muscles should be taken 
into account in patient management as well as in the selection of outcome 
measures in future trials. Based on the histopathological alterations observed in 
presymptomatic Ala-expanded-PABPN1 carriers (Chapter 8 and 9), the 
quadriceps muscle remains the target muscle for biopsies. 
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General discussion 
After the summary of our results, we will now relate our findings to the 
observations in other recent studies.  
 
Figure 2: A time frame showing key publications about OPMD until the 
end of the 20th century in the background (grey) and in the foreground 
(black) the publications of the studies mentioned in this thesis (Italic) 
completed with other important publications about OPMD from 2003 to 
2017.[4-7] It shows that the studies in this thesis have shed light on clinical 
features of OPMD and the patients’ perspective, as well as pathophysiological 
features. Our publications described e.g. the occurrence of weakness of the 
pelvic girdle and proximal leg muscles in OPMD, as did Richard et al.[7] 
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Our pilot study describes the clinical and genetic features of 16 patients from 
five different OPMD families (Part II; Chapter 2). The family history was 
assessed in each family, and the family trees were extended. Participants 
contacted their family members and informed them about the study and the 
neuromuscular service at our centre. Many patients now visit the neurologist 
early in the course of the disease to be informed about the disorder and 
symptomatic treatment options and to learn about ongoing studies. This has 
resulted in an increased recognition of OPMD and a decrease in patient delay.  
At the same time, some affected family members are still reluctant to visit the 
hospital, since they consider this useless in the absence of a cure for the 
disease. 
Furthermore, the publication of our studies has also resulted in a reduction in 
the doctor’s delay for OPMD, and several “new” patients have been referred to 
the Neuromuscular Centre Nijmegen. This growing number of patients enabled 
us to perform the studies described in this thesis and to extent the knowledge 
on the clinical features of OPMD, the patients’ perspective, symptomatic 
treatment and pathophysiological features. 
Clinical features of OPMD and the patients’ perspective 
 
So far, OPMD had been considered as a “benign” muscle disease with a 
relatively mild initial disease course with no or only mild functional disabilities. 
We have shown that OPMD frequently causes impairments in daily life activities 
(Part IV; Chapter 7); nearly all participants of our questionnaire study reported 
impairments in daily life activities, even those younger than 60 year. 
Additionally, this study showed that fatigue and pain occur in more than half of 
the OPMD patients and that fatigue severity was correlated with the 
impairments in daily life activities. This is similar to other neuromuscular 
disorders, in which fatigue severity also correlates with severity of impairment of 
daily life activities. Kalkman et al. showed that the majority of patients with 
facioscapulohumeral muscular dystrophy (FSHD; 61%), myotonic dystrophy 
type 1 (MD; 74%) or hereditary motor and sensory neuropathy type I (HMSN; 
64%) experienced severe fatigue, which was associated with severe impairment 
in daily life activities. [8] 
The distribution pattern of the pain in our cohort - mostly located in neck, upper 
arms and upper legs - suggested that the pain might be related to the muscle 
weakness pattern in OPMD. The pain in the neck may also be caused by the 
‘astrologist’s posture’ (retroflexion of the neck combined with downward gaze to 
compensate for severe bilateral ptosis) (Part III; Chapter 4).  
514290-L-sub01-bw-vdSluijs
Processed on: 6-10-2017 PDF page: 158
Chapter 10 Summary, discussion and future perspectives 
 
 
158 
Comparable to the presence of pain in more than half of our OPMD patients, 
pain is also common in many other neuromuscular disorders. Albresch et al. 
described that in a sample of 811 patients, suffering from different forms of 
slowly progressive NMD (not including OPMD), 83% reported to experience 
pain, which significantly interrupted daily life activities. [9] Jensen et al. showed 
that 82% and 64% of patients with FSHD and MD, respectively, reported 
pain.[10] They also showed that pain interferes with daily life activities. In 
contrast, pain was not related to the level of disabilities in our OPMD cohort. 
This is probably due to the higher prevalence and severity of pain in FSHD than 
in OPMD, which could be caused by the different patterns of muscle weakness, 
different pathophysiological mechanisms, or diverse modes of adaptation to the 
limitations in daily life activities and subsequent difference in overuse of 
muscles. In FSHD the trunk flexors are among the weakest muscle groups and 
the imbalance between the extensors and flexors of the trunk leads to low back 
pain. [10] 
Thus, pain and fatigue occur regularly in OPMD patients as in other patients 
with neuromuscular disorders,[11] and these symptoms have to be added to the 
features of OPMD. 
Another feature that we have added to the clinical OPMD spectrum is cognitive 
impairment, which we observed in patients with severe genetic defects (Part III; 
Chapter 6): two unrelated OPMD patients, one with compound heterozygous 
mutations ((GCN)12/(GCN)16) and another with a long repeat length 
((GCN)17), developed frontotemporal dementia (FTD). In both patients the 
cognitive symptoms were more pronounced than the muscle weakness at the 
time of referral. Recently, we encountered a third OPMD patient unrelated to the 
other two, who had FTD. In addition, our clinical experience reveals mild frontal 
function disturbances like social disinhibition in a subset of patients. These 
findings support the earlier reports of brain involvement in a subset of OPMD 
cases and they add that a cognitive decline may even precede pelvic girdle and 
proximal leg muscle weakness.[12-14] PABPN1 mutations should therefore be 
considered in FTD patients with mild muscle weakness (including dysphagia 
and ptosis), or those with a positive family history of either FTD or muscular 
dystrophy.  
Cognitive impairment has not been recognized as a feature of OPMD for long. 
In OPMD patients with a less severe genetic defect, brain involvement probably 
does not occur or it is not severe enough to become clinically manifest during 
normal life span. Neuropsychological evaluation in 11 heterozygous OPMD 
patients without cognitive complaints showed that these patients were less 
efficient in several tests than a matched control group, particularly in those 
testing executive functions.[15]  
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OPMD is not the only muscular disorder associated with cognitive impairment. 
Myotonic dystrophy type I, which is another autosomal dominantly inherited 
trinucleotide repeat disease, probably has the most pronounced cognitive and 
social-emotional symptoms. It is in fact a multisystem disease with muscle 
involvement, in which the cognitive symptoms include mental impairment, 
executive dysfunction and avoidant personality traits. These cognitive 
impairments seem to eventually increase with age. [16-19] Furthermore, there 
are some similarities between patients  with on the one hand OPMD and FTD, 
and on the other hand those who have motor neuron disease (MND) in 
combination with FTD, especially the MND with bulbar dysfunction. These 
similarities exemplify that OPMD is a differential diagnosis in the spectrum of 
motor neuron disease and FTD. 
An important finding of our prospective observational study in 40 OPMD 
patients (Part V; Chapter 8) was the variation in the clinical manifestation of 
OPMD in this Dutch cohort. The initial symptom/sign was ptosis in 17 patients 
(43%), dysphagia in 12 (30%), and limb girdle weakness in 10 (25%). The 
combination of ptosis and dysphagia, referred to in the name of the disease 
OPMD, was reported at onset by only one patient (3%). Dysphagia was the 
most frequent current symptom (98%), followed by ptosis (88%) and weakness 
of the pelvic girdle and proximal leg muscles (85%). The weakness of the pelvic 
girdle and proximal leg muscles varied from mild (MRC 4) to severe (MRC 2). 
Other common symptoms/signs were: dysphonia (70%) and facial 
weakness/limited facial expression (60%). In addition, axial muscles were also 
affected: neck flexor weakness and neck extensor weakness occurred in 
respectively 48% and 28% of the patients. None of the patients initially 
presented with external ophthalmoplegia and diplopia, but it gradually 
developed in 43% and 18% of patients respectively (at a mean age of 60 and 
63 years). 
The prevalence of weakness of the pelvic girdle and proximal leg muscles 
(85%) observed in this prospective observational study was higher than that 
reported of other OPMD populations from: Israel (Bukhara Jews; 20%), 
Uruguay (34%), France (52%), Germany (56%), Italy (60%), New Mexico (65%) 
and Quebec (Canada, 71%).[20-26] The weakness of the pelvic girdle and 
proximal leg muscles was even the initial symptom in 25% of our patients, 
which is higher than that observed in an OPMD cohort in the United Kingdom 
(10%).[27] Our prospective observational study in 40 OPMD patients confirmed 
(Part V; Chapter 8) our previous pilot study, which suggested that limb girdle 
weakness occurs frequently and prominently in the Dutch OPMD cohort (Part II; 
Chapter 2). Our findings also confirmed the observations in the Danish OPMD 
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cohort (n=13): limb weakness can be common in OPMD and can be even the 
presenting symptom in five patients [28].  
In summary: the clinical features of OPMD are not restricted to ptosis and 
dysphagia. In contrast, even in the early stage of the disease weakness of the 
pelvic girdle and proximal leg muscles can occur, especially of the hip flexors 
and hip adductors. Other additional features can be pain, fatigue and cognitive 
impairments. 
 
Figure 3: The clinical features of OPMD: beyond dysphagia and ptosis. 
Left: Weakness pattern of OPMD known so far: The major diagnostic criteria 
include ptosis and dysphagia (https://www.mda.org/disease/oculopharyngeal-
muscular-dystrophy).  
Right: The clinical features of OPMD are not restricted to ptosis and dysphagia; 
even in the early stage of the disease weakness of the pelvic girdle and 
proximal leg muscles can occur, especially of the hip flexors and hip adductors. 
Additional features include pain, fatigue and cognitive impairments (particularly 
in those with severe genotype). 
The high prevalence of weakness of the pelvic girdle and proximal leg muscles 
in the Dutch OPMD population might be partly related to the large average 
mutation size of the patients in our study, leading to a more severe disease 
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course. Worldwide, most OPMD patients have the (GCN)13 expansion [2;27-
29]; in the Dutch OPMD cohort only two (5%) had this mutation, 31% had the 
(GCN)16 expansion (Part V;Chapter 8). However, weakness of the pelvic 
girdle and proximal leg muscles can also be a prominent feature in patients with 
a (GCN)13 expansion.[28] 
The presumed (inverse) relation between repeat length and occurrence of 
proximal weakness and age at diagnosis/onset has been confirmed in a large 
French cohort (n=354) recently.[7] They saw that in heterozygous patients with 
a GCN expansion of 11-14, proximal weakness was a late clinical symptom, 
whereas in patients with larger expansions (>(GCN)14) proximal weakness was 
often present at the time of diagnosis. In their heterozygous patients with a 
GCN13 allele (n=176), the mean age at diagnosis was 64 ± 10 (SD) years. In 
half of their patients who were compound heterozygous for (GCN)11/(GCN)12 
(n=9), proximal weakness appeared around the age of 60 years, 5-10 years 
after the onset of bilateral ptosis. In addition, they described weakness of the 
lower extremities in homozygous patients. Four out of the nine patients who 
were homozygous for (GCN)11, showed proximal and especially distal muscle 
weakness with myalgia and difficulty with walking, but these patients were older 
than 65 years of age. The patients who were homozygous for (GCN)12 (n=2) or 
(GCN)13 (n=2) all had proximal muscle weakness of their lower limbs. In the 
description of these patients cognitive impairment is not mentioned. 
Furthermore, in this French study the (GCN)11 expansion was mentioned as a 
dominant mutation, like Richard et al. described earlier.[7,30] This in contrast 
with the initial publication of Brais et al. in 1998, who considered the (GCN)11 
allele either as a polymorphism which acts as a severity modifier of the 
dominant OPMD phenotype, or as a recessive mutation leading to a mild OPMD 
phenotype. [2] Hence, nearly twenty years after the first publication of the 
PABPN1 mutation, the genetic spectrum now includes (GCN)11 expansions as 
dominant mutations up to the (GCN)18 expansion that was published by Jouan. 
[2,14] This has consequences for clinical diagnosis and genetic counseling. 
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Figure 4: The current genetic characterization of OPMD 
Nearly twenty years after the first publication of the PABPN1 mutation the 
genetic spectrum now includes (GCN)11 up to (GCN)18 expansions as 
dominant mutations. The (GCN)11 allele was initially described as either a 
polymorphism which acts as a severity modifier of the dominant OPMD 
phenotype or as a recessive mutation leading to a mild OPMD phenotype.[2] In 
2015 however, the (GCN)11 expansion was reported as a dominant 
mutation.[30]. In addition, in 2014 the (GCN)18 expansion was described for the 
first time,[14] while the longest expansion reported so far was (GCN)17. 
Another possible explanation for the high prevalence of weakness of the pelvic 
girdle and proximal leg muscles in the Dutch OPMD population was the relative 
old age at the time of the study (mean age 60 years (range 41–81)), while the 
mean age of e.g. the French cohort was 54 years (range 40-72), in which cohort 
the prevalence of weakness of limb muscles was 52 %.[22] However, our final 
study (a multidimensional approach to investigate the involvement of pelvic 
girdle and proximal leg muscles in early OPMD; Part V; Chapter 9) 
demonstrates that involvement of pelvic girdle and proximal leg muscles can be 
a relatively early feature of OPMD, occurring long before the age of 60 and that 
this results in  impaired ability to perform activities in daily living. In this study 
most patients (57%) had (GCN)14 or (GCN)13 expansion. This study confirmed 
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once more our pilot study showing that weakness of the pelvic girdle and 
proximal leg muscles can occur early in the course of the disease (Part II; 
Chapter 2). 
Hence, the high prevalence of weakness of the pelvic girdle and proximal leg 
muscles in the Dutch OPMD population is likely to be related to the large 
mutation size and the relatively old age. This cannot, however, fully explain the 
difference with other cohorts, so other factors should also contribute to this. This 
was our motivation to study the hip girdle and proximal leg function in OPMD 
with a unbiased approach in Chapter 9. 
Symptomatic treatment 
 
Furthermore, this study was expected to promote symptomatic treatment. First 
(Part III; Chapter 5), we reported that the astrologist’s posture (retroflexion of 
the neck combined with downward gaze to compensate for severe bilateral 
ptosis), although a beneficial compensation for preservation of the visual field, 
has a negative effect on swallowing. A subjective and objective reduction of 
swallowing problems was observed when patients were instructed to eat and 
drink with a slightly flexed head position. Based on this data, speech therapists, 
neurologists and ophthalmologists can alleviate the swallowing problems by 
teaching patients to eliminate the compensatory retroflexion of the head during 
eating and drinking (for example, eating and watching TV should not be 
combined). This recommendation is an addition to surgical ptosis correction and 
cricopharyngotomy. Almost all OPMD patients underwent surgical ptosis 
correction and often more than once, whereas cricopharyngotomy is only 
necessary in a minority of patients.   
Additionally, the results of our questionnaire study of the patients’ perspective 
(Part IV; Chapter 7) suggested that symptomatic management in OPMD 
patients should include therapies aimed at the reduction of fatigue, pain and 
functional impairments, similarly as in other neuromuscular disorders. As 
mentioned earlier, fatigue and pain also occur frequently in FSHD patients. 
Aerobic exercise training (AET) and cognitive-behavioral therapy (CBT) has 
proven to be effective in reducing chronic fatigue and increasing social 
participation in FSHD.[31] In addition, a 6-month home-based exercise program 
in FSHD patients resulted in significant functional benefits.[32] And another 
randomized controlled study showed that regular endurance training improves 
fitness, walking speed, and self-assessed health in FSHD patients.[33] Based 
on these results and clinical similarity between the muscular dystrophies, AET 
and CBT could be considered for OPMD patients.  
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Finally, weakness of the pelvic girdle and proximal leg muscles was the 
complaint that was most frequent spontaneously reported by the participants of 
our questionnaire study (Part IV; Chapter 7). In addition, 69% of the patients 
scored limitations on de SIP category “ambulation”. The recent study of Youssof 
et al. also demonstrated that hip flexion weakness was associated with impaired 
ambulation in OPMD patients [34]. Therefore, physicians should pay attention to 
the occurrence and consequences of pelvic girdle and proximal limb muscle 
weakness during the diagnostic process and rehabilitation of OPMD patients. 
Based on the results of this thesis we recommend the following lifestyle advices 
to  OPMD patients. A Dutch translation is included on page 193. 
  
 
OPMD LIFESTYLE ADVICES 
- Be energy conscious. 
Distribute your activities over the day/week and make choices. An 
occupational therapist can support you with planning your activities 
energy sufficient. 
- Keep moving.  
Aerobic exercise training is good for your general physical condition 
and muscle fitness. There are many ways to train, even in case of 
muscular weakness. Do not over-train. A physical therapist can 
advise and support you in making a training schedule. 
- Keep a varied and balanced diet and avoid weight loss.  
If necessary, use food supplements in consultation with your 
physician or dietician. 
- Be aware of your head position during eating and drinking. 
Keep your head in a slightly flexed forward position during eating and 
drinking to reduce your swallowing problems. A speech language 
therapist can advise and support you with swallowing problems. 
- Visit your (in OPMD specialized) neurologist and rehabilitation 
physician annually to be sure of the best care.  
- Devices exist to help you.  
Use the devices if necessary. They increase your functional abilities 
and independence. 
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Pathophysiology of OPMD 
 
In addition, this study was expected to contribute to the knowledge on the 
pathophysiology of OPMD needed to develop targeted therapies. The molecular 
pathogenesis of the disease and the role of the aggregates in the pathogenesis 
is still largely unknown. The presence of aggregates in symptomatic OPMD 
patients was first described in 1980.[35] After the discovery of the PABPN1 
mutation Calado et al. detected the PAPBN1 protein in the aggregates.[2;36] In 
addition, they demonstrated that the aggregates contain ubiquitin, subunits of 
the proteasome, and a less soluble form of PABPN1 as well as poly(A) RNA 
(mRNA). They suggested that the polyalanine expansions in PABPN1 induce a 
misfolding and aggregation of the protein into insoluble inclusions, which is 
comparable to processes in neurodegenerative diseases that are caused by 
CAG/polyglutamine expansions. Furthermore, because the authors 
demonstrated that the aggregates sequester poly(A) RNA, they suggested that 
in OPMD, the polyalanine expansions in the PABPN1 protein may interfere with 
the cellular traffic of poly(A) RNA. PABPN1 is a multifunctional regulator of 
mRNA processing. [37] 
More recently, Raz and Raz suggested that muscle weakness in OPMD is a 
paradigm for muscle aging.[6] They discussed recent studies that showed that 
PABPN1 levels were lower in skeletal muscles compared with that in other 
tissues, and that PABPN1 expression declines from midlife onward, specifically 
in skeletal muscles.[38] They proposed that in OPMD, aggregation of expanded 
PABPN1 causes an additional decline in the level of the functional protein, 
which is associated with severe muscle weakness in OPMD. Although OPMD is 
often grouped within the muscular dystrophies, the studies of Anvar et al. on 
RNA expression profiles in OPMD muscles and OPMD models revealed higher 
molecular similarities with muscles from the elderly rather than with muscular 
dystrophies or myopathies.[38] Riaz et al. hypothesized that altered PABPN1 
expression levels might be an underlying cause of muscle wasting in OPMD. 
They down-regulated PABPN1 in mouse tibialis anterior and found that a mild 
reduction in PABPN1 levels causes muscle pathology including myofibre 
atrophy, thickening of extracellular matrix and myofibre-type transition.[39] 
Recently, Garcia-Castaneda et al. investigated functional effects of PABPN1 
and an OPMD mutation (PABPN1-17A), using myotubes that were transfected 
with cDNAs which encoded these proteins.[40] Their results demonstrated that 
PABPN1 proteins regulate essential processes during myotube formation and 
supported the notion that OPMD involves disruption of myogenesis, nuclear 
structure, and homeostasis of Ca2+. Despite all the studies mentioned here, the 
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underlying mechanism causing muscle weakness and other symptoms in 
OPMD is still poorly understood.  
Our study presented in Chapter 8 reveals an important insight: intranuclear 
aggregates but not mitochondrial changes occur before clinical onset in Ala-
expanded-PABPN1 carriers. The presence of aggregates in symptomatic 
OPMD patients had already been reported in 1980,[35] but the presence of 
aggregates before clinical onset is a novel finding. This observation can direct 
future studies on the pathophysiology of this disease and the role of the 
intranuclear aggregates in OPMD pathology in particular. Furthermore, this 
observation suggests that therapeutical interventions to prevent aggregate 
formation should preferably start before clinical onset. 
The studies discussed in the previous paragraphs investigated muscle 
specimens or myotubes, however Dion et al. found ubiquitinated PABPN1-
positive intranuclear aggregates in neuronal cells of transgenic mice expressing 
the expanded form of human PABPN1.[41] By using the same antibodies 
against PABPN1 as in the transgenic mice, they also showed nuclear 
aggregates containing PABPN1 in cerebellar neurons of postmortem brain 
tissue of an OPMD patient. This is interesting in the scope of the clinical 
observation of brain involvement in a subset of OPMD patients (Part III; 
Chapter 6). Future studies on the pathophysiology should beside muscle 
specimens include brain specimens if possible. 
Finally, the nuclear insoluble aggregates have long been suggested to be a 
specific pathogenic mark of OPMD. In 2016, however, Matsubara et al. 
published a case-report in which they described a case of inclusion body 
myopathy associated with Paget disease of bone and FTD with a novel 
mutation in the valosin-containing protein gene.[42] The muscle biopsy of this 
patient revealed PABPN1-positive nuclear inclusions. The ultrastructure of 
those nuclear inclusions were indistinguishable from the OPMD aggregates.[42] 
Although this suggests that the nuclear insoluble aggregates caused by mutant 
PABPN1 may not be specific for OPMD, it is interesting that this case had a late 
onset myopathy in combination with FTD - as the patients we described with 
OPMD and FTD (Part III; Chapter 6). This opens the possibility that the two 
disorders, both the combination of late onset myopathy with FTD, share 
pathophysiological mechanisms. It also exemplifies that the aggregates are no 
longer pathognomonic for OPMD. 
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Outcome measures required for trial preparedness 
 
Finally, this study was set up to improve the outcome measures required for trial 
preparedness.  
Although the quadriceps muscles are frequently used as a functional outcome 
measure (i.e. muscle strength) in many neuromuscular disorders, this muscle 
does not seem to be the appropriate muscle to be assessed clinically as a 
measure of limb girdle function in OPMD. Our final study (a multidimensional 
approach to investigate the involvement of pelvic girdle and proximal leg 
muscles in early OPMD; Part V; Chapter 9) suggests that the hip flexors, hip 
adductors and hamstrings are the appropriate muscles to test. They can be 
assessed in different ways: with functional tests, such as the timed up and go 
test (TUGT) or climbing stairs, with questionnaires that focus on these 
functions, and with (quantitative) muscle strength measurements combined with 
MRI fat fraction assessment. The quadriceps muscle remains a good target 
muscle for biopsies, if muscle specimen is required. The quadriceps muscle is 
relatively easy to access and histopathological alterations can be observed 
even in presymptomatic Ala-expanded-PABPN1 carriers. These findings are 
important for the design of outcome measures in future clinical trials. 
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Future perspectives 
Important topics in OPMD research that need further exploration are the course 
of the disease (longitudinal data), its pathophysiology, brain involvement, and 
symptomatic as well as disease modifying therapeutic options.  
The studies in this thesis are cross-sectional while there is still a lack of 
longitudinal data. A follow-up study with a multidimensional approach (e.g. 
including measurements of muscle strength, functional tests and MR imaging) 
that lasts for several years with multiple assessments, at baseline and after 2 
and 4 years, for example, will give useful information that is currently lacking. 
Such a longitudinal study has already been started in the Neuromuscular 
Centre of the Radboud University Medical Centre: “OPMD Forte” (see 
below).[43] All participating patients of the OPMD Forte study (n=50) are 
measured in a multidimensional approach once, more assessments should 
follow. Longitudinal data are necessary for future therapeutic trails to select 
appropriate outcome measures, the most sensitive and relevant biomarker for 
progression over time. 
 
Despite all the pathophysiological studies so far, the underlying mechanism 
causing muscle weakness and other symptoms in OPMD is still poorly 
understood. The molecular pathogenesis of the disease and the role of the 
aggregates in the pathogenesis is largely unknown. Further study of animal 
models and investigation of muscle specimens of OPMD patients will contribute 
to improve understanding of the underlying mechanism and to find therapeutic 
targets. 
For biopsies, muscle tissue is relatively easy to access. This is however not the 
case for brain tissue; as we described brain involvement in OPMD, it would be 
“OPMD Forte”, an extensive protocol including: 
- Measurements of the degree and extent of muscle weakness: MRC, 
dynamometry, bite force and tongue strength 
- Fat fraction and the degree of inflammation in muscles of the legs and 
pharynx using MRI and muscle ultrasound 
- Functional capacity of the arms and legs (Motor Function Measure) 
- Maximal capacity of swallowing, chewing and speech, including 
swallowing speed and phonation time 
- Subjective complaints including questionnaires on daily functioning 
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interesting to investigate this tissue (of OPMD patients or OPMD models) as 
well. An autopsy study can contribute to the understanding of brain involvement. 
Furthermore, OPMD can act as a good model for neurodegenerative repeat 
disorders with aggregate formation, such as Huntington’s disease, because 
muscle tissue is relatively easy access for biopsies in contrast to brain tissue. 
Besides studies of brain tissue the investigation of cognitive functions in a larger 
cohort including patients with different genetic defects will improve the 
understanding and recognition of potential cognitive impairment in OPMD 
patients. Such a study should include a neuropsychological and a 
neuropsychiatric assessment with e.g. Frontal Assessment Battery, Beck 
Depression Inventory and Neuropsychiatric Inventory. This assessment can be 
completed with MRI studies of the brain. 
Another important topic for future studies is its treatment: that includes both 
symptomatic as well as disease modifying options. Voet et al. investigated the 
effect of aerobic exercise training (AET) and cognitive-behavioral therapy (CBT) 
on chronic fatigue in patients with facioscapulohumeral muscular dystrophy 
(FSHD).[31] Their randomized clinical trial showed that AET and CBT reduces 
chronic fatigue and increases social participation in FSHD. Based on these 
results, AET and CBT might also be offered to OPMD patients. Preferably the 
effect of AET and CBT on chronic fatigue in OPMD should be studied in a future 
trial. 
To date, an approved pharmacological treatment for OPMD is not available. 
Some therapeutic interventions, such as doxycycline and trehalose, have been 
studied in cell and animal models. A phase 2a open label study with trehalose 
has been performed in OPMD patients, but additional research in a larger 
cohort is necessary to prove beneficial effect on the symptoms and disease 
course. It is required to conduct future translational studies to develop safe and 
working therapeutic interventions for OPMD. Furthermore, gene editing using 
the CRISPR/Cas9 technique will be investigated to try to modify the PABPN1 
gene. The CRISPR/Cas system is a bacterial immune system, which has been 
modified to edit genomes. It can be used to cut genome at a desired location, 
allowing the existing genes to be removed and/or new ones to be added. The 
CRISPR/Cas9 technique can be applied in vivo for example by intramuscular 
injecting or to modify the genome of autologous haemangioblasts for 
intravenous administration. In the case of a muscle disorder the modified 
haemangioblast will be deposited into muscles and develop to myoblasts and 
finally muscle fibres. This technique is currently under examination in a mouse 
model of myotonic dystrophy type 1 (DM1).[44] As in OPMD, myotonic 
dystrophy is also caused by a repeat expansion. In OPMD, however, the repeat 
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expansion is very short and a GCN repeat occurs not only in the PABPN1 gene 
but also elsewhere in the genome. Even though the CRISPR/Cas9 technique 
can be used to target a locus very precisely, it is unable to cut one or some 
GCN repeats. Nevertheless, gene editing is not a utopia anymore. 
 
  
Recommendations for future research 
- Perform a longitudinal study to collect data on the disease course, to select 
appropriate outcome measures for future trials; to identify the most 
sensitive and relevant biomarker for progression over time 
- Perform more pathophysiological studies to understand the underlying 
mechanism better and to find therapeutic targets for disease modifying 
therapies. 
- Investigate postmortem brain tissue of OPMD patients (autopsy study); do 
aggregates occur in (frontotemporal) brain tissue and do other alterations 
in brain tissue exist? 
- Investigate cognitive functions using a neuropsychological and 
neuropsychiatric assessment to describe and recognize the possible 
cognitive impairment better. 
- Investigate the effect of aerobic exercise training and cognitive-behavioral 
therapy on chronic fatigue in patients with OPMD 
- Conduct translational studies to develop safe and working therapeutic 
interventions for OPMD 
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Oculopharyngeale spierdystrofie 
Oculopahryngeale spierdystrofie (OPMD) is een zeldzame erfelijke spierziekte. 
Naar schatting heeft in Europa 1 op 100.000 tot 200.000 mensen OPMD. Deze 
spierziekte manifesteert zich meestal pas na het 40ste levensjaar en wordt 
gekenmerkt door hangende bovenoogleden (ptosis), slikklachten (dysfagie) en 
zwakte van de heup- en bovenbeenspieren. De klachten zijn heel langzaam 
progressief, met een normale levensverwachting. De eerste beschrijving dateert 
al uit 1915.[1] In 1980 werd voor het eerst het specifieke kenmerk op 
microscopisch niveau beschreven: bij OPMD patiënten ontstaan namelijk 
karakteristieke ophopingen van eiwit (aggregaten) in de kernen van spiercellen 
(figuur 2).[2] 
  
Figuur 1: klinische kenmerken van OPMD 
Links en midden: de blauwe accenten geven aan waar de klachten van de 
ziekte zitten: ptosis en dysfagie.  
Rechts: 78 jaar oude patiënt met OPMD met ptosis en zwakte van 
aangezichtsspieren onder andere te zien aan zijn horizontale mond. Hij 
probeert de ptosis te compenseren door zijn wenkbrauwen op te trekken.  
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Figuur 2: microscopische kenmerken van OPMD 
Links: een spier is opgebouwd uit spiervezelbundels, en een spiervezelbundel 
is opgebouwd uit spiervezels (=spiercellen). 
Midden: lichtmicroscopisch beeld van een dwarsdoorsnede van een 
spiervezelbundel van een OPMD patiënt. Er zijn meerdere spiervezels 
zichtbaar. In de spiervezel links van het midden zit een opheldering met paarse 
rand dit is een zogenaamde rimmed vacuole, een afwijking die in verschillende 
spierziekten wordt waargenomen. De donkerpaarse gebiedjes aan de rand van 
de vezels (en enkele midden in de vezels) zijn celkernen. Bij OPMD patiënten 
wordt in 2-5% van die celkernen aggregaten (eiwitophopingen) gevonden. 
Rechts: opname gemaakt met een electronenmicroscoop van een aggregaat in 
de kern van een spiercel van een OPMD patiënt.  
 
De oorzaak van OPMD is een verandering (mutatie) in het erfelijk materiaal 
(DNA) in het Poly-Adenylate-Binding-Protein-Nuclear 1 (PABPN1) gen. Deze 
mutatie werd in 1998 voor het eerst beschreven in de Frans-Canadese OPMD 
patiëntenpopulatie, de op dat moment grootste bekende groep OPMD 
patiënten.[3] Het ziektebeeld was toen al in verschillende bevolkingsgroepen 
gerapporteerd. In Nederland werd OPMD in die tijd nog nauwelijks herkend. Dit 
kwam deels door sommige patiënten zelf (“patient’s delay”), die de symptomen1  
ptosis en dysfagie niet herkenden als kenmerken van een ziekte. Meerdere 
OPMD patiënten dachten dat de ptosis en dysfagie normale verschijnselen van 
veroudering waren in hun familie. Deels kwam het nauwelijks herkend worden 
van de ziekte doordat artsen deze zeldzame ziekte niet kenden (“doctor’s 
delay”).  
Het contact met de eerste Nederlandse OPMD patiënten riep bij ons vragen op. 
Het viel bijvoorbeeld op dat die patiënten meer zwakte van hun 
                                                          
1 Symptoom = kenmerk of klacht passend bij een aandoening of ziekte 
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bovenbeenspieren hadden dan beschreven in andere OPMD patiënten. Om de 
kennis van de klinische, histopathologisch en genetische kenmerken2  van de 
Nederlandse OPMD patiënten te verbeteren besloten we de eerste OPMD 
families systematisch te gaan onderzoeken.   
De meeste OPMD onderzoeken richtten zich destijds op basaal 
(histopathologisch en genetisch) onderzoek en niet op de gevolgen van de 
ziekte voor de patiënt en de impact daarvan op zijn dagelijkse activiteiten. Om 
meer inzicht te krijgen in deze aspecten van OPMD hebben we een onderzoek 
opgezet met vragenlijsten gericht op beperkingen in dagelijkse activiteiten van 
de patiënten, en op het voorkomen van vermoeidheid en pijn. 
Verder was niet bekend wat de betekenis was van de aggregaten in de 
spiercellen van OPMD patiënten. En het was niet bekend of de aggregaten 
ontstaan als de patiënt al klachten heeft of dat ze ontstaan voordat de patiënt 
klachten krijgt. 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                          
2 Klinische kenmerken = klachten en verschijnselen van de patient; histopathologische 
kenmerken = (microscopsiche) veranderingen op weefselniveau, in dit geval op niveau 
van spierweefsel ; genetische kenmerken = veranderingen op niveau van het erfelijk 
materiaal (DNA) 
De vragen voortgekomen uit het contact met de eerste Nederlandse 
OPMD patiënten leidden tot de doelstellingen van dit proefschrift 
(nummers komen overeen met de delen (parts) van dit proefschrift):   
II-III: het onderzoeken en documenteren van de klinische, histopathologische 
en genetische kenmerken van de Nederlandse OPMD patiënten; en deze 
kenmerken vergelijken met die van OPMD patiënten in andere 
bevolkingsgroepen 
IV: het onderzoeken van de gevolgen van OPMD op het voorkomen van 
vermoeidheid, pijn en beperkingen in het dagelijks leven, en; 
V: het bevestigen van de resultaten van onze pilot studie (deel II) in een 
grotere groep Nederlandse patiënten en het verkrijgen van meer 
gedetailleerde informatie over de klinische kenmerken van OPMD; 
onderzoeken van de histopathologische kenmerken in personen die de 
genmutatie hebben maar nog geen klachten hebben (presymptomaten); en 
de mate van betrokkenheid van heup- en bovenbeenspieren onderzoeken 
met behulp van een multidimensionele benadering in relatief jonge OPMD 
patiënten en presymptomaten. 
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De verwachting was dat de onderzoeken zouden bijdragen aan het verbeteren 
van de herkenning (van de klinische kenmerken) van OPMD, aan het 
bevorderen van symptomatische3  behandelingen, aan het vergroten van de 
kennis van de pathofysiologie4  ten behoefte van gerichte therapieën, en aan 
het verbeteren van uitkomstmaten voor toekomstig onderzoek. Tegelijkertijd 
bood deze studie de mogelijkheid om samenwerking te starten met Dr. V. Raz. 
Zij houdt zich aan de afdeling humane genetica van het Leids Universitair 
Medisch Centrum bezig met basaal onderzoek gericht op cellulaire processen 
in spierziekten, die zich op latere leeftijd manifesteren, en in normale 
veroudering5.  Deze samenwerking is gericht op het combineren van klinische 
en histopathologische kenmerken van patiënten en diermodellen ten behoefte 
van het verbeteren van de kennis van de pathofysiologie.   
De onderzoeken zijn beschreven in deel II tot en met deel V van dit proefschrift. 
Deel I bevat de introductie zoals hierboven samengevat. Deel  II presenteert 
onze eerste klinische en genetische observaties. Hoofdstuk 2 is het resultaat 
van de eerste observationele studie6  gericht op de klinische, genetische en 
histopathologische kenmerken van Nederlandse OPMD patiënten.  Het is een  
beschrijving van 16 patiënten uit vijf Nederlandse OPMD families. De diagnose 
OPMD was in een familie door middel van een spierbiopt en in vier families met 
genetisch onderzoek bevestigd. De klinische kenmerken van de Nederlandse 
OPMD patiënten bleken grotendeels gelijk aan het fenotype7  van niet-
Nederlandse patiënten. Alle 16 patiënten hadden ptosis. Zeven patiënten  
hadden een ptosiscorrectie8  ondergaan en bij drie patiënten was een operatie 
gepland. Alle patiënten klaagden over dysfagie. Zij hadden meer tijd nodig voor 
het kauwen en slikken om verslikken te voorkomen. Vier patiënten vielen af 
door ernstige dysfagie, twee patiënten hadden een calorierijk dieet om 
gewichtsverlies te voorkomen, en twee anderen hadden een cricopharyngeale 
myotomie9  ondergaan. Verder werd onze observatie tijdens het contact met de 
eerste Nederlandse OPMD patiënten, dat zij meer zwakte van hun 
bovenbeenspieren hadden dan beschreven in andere OPMD patiënten, 
bevestigd. Opvallend was dat spierzwakte van de heup- en bovenbeenspieren 
                                                          
3 Symptomatisch = met betrekking tot de verschijnselen van de ziekte 
4 Pathofysiologie = effecten van de aandoening op weefsel en of orgaan 
5 https://www.lumc.nl/org/humane-genetica/research/research-line-
1/MuscleAgeingandOculopharyngealMuscularDystrophy(OPMD) 
6 Bij observationale studie worden er door de onderzoeker patiëntgegevens verzameld, 
maar is er geen sprake van een interventie/therapie/behandeling. 
7 Klinische fenotype = verzameling van klachten en verschijnselen van een patiënt 
8 Ptosiscorrectie = operatie om hangende oogleden minder te laten hangen  
9 Cricopharyngeale myotomie = operatie waarbij de bovenste kringspier van de slokdarm 
wordt doorgenomen 
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al vroeg in het ziekteproces optrad en de belangrijkste klacht bleef in een deel 
van de patiënten. 
Hoofdstuk 3 beschrijft de resultaten van genetische analyse in vier 
verschillende Nederlandse OPMD families. We identificeerden een nieuwe 
mutatie in het PABPN1 gen in twee van de vier families. Een normaal PABPN1 
gen heeft 6 (GCG) codogenen10  gevolgd door (GCA)3GCG, samen 
(GCG)6(GCA)3GCG oftewel (GCN)10. De 10 GCN codogenen vormen de 
genetische code voor tien maal het aminozuur alanine11  in het PABPN1 eiwit, 
want zowel GCG als GCA codeert voor het aminozuur alanine. Wereldwijd de 
meest voorkomende mutatie in OPMD is (GCG)9(GCA)3GCG, oftewel 
(GCN)13, waardoor er drie alanine aminozuren worden toegevoegd aan het 
PABPN1 eiwit. Wij vonden in twee families een duplicatie van (GCA)2(GCG)2 in 
plaats van een verlenging van de GCG repeat. Deze patiënten hadden  een  
(GCG)6(GCA)2(GCG)2(GCA)3GCG repeat in plaats van normaal 
(GCG)6(GCA)3GCG in het eerste exon van het PABPN1 gen (figuur 3A). 
De identificatie van de nieuwe mutatie in de Nederlandse families ondersteunt 
de theorie van “unequal crossing-over” (figuur 3A) als onderliggend moleculair 
mechanisme voor het ontstaan van de mutaties in het PABPN1 gen. Nakanato 
et al. had in twee niet-gerelateerde Japanse families twee andere mutaties 
gevonden: (GCG)6GCA(GCG)3(GCA)3GCG en 
(GCG)6(GCA)3(GCG)2(GCA)3GCG in plaats van normaal 
(GCG)6(GCA)3GCG.[4] Zij concludeerden reeds dat deze mutaties niet kunnen 
worden veroorzaakt door het meest voorkomende mechanisme van verlenging 
van de repeat in het DNA het zo geheten “slippage” (figuur 3B).  Daarom 
opperden zij dat deze mutaties het resultaat zijn van “unequal crossing-over” 
(figuur 3A).  
 
  
                                                          
10 Codogen = een drietal basen in DNA, die een genetische code in zich dragen 
11 Aminozuren = bouwstenen van eiwitten; één van de aminozuren is alanine  
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Figuur 3A: De nieuw geïdentificeerde PABPN1 mutatie in twee niet-
gerelateerde Nederlandse OPMD families. 
Deze mutatie ondersteunde de theorie van “unequal crossing-over” als 
moleculair mechanisme dat OPMD verzoorzaakt. Bij “ equal crossing-over” 
wisselt het gehele segment van allel A van plaats met het gehele segment van 
allel B. Bij “ unequal crossing-over” wisselt een deel van het segment van allel B 
van plaats met het hele segment van allel A. Dit resulteert in een verkort 
segment B op chromosoom A en een verlengd segment op chromosoom B 
(bestaande uit het hele segment van allel A en een deel van het segment van 
allel B). 
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Figuur 3B: “Slippage” model 
Het idee is dat “slippage” optreedt in delen van het DNA waar zich herhalende 
patronen (repeats) bevinden, bijvoorbeeld GCG of CAG. Tijdens DNA 
vermenigvuldiging kan de te vormen DNA streng los komen van de te kopiëren 
DNA streng waarbij een lus ontstaat met als gevolg toevoeging van 1 of 
meerdere repeats aan de nieuw gevormde DNA streng.  
 
Deel III van dit proefschrift bevat drie specifieke klinische observaties. Als 
eerste (hoofdstuk 4), viel ons op dat de houding van het hoofd het onderscheid 
kan maken tussen de twee meest voorkomende spierziekten met ptosis: OPMD 
en chronische progressieve externe ophthalmoplegie (CPEO). Bij patiënten met 
OPMD is de bewegelijkheid van de ogen grotendeels in stand gebleven 
waardoor zij hun ptosis kunnen compenseren door hun hoofd achterover te 
houden en onder hun hangende oogleden door te kijken, dit wordt de 
“astrologen houding” genoemd. Patiënten met CPEO kunnen de “astrologen 
houding” niet gebruiken, omdat bij hen de bewegelijkheid van de ogen is 
beperkt door zwakte van de externe oogspieren. Hierdoor kan hun oogbol 
minder goed naar beneden bewegen. Bij een patiënt met ptosis en “astrologen 
houding” moet dus gedacht worden aan OPMD. 
Hoofdstuk 5 laat zien dat hoewel de “astrologen houding” voorkomt dat de 
oogleden voor het zicht van de patiënt hangen, deze houding een negatief 
effect heeft op het slikken. De studie laat zien dat er een relatie is tussen de 
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mate waarin de patiënt het hoofd achterover houdt en toename van de 
dysfagie. Tevens wordt aangetoond dat instructies om tijdens eten en drinken 
het hoofd licht voorover te laten zakken de dysfagie subjectief en objectief doet 
afnemen.  
In hoofdstuk 6 beschrijven we twee OPMD patiënten uit verschillende families 
die frontotemporale dementie (FTD) ontwikkelen. Beiden hadden een “ernstige” 
mutatie. De eerste patiënt heeft in plaats van één, twee afwijkende genen 
(GCN)12/(GCN)16, de andere patiënt heeft een lange mutatie (GCN)17. Deze 
patiënten ondersteunen eerdere artikelen over cognitieve achteruitgang in 
OPMD en de mogelijke relatie met ernstige mutaties. Bij patiënten met FTD en 
spierzwakte (inclusief dysfagie en ptosis), of patiënten met positieve familie-
anamnese van FTD of spierdystrofie moet gedacht worden aan  “ernstige” 
PABNP1 mutaties. 
Deze drie hoofdstukken geven samen handvatten voor klinische herkenning 
van OPMD en een belangrijk symptomatisch behandeladvies voor de dysfagie. 
Deel IV (hoofdstuk 7) beschrijft onze vragenlijststudie gericht op de gevolgen 
van OPMD op het voorkomen van vermoeidheid, pijn en beperkingen in het 
dagelijks leven. OPMD werd tot nu toe beschouwd als een “goedaardige” 
spierziekte met zeker in het begin weinig of geen invloed op het functioneren 
van de patiënt. 35 genetisch bevestigde OPMD patiënten vulden de 
vragenlijsten in. Vermoeidheid en pijn kwam bij meer dan de helft van de 
patiënten voor (beide in 54% van de patiënten). Bijna alle patiënten ervaarden 
beperkingen in het dagelijks functioneren (94%), ook patiënten jonger dan 60 
jaar. De ernst van de vermoeidheid was gerelateerd aan de functionele 
beperkingen. 
De hoge prevalentie12  van vermoeidheid, pijn en beperkingen in het dagelijks 
leven in de Nederlandse patiënten kan deels het gevolg kan zijn van de relatief 
lange mutaties van de deelnemende patiënten in vergelijking met 
patiëntengroepen uit andere landen, leidend tot ernstiger beloop van de ziekte. 
Wereldwijd is de meest voorkomende mutatie (GCN)13; van de 35 
deelnemende patiënten hadden slechts 2 de (GCN)13 mutatie en meer dan een 
derde (16 van 35) had een (GCN)16 mutatie. Aangezien de gemiddelde duur 
dat patiënten verschijnselen van de ziekte hadden 11,2 jaar was, 
overeenkomend met een gemiddelde progressie, lijken pijn en vermoeidheid 
niet alleen voor te komen bij gevorderde ziekte. De resultaten van deze studie 
suggereren dat bij symptomatische behandeling van OPMD patiënten ook 
aandacht besteed moet worden aan het reduceren van ernstige vermoeidheid, 
pijn en functionele beperkingen, zoals bij andere spierziekten. 
                                                          
12 Prevalentie = het aantal patiënten met in dit geval vermoeidheid, pijn of beperkingen in 
het dagelijks leven op een gegeven moment. 
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Deel V bevat de resultaten van twee systematische studies in OPMD. 
Hoofdstuk 8 is een prospectieve studie met 40 OPMD patiënten en 18 
volwassen kinderen zonder klachten van genetisch bewezen OPMD patiënten. 
Zes van de volwassen kinderen bleken de OPMD mutatie te hebben 
(=presymptomaten). Deze studie bevat een gestructureerd interview over het 
ziektebeloop, een neurologisch onderzoek en een spierbiopt. Door ook 
spierbiopten te onderzoeken van personen met de OPMD mutatie zonder 
klachten hadden we de unieke mogelijkheid om het spierweefsel te 
onderzoeken voorafgaand aan ziektesymptomen. Eén patiënt overleed tijdens 
de studie en gaf toestemming tot obductie. 
De belangrijkste bevinding van deze studie was de aanwezigheid van 
aggregaten en de afwezigheid van mitochondriële veranderingen13  in 
spierweefsel van presymptomaten. De PABPN1 mutatie zorgt er dus voor dat er 
aggregaten in de kernen van spiercellen worden gevormd voordat er 
spierzwakte optreedt en dat mitochondriële veranderingen pas in een later 
stadium ontstaan. De obductie toonde aan dat spierzwakte gecorreleerd is met 
histopathologische bevindingen in vijf verschillende spieren van één patiënt.  
Een ander belangrijk resultaat van deze studie is de grote variatie in klinische 
manifestatie van OPMD binnen de Nederlandse OPMD populatie. Naast de 
karakteristieke OPMD verschijnselen, ptosis en dysfagie, kwamen andere 
verschijnselen zoals zwakte van de spieren van heup en bovenbeenspieren 
(85%) en zwakte van de spieren van ogen (43%) frequent voor. Deze studie 
bevestigde de bevindingen, beschreven in deel II/hoofdstuk 2, dat spierzwakte 
van de heup en bovenbeenspieren frequent en prominent voorkomt bij de 
Nederlandse OPMD patiënten. Daarnaast toont onze studie het brede spectrum 
van aangedane spieren, en de grote variatie in krachtsverlies van aangedane 
spieren gedurende het ziekteproces. Aangezien de diagnose OPMD niet altijd 
wordt herkend, hebben onze bevindingen naar verwachting een direct gevolg 
op ziekte herkenning. 
Tenslotte wordt in hoofdstuk 9 een studie beschreven waarin met behulp van 
een multidimensionele benadering (oa krachtmetingen, functionele testen, 
vragenlijsten, MRI) de zwakte en veranderingen van heup- en 
bovenbeenspieren werden onderzocht bij relatief jonge OPMD patiënten. Deze 
studie toonde aan dat de heup- en bovenbeenspieren ook al vroeger in het 
ziektebeeld van OPMD kunnen zijn aangedaan. De zwakte kan reeds voor het 
60ste levensjaar optreden en resulteren in beperkingen van activiteiten in het 
dagelijks leven. Tevens toonde deze studie aan dat heupbuigers, 
                                                          
13 Mitochondriële veranderingen zijn veranderingen in mitochondriën. Mitochondriën zijn 
onderdelen van de cel die energie leveren. 
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heupadductoren14  en hamstrings het meest frequent zijn aangedaan. Wij 
suggereren dan ook dat deze spieren de aangewezen spieren zijn om klinisch 
(krachtmetingen en functionele testen) en radiologisch (MRI) te onderzoeken 
voor het monitoren van het klinisch beloop van de ziekte en voor therapeutisch 
adviezen. Tevens moet overwogen worden metingen aan deze spieren te 
gebruiken als uitkomstmaten voor toekomstige trials15.  
Deel VI bevat de Engelstalige samenvatting, de algemene discussie en 
suggesties voor toekomstig onderzoek. In de algemene discussie worden onze 
bevindingen in relatie gebracht met bevindingen van andere recente studies.  
De verwachting was dat de onderzoeken zouden bijdragen aan het verbeteren 
van de herkenning (van de klinische kenmerken) van OPMD, aan het promoten 
van symptomatische behandelingen, aan het vergroten van de kennis van de 
pathofysiologie ten behoefte van gerichte therapieën, en aan het verbeteren 
van uitkomstmaten voor toekomstig onderzoek. 
Deelnemers van onze pilot studie, beschreven in deel II/hoofdstuk 2, hebben 
contact opgenomen met hun familieleden, die ook klachten van OPMD hadden, 
en hen op de hoogte gebracht van onze studie en de zorg die het Spierziekten 
Centrum Nijmegen hen kan bieden. Er zijn nu meer patiënten die vroeg in het 
ziektebeloop een neuroloog bezoeken om geïnformeerd te worden over het 
ziekte beloop, de mogelijke symptomatische behandelingen en de lopende 
studies. Dit heeft er toe geleid dat OPMD beter wordt herkend en dat de 
“patient’s delay” is afgenomen. 
Tevens heeft onze studie bijgedragen aan een afname van de “doctor’s delay”, 
en verschillende “nieuwe” patiënten zijn naar ons centrum verwezen. 
Klinische kenmerken 
Onze studies laten zien dat de symptomen van OPMD zich niet beperken tot 
ptosis en dysfagie (figuur 4). Integendeel, zelfs in een vroeg stadium van de 
ziekte kan zich spierzwakte van de heup- en bovenbeenspieren voordoen, met 
name van de heupbuigers en heupadductoren. Andere bijkomende symptomen 
kunnen zijn pijn, vermoeidheid en cognitieve achteruitgang (dit laatste bij 
patiënten met lange of dubbele mutatie). 
  
                                                          
14 Heupadductoren = heupspieren waarmee de benen naar elkaar toe worden 
bewogen 
15 Trial = wetenschappelijk onderzoek om te testen of een medicijn of 
behandeling werkt 
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Figuur 4: De Klinische kenmerken van OPMD: meer dan ptosis en 
slikklachten.  
Links: patroon van spierzwakte bij OPMD zoals bekend: de belangrijkste 
diagnostische criteria bevatten ptosis en dysfagie 
(https://www.mda.org/disease/oculopharyngeal-muscular-dystrophy).  
Rechts: De klinische kenmerken van OPMD zijn niet beperkt tot ptosis en 
dysfagie; zelfs in een vroeg stadium van de ziekte kan zwakte van de heup- en 
bovenbeenspieren optreden. Bijkomende verschijnselen zijn pijn, vermoeidheid 
en cognitieve achteruitgang (dit laatste in patiënten met lange of dubbel 
mutatie). 
 
De hoge prevalentie van zwakte van de heup- en bovenbeenspieren bij 
Nederlandse OPMD patiënten kan deels het gevolg zijn van de lengte van de 
mutatie van de aan onze studies deelnemende patiënten. Wereldwijd hebben 
de meeste OPMD patiënten een (GCN)13 mutatie; van de patiënten die deel 
hebben genomen aan de studie beschreven in hoofdstuk 8 hadden maar 2 
patiënten de (GCN)13 mutatie en had 31% een (GCN)16 mutatie. Echter 
zwakte van de heup- en bovenbeenspieren kan ook prominent aanwezig zijn bij 
patiënten met een (GCN)13 mutatie zoals Witting et al beschreven in een 
Deense groep patiënten. 
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Symptomatische behandeling 
We hebben laten zien dat de “astrologen houding”, het achterover houden van 
het hoofd om onder de hangend bovenoogleden door te kijken, een negatief 
effect heeft op het slikken. Er treedt een verbetering op van het slikken door 
tijdens eten rechtop te zitten en het hoofd iets voor over te laten zakken. Een 
gespecialiseerd logopediste kan de patiënt hierbij adviseren. OPMD patiënten 
moeten TV kijken en eten ook niet combineren. Deze adviezen zijn een 
aanvulling op de operatieve behandelingen: ptosiscorrectie of cricopharyngeale 
myotomie. Bijna alle OPMD patiënten ondergaan 1 of meerdere 
ptosiscorrecties. Oculopharyngeale myotomie is in de minderheid van de 
patiënten noodzakelijk.  
De resultaten van onze vragenlijststudie, gericht op het onderzoeken van de 
gevolgen van OPMD voor patiënten (hoofdstuk 7), suggereren dat aan de 
behandeling van OPMD patiënten therapieën moeten worden toegevoegd 
gericht op het reduceren van vermoeidheid, pijn en beperkingen in het dagelijks 
leven. 
Tenslotte, zwakte van de heup- en bovenbeensspieren was de meest frequent 
spontaan gerapporteerde klacht van de deelnemers aan het 
vragenlijstonderzoek. 69% van de patiënten scoorden op de vragenlijsten 
beperkingen met betrekking tot het lopen/bewegen. Daarom moeten 
behandelaars zowel bij het stellen van de diagnose als bij de symptomatische 
behandeling aandacht besteden aan het voorkomen van zwakte van de heup- 
en bovenbeensspieren. 
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Gebaseerd op de resultaten van de studies in dit proefschrift willen we de 
volgende leefstijladviezen voor OPMD patiënten aanbevelen: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OPMD LEEFWIJZER 
- Ga bewust om met uw energie  
Verdeel uw activiteiten over de dag/week en maak keuzes. Een 
ergotherapeut kan u ondersteunen bij het plannen van uw activiteiten 
en het verdelen van uw energie. 
- Blijf in beweging 
Conditietraining is goed voor uw algemene conditie en voor uw 
spieren. Er zijn verschillende manieren om te trainen, ook als er 
sprake is van spierzwakte. Ga niet overbelasten. Een fysiotherapeut 
gespecialiseerd in spierziekten kan u adviseren en begeleiden bij het 
maken van een goed trainingsschema. 
- Zorg voor gevarieerde en uitgebalanceerde voeding 
Gebruik indien nodig voedingssupplementen in overleg met uw arts 
of diëtist.  
- Wees u bewust van de houding van uw romp en uw hoofd 
tijdens eten en drinken 
Zit rechtop tijdens eten en drinken en laat uw hoofd iets voorover 
zakken om problemen met slikken te beperken. Een gespecialiseerd 
logopedist kan de voor u optimale houding en de juiste sliktechniek 
vaststellen.  
- Bezoek jaarlijks uw (in OPMD gespecialiseerde) neuroloog en 
revalidatiearts om zeker te zijn van de beste zorg. 
- Hulpmiddelen zijn er om u te helpen 
Gebruik hulpmiddelen indien nodig. Zij vergroten uw mogelijkheden 
en onafhankelijkheid. Een ergotherapeut kan u helpen de juiste 
keuze te maken. 
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Histopathologie 
Hoe de mutatie leidt tot de verschijnselen van de ziekte is nog steeds 
grotendeels onduidelijk; dit geldt ook voor de rol van de aggregaten in dit 
proces. Door spierweefsel te onderzoeken van presymptomaten hebben wij 
laten zien dat de aggregaten in kernen van spiercellen van OPMD patiënten 
reeds aanwezig zijn voordat de patiënt klachten krijgt van de ziekte. Deze 
observatie kan richting geven aan toekomstig onderzoek naar de 
pathofysiologie van de ziekte en de rol van de aggregaten in het bijzonder. 
Bovendien suggereert deze observatie dat therapieën om de vorming van 
aggregaten te voorkomen zullen moeten worden begonnen voordat patiënten 
klachten krijgen. 
 
Uitkomstmaten voor toekomstig onderzoek 
De resultaten van onze laatste studie (een multidimensionele benadering van 
de zwakte en veranderingen van heup- en bovenbeenspieren; beschreven in 
hoofdstuk 9) suggereren dat de heupbuigers, heupadductoren en hamstrings de 
aangewezen spieren zijn om te testen met vragenlijsten, krachtmetingen, 
functionele testen (bv traplopen) en MRI. Biopten, om spiercellen te kunnen 
onderzoeken, kunnen uit de quadricepsspier worden genomen. De 
quadricepsspier is makkelijk toegankelijk voor een biopt in tegenstelling tot de 
heupbuigers. Deze resultaten zijn van belang voor het bepalen uitkomsten 
maten voor toekomstige trials.  
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Tenslotte aanbevelingen voor toekomstig onderzoek:  
 
 
 
 
 
 
 
 
 
 
 
 
 
*longitudinaal onderzoek is onderzoek waarbij herhaaldelijk en steeds op dezelfde 
manier metingen worden verricht om een ontwikkeling/beloop in kaart te brengen.  
**biomarker = kenmerk dat objectief wordt gemeten en als indicator wordt gebruikt voor 
(progressie van) pathogene processen of reacties op een therapeutische interventie. 
***translationeel onderzoek vertaalt resultaten uit basaal onderzoek naar toepassingen in 
de praktijk.  
  
Aanbevelingen voor toekomstig onderzoek 
- Het uitvoeren van studies gericht op het verzamelen van 
longitudinale* data over het ziektebeloop, gericht op het selecteren 
van uitkomstmaten voor toekomstige trials; sensitieve en relevante 
biomarkers**.  
- Het verrichten van meer pathofysiologische studies om 
onderliggende mechanismen van de ziekte te ontraffelen en om 
therapeutische doelwitten te vinden voor ziekteproces 
beïnvloedende therapieën.  
- Het onderzoeken van het voorkomen van aggregaten in 
(frontotemporaal) hersenweefsel en andere veranderingen van 
hersenweefsel in postmortem hersenweefsel van OPMD patiënten 
(obductie studie). 
- Het onderzoeken van cognitieve functies gebruikmakend van een 
neuropsychologische en neuropsychiatrische assessment met als 
doel het beschrijven en herkennen van mogelijke cognitieve 
achteruitgang bij OPMD patiënten.  
- Het onderzoeken van het effect van fysieke training en cognitieve 
gedragstherapie op chronische vermoeidheid bij OPMD patiënten.  
- Toewerken naar toekomstig translationeel*** onderzoek om veilige 
en werkzame therapieën te ontwikkelen voor OPMD 
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Dankwoord 
Op deze plaats wil graag iedereen bedanken die op een of andere manier heeft 
bijgedragen aan het tot stand komen van dit proefschrift. Ook degenen die niet 
expliciet worden genoemd mogen zich aangesproken voelen door mijn oprechte 
dankbetuiging. 
In de eerste plaats wil ik graag alle OPMD patiënten en hun familieleden 
bedanken voor deelname aan onze studies. Bijzonder dat ik een inkijkje kreeg 
in uw dagelijks leven en dat u uw persoonlijke verhalen met mij wilde delen. Ik 
heb meerderen van u thuis mogen bezoeken, familiealbums met u mogen 
bekijken en met u mogen lunchen. Hartelijk dank voor alles. 
Baziel van Engelen, jij bood mij destijds de mogelijkheid tot het doen van een 
wetenschappelijke stage met als onderwerp OPMD. Onder jouw begeleiding is 
dat uitgegroeid tot dit proefschrift. Ik wil je bedanken voor je vertrouwen in mij 
en de mogelijkheden die je mij hebt gegeven. Ik heb veel geleerd van de 
discussies en brainstormsessies. Ook stelde ik je oprechte interesse in mijn 
persoonlijke leven altijd erg op prijs. 
Nicol Voermans, jij bent pas later betrokken geraakt bij mijn onderzoek als 
copromotor. Een betere copromotor had ik mij niet kunnen wensen. Jij hebt mij 
enorm gestimuleerd om dit proefschrift af te maken, dank hiervoor. Deadlines 
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